Cardiac conduction system capture

Description

The disclosure herein relates to systems, methods, and devices for use in determining cardiac conduction system capture of, for example, ventricle from atrium (VfA) cardiac therapy.

Implantable medical devices (IMDs), such as implantable pacemakers, cardioverters, defibrillators, or pacemaker-cardioverter-defibrillators, provide therapeutic electrical stimulation to the heart. IMDs may provide pacing to address bradycardia, or pacing or shocks in order to terminate tachyarrhythmia, such as tachycardia or fibrillation. In some cases, the medical device may sense intrinsic depolarizations of the heart, detect arrhythmia based on the intrinsic depolarizations (or absence thereof), and control delivery of electrical stimulation to the heart if arrhythmia is detected based on the intrinsic depolarizations.

IMDs may also provide cardiac resynchronization therapy (CRT), which is a form of pacing. CRT involves the delivery of pacing to the left ventricle, or both the left and right ventricles. The timing and location of the delivery of pacing pulses to the ventricle(s) may be selected to improve the coordination and efficiency of ventricular contraction.

Systems for implanting medical devices may include workstations or other equipment in addition to the implantable medical device itself. In some cases, these other pieces of equipment assist the physician or other technician with placing the intracardiac leads at particular locations on or in the heart. In some cases, the equipment provides information to the physician about the electrical activity of the heart and the location of the intracardiac lead.

When implanting a pacing electrode and during delivery of pacing therapy using such pacing electrode, it can be challenging to determine whether the pacing electrode and pacing therapy delivered thereby have captured the cardiac conduction system or other cardiac tissue.

SUMMARY

The illustrative systems, devices, and methods described herein may be configured to assist a user (e.g., a physician) determining whether a pacing electrode such as ventricle from atrium (VfA) pacing electrode, and the cardiac therapy delivered thereby, has captured the cardiac conduction system as opposed to other cardiac tissue during one or both of implantation and after implantation. Further, the illustrative systems, devices, and methods described herein may be configured to assist a user (e.g., a physician) determining whether the patient has A-V block (e.g., no natural conduction from the atria to ventricles across the A-V node).

In one or more embodiments, the systems, devices, and methods may be described as being noninvasive. For example, in some embodiments, the systems, devices, and methods may not need, or include, implantable devices such as leads, probes, sensors, catheters, implantable electrodes, etc. to monitor, or acquire, a plurality of cardiac signals from tissue of the patient for use in determining capture of the cardiac conduction system (as opposed to capture of other cardiac tissue) and A-V block. Instead, the systems, devices, and methods may use electrical measurements taken noninvasively using, e.g., a plurality of external electrodes attached to the skin of a patient about the patient's torso. In one or more embodiments, the systems, devices, and methods may be described as being invasive in that such systems, devices, and methods may utilize implantable electrodes to monitor electrical activity for using in determining, or evaluating, cardiac conduction system capture and/or A-V block. Additionally, it is be understood that both invasive and non-invasive apparatus and processes may be used at the same time or simultaneously in some embodiments.

It may be described that the illustrative systems, devices, and methods relate to ventricle from atrium (VfA) pacing as will be further described herein. The VfA pacing may result in capture of myocardium alone without capturing the cardiac conduction system. Determination of capture of the cardiac conduction system may be described as being useful for determining, or evaluating, placement of the lead and/or pacing device delivering VfA pacing therapy. In one embodiment, the illustrative systems, devices, and methods may be generally described as including delivering pacing at an A-V delay, or interval, equal to 70% of patient's intrinsic A-V delay and progressively decreasing the A-V delay, or interval, in steps of about 10 milliseconds (ms) to about 20 ms until a predefined minimum of 60 ms. Electrical activity from one or more of an external electrode apparatus and interval electrode apparatus (e.g., activation times, electrograms, and electrocardiograms) may be measured, and dyssynchrony information may be determined, or generated, based on the measured electrical activity.

In the absence of cardiac conduction system capture, dyssynchrony at shorter A-V pacing intervals may increase to due to cell-to-cell conduction. In one or more embodiments, capture of the cardiac conduction system may be determined if an electrical dyssynchrony value (e.g., generated from electrical activity monitored from electrode apparatus) is low at an initial A-V delay, or interval, pacing (e.g., standard deviation of activation times (SDAT) is less than or equal to about 25 ms, average left ventricular or thoracic surrogate electrical activation times (LVAT) is less than or equal to about 40 ms, etc.) and the electrical dyssynchrony value continues to stay low at shorter A-V pacing intervals. In one or more embodiments, capture of the cardiac conduction system may be determined if electrocardiograms (ECG) and/or electrograms (EGM) at short A-V pacing intervals are similar (e.g., closely match, within a tolerance level, etc.) to the ECGs and/or EGMs at longer AV pacing intervals in terms of one or both of QRS morphology and duration.

One illustrative system may include electrode apparatus comprising a plurality of electrodes to monitor electrical activity from tissue of a patient and computing apparatus comprising processing circuitry and coupled to the electrode apparatus. The computing apparatus may be configured to monitor electrical activity of the patient's heart using one or more electrodes of the plurality of electrodes during delivery of ventricle from atrium (VfA) pacing therapy at a plurality of diagnostic A-V delays, wherein each of the plurality of diagnostic A-V delays are less than the patient's intrinsic A-V delay, and determine whether the VfA pacing therapy has captured the cardiac conduction system based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delays.

One illustrative method may include monitoring electrical activity of the patient's heart using one or more electrodes of a plurality of electrodes during delivery of ventricle from atrium (VfA) pacing therapy at a plurality of diagnostic A-V delays, wherein each of the plurality of diagnostic A-V delays are less than the patient's intrinsic A-V delay, and determining whether the VfA pacing therapy has captured the cardiac conduction system based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delays.

One illustrative implantable medical device may include a plurality of electrodes comprising a right atrial electrode positionable within the right atrium to deliver cardiac therapy to, or sense electrical activity of, the right atrium of a patient's heart, and a tissue-piercing electrode implantable through the right atrial endocardium and central fibrous body to deliver cardiac therapy to, or sense electrical activity of, the left ventricle of a patient's heart. The illustrative device may further include a therapy delivery circuit operably coupled to the plurality of electrodes to deliver cardiac therapy to the patient's heart and a sensing circuit operably coupled to the plurality of electrodes to sense electrical activity of the patient's heart. The illustrative device may further include a controller comprising processing circuitry operably coupled to the therapy delivery circuit and the sensing circuit. The controller may be configured to deliver ventricle from atrium (VfA) pacing therapy using at least the tissue-piercing electrode at a plurality of diagnostic A-V delays, wherein each of the plurality of diagnostic A-V delays are less than the patient's intrinsic A-V delay, monitor electrical activity of the patient's heart using one or more electrodes of the plurality of electrodes during delivery of VfA pacing therapy at the plurality of diagnostic A-V delays, and determine whether the VfA pacing therapy has captured the cardiac conduction system based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delays.

The above summary is not intended to describe each embodiment or every implementation of the present disclosure. A more complete understanding will become apparent and appreciated by referring to the following detailed description and claims taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a conceptual diagram of an illustrative cardiac therapy system including an intracardiac medical device implanted in a patient's heart and a separate medical device positioned outside of the patient's heart.

FIG. 2 is an enlarged conceptual diagram of the intracardiac medical device of FIG. 1 and anatomical structures of the patient's heart.

FIG. 3 is a conceptual diagram of a map of a patient's heart in a standard 17 segment view of the left ventricle showing various electrode implantation locations for use with the illustrative systems and devices described herein.

FIG. 4 is a perspective view of an illustrative intracardiac medical device having a distal fixation and electrode assembly that includes a distal housing-based electrode implemented as a ring electrode for use with the illustrative systems and devices described herein.

FIG. 5 is a perspective view of another illustrative intracardiac medical device for use with the illustrative systems and devices described herein.

FIG. 6 is a block diagram of illustrative circuitry that may be enclosed within the housing of the medical devices of FIGS. 1-2 and 4-5, for example, to provide the functionality and therapy described herein.

FIG. 7 is a block diagram of an illustrative method of determining cardiac conduction system capture.

FIGS. 8A-8C are graphs of dyssynchrony over decreasing A-V delays, or intervals, depicting various scenarios of cardiac conduction system capture, no cardiac conduction system capture, and A-V block.

FIG. 9 is a diagram of an illustrative system including electrode apparatus, display apparatus, and computing apparatus.

FIGS. 10-11 are diagrams of illustrative external electrode apparatus for measuring torso-surface potentials.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

In the following detailed description of illustrative embodiments, reference is made to the accompanying figures of the drawing which form a part hereof, and in which are shown, by way of illustration, specific embodiments which may be practiced. It is to be understood that other embodiments may be utilized, and structural changes may be made without departing from (e.g., still falling within) the scope of the disclosure presented hereby.

Illustrative systems, methods, and devices shall be described with reference to FIGS. 1-11. It will be apparent to one skilled in the art that elements or processes from one embodiment may be used in combination with elements or processes of the other embodiments, and that the possible embodiments of such systems, methods, and devices using combinations of features set forth herein is not limited to the specific embodiments shown in the Figures and/or described herein. Further, it will be recognized that the embodiments described herein may include many elements that are not necessarily shown to scale. Still further, it will be recognized that timing of the processes and the size and shape of various elements herein may be modified but still fall within the scope of the present disclosure, although certain timings, one or more shapes and/or sizes, or types of elements, may be advantageous over others.

FIG. 1 depicts an illustrative ventricle from atrium (VfA) cardiac therapy system that may be configured to be used with, for example, the systems and methods described herein with respect to FIGS. 1-11. Although it is to be understood that the present disclosure may utilize one or both of leadless and leaded implantable medical devices, the illustrative cardiac therapy system of FIG. 1 includes a leadless intracardiac medical device 10 that may be configured for single or dual chamber therapy and implanted in a patient's heart 8. In some embodiments, the device 10 may be configured for single chamber pacing and may, for example, switch between single chamber and multiple chamber pacing (e.g., dual or triple chamber pacing). As used herein, “intracardiac” refers to a device configured to be implanted entirely within a patient's heart, for example, to provide cardiac therapy. The device 10 is shown implanted in the right atrium (RA) of the patient's heart 8 in a target implant region 4. The device 10 may include one or more fixation members 20 that anchor a distal end of the device 10 against the atrial endocardium in a target implant region 4. The target implant region 4 may lie between the Bundle of His 5 and the coronary sinus 3 and may be adjacent, or next to, the tricuspid valve 6. The device 10 may be described as a ventricle-from-atrium device because, for example, the device 10 may perform, or execute, one or both of sensing electrical activity from and providing therapy to one or both ventricles (e.g., right ventricle, left ventricle, or both ventricles, depending on the circumstances) while being generally disposed in the right atrium. In particular, the device 10 may include a tissue-piercing electrode that may be implanted in the basal and/or septal region of the left ventricular myocardium of the patient's heart from the triangle of Koch region of the right atrium through the right atrial endocardium and central fibrous body.

The device 10 may be described as a leadless implantable medical device. As used herein, “leadless” refers to a device being free of a lead extending out of the patient's heart 8. Further, although a leadless device may have a lead, the lead would not extend from outside of the patient's heart to inside of the patient's heart or would not extend from inside of the patient's heart to outside of the patient's heart. Some leadless devices may be introduced through a vein, but once implanted, the device is free of, or may not include, any transvenous lead and may be configured to provide cardiac therapy without using any transvenous lead. Further, a leadless VfA device, in particular, does not use a lead to operably connect to an electrode in the ventricle when a housing of the device is positioned in the atrium. Additionally, a leadless electrode may be coupled to the housing of the medical device without using a lead between the electrode and the housing.

The device 10 may include a dart electrode assembly 12 defining, or having, a straight shaft extending from a distal end region of device 10. The dart electrode assembly 12 may be placed, or at least configured to be placed, through the atrial myocardium and the central fibrous body and into the ventricular myocardium 14, or along the ventricular septum, without perforating entirely through the ventricular endocardial or epicardial surfaces. The dart electrode assembly 12 may carry, or include, an electrode at a distal end region of the shaft such that the electrode may be positioned within the ventricular myocardium for sensing ventricular signals and delivering ventricular pacing pulses (e.g., to depolarize the left ventricle and/or right ventricle to initiate a contraction of the left ventricle and/or right ventricle). In some examples, the electrode at the distal end region of the shaft is a cathode electrode provided for use in a bipolar electrode pair for pacing and sensing. While the implant region 4 as illustrated may enable one or more electrodes of the dart electrode assembly 12 to be positioned in the ventricular myocardium, it is recognized that a device having the aspects disclosed herein may be implanted at other locations for multiple chamber pacing (e.g., dual or triple chamber pacing), single chamber pacing with multiple chamber sensing, single chamber pacing and/or sensing, or other clinical therapy and applications as appropriate.

It is to be understood that although device 10 is described herein as including a single dart electrode assembly, the device 10 may include more than one dart electrode assembly placed, or configured to be placed, through the atrial myocardium and the central fibrous body, and into the ventricular myocardium 14, or along the ventricular septum, without perforating entirely through the ventricular endocardial or epicardial surfaces. Additionally, each dart electrode assembly may carry, or include, more than a single electrode at the distal end region, or along other regions (e.g., proximal or central regions), of the shaft.

The cardiac therapy system 2 may also include a separate medical device 50 (depicted diagrammatically in FIG. 1), which may be positioned outside the patient's heart 8 (e.g., subcutaneously) and may be operably coupled to the patient's heart 8 to deliver cardiac therapy thereto. In one example, separate medical device 50 may be an extravascular ICD. In some embodiments, an extravascular ICD may include a defibrillation lead including, or carrying, a defibrillation electrode. A therapy vector may exist between the defibrillation electrode on the defibrillation lead and a housing electrode of the ICD. Further, one or more electrodes of the ICD may also be used for sensing electrical signals related to the patient's heart 8. The ICD may be configured to deliver shock therapy including one or more defibrillation or cardioversion shocks. For example, if an arrhythmia is sensed, the ICD may send a pulse via the electrical lead wires to shock the heart and restore its normal rhythm. In some examples, the ICD may deliver shock therapy without placing electrical lead wires within the heart or attaching electrical wires directly to the heart (subcutaneous ICDs). Examples of extravascular, subcutaneous ICDs that may be used with the system 2 described herein may be described in U.S. Pat. No. 9,278,229 (Reinke et al.), issued 8 Mar. 2016, which is incorporated herein by reference in its entirety.

In the case of shock therapy (e.g., defibrillation shocks provided by the defibrillation electrode of the defibrillation lead), the separate medical device 50 (e.g., extravascular ICD) may include a control circuit that uses a therapy delivery circuit to generate defibrillation shocks having any of a number of waveform properties, including leading-edge voltage, tilt, delivered energy, pulse phases, and the like. The therapy delivery circuit may, for instance, generate monophasic, biphasic, or multiphasic waveforms. Additionally, the therapy delivery circuit may generate defibrillation waveforms having different amounts of energy. For example, the therapy delivery circuit may generate defibrillation waveforms that deliver a total of between approximately 60-80 Joules (J) of energy for subcutaneous defibrillation.

The separate medical device 50 may further include a sensing circuit. The sensing circuit may be configured to obtain electrical signals sensed via one or more combinations of electrodes and to process the obtained signals. The components of the sensing circuit may include analog components, digital components, or a combination thereof. The sensing circuit may, for example, include one or more sense amplifiers, filters, rectifiers, threshold detectors, analog-to-digital converters (ADCs), or the like. The sensing circuit may convert the sensed signals to digital form and provide the digital signals to the control circuit for processing and/or analysis. For example, the sensing circuit may amplify signals from sensing electrodes and convert the amplified signals to multi-bit digital signals by an ADC, and then provide the digital signals to the control circuit. In one or more embodiments, the sensing circuit may also compare processed signals to a threshold to detect the existence of atrial or ventricular depolarizations (e.g., P- or R-waves) and indicate the existence of the atrial depolarization (e.g., P-waves) or ventricular depolarizations (e.g., R-waves) to the control circuit.

The device 10 and the separate medical device 50 may cooperate to provide cardiac therapy to the patient's heart 8. For example, the device 10 and the separate medical device 50 may be used to detect tachycardia, monitor tachycardia, and/or provide tachycardia-related therapy. For example, the device 10 may communicate with the separate medical device 50 wirelessly to trigger shock therapy using the separate medical device 50. As used herein, “wirelessly” refers to an operative coupling or connection without using a metal conductor between the device 10 and the separate medical device 50. In one example, wireless communication may use a distinctive, signaling, or triggering electrical-pulse provided by the device 10 that conducts through the patient's tissue and is detectable by the separate medical device 50. In another example, wireless communication may use a communication interface (e.g., an antenna) of the device 10 to provide electromagnetic radiation that propagates through patient's tissue and is detectable, for example, using a communication interface (e.g., an antenna) of the separate medical device 50.

FIG. 2 is an enlarged conceptual diagram of the intracardiac medical device 10 of FIG. 1 and anatomical structures of the patient's heart 8. In particular, the device 10 is configured to sense cardiac signals and/or deliver pacing therapy. The intracardiac device 10 may include a housing 30. The housing 30 may define a hermetically-sealed internal cavity in which internal components of the device 10 reside, such as a sensing circuit, therapy delivery circuit, control circuit, memory, telemetry circuit, other optional sensors, and a power source as generally described in conjunction with FIG. 6. The housing 30 may include (e.g., be formed of or from) an electrically conductive material such as, e.g., titanium or titanium alloy, stainless steel, MP35N (a non-magnetic nickel-cobalt-chromium-molybdenum alloy), platinum alloy, or other bio-compatible metal or metal alloy. In other examples, the housing 30 may include (e.g., be formed of or from) a non-conductive material including ceramic, glass, sapphire, silicone, polyurethane, epoxy, acetyl co-polymer plastics, polyether ether ketone (PEEK), a liquid crystal polymer, or other biocompatible polymer.

In at least one embodiment, the housing 30 may be described as extending between a distal end region 32 and a proximal end region 34 and as defining a generally-cylindrical shape, e.g., to facilitate catheter delivery. In other embodiments, the housing 30 may be prismatic or any other shape to perform the functionality and utility described herein. The housing 30 may include a delivery tool interface member 26, e.g., defined, or positioned, at the proximal end region 34, for engaging with a delivery tool during implantation of the device 10.

All or a portion of the housing 30 may function as a sensing and/or pacing electrode during cardiac therapy. In the example shown, the housing 30 includes a proximal housing-based electrode 24 that circumscribes a proximal portion (e.g., closer to the proximal end region 34 than the distal end region 32) of the housing 30. When the housing 30 is (e.g., defines, formed from, etc.) an electrically-conductive material, such as a titanium alloy or other examples listed above, portions of the housing 30 may be electrically insulated by a non-conductive material, such as a coating of parylene, polyurethane, silicone, epoxy, or other biocompatible polymer, leaving one or more discrete areas of conductive material exposed to form, or define, the proximal housing-based electrode 24. When the housing 30 is (e.g., defines, formed from, etc.) a non-conductive material, such as a ceramic, glass or polymer material, an electrically-conductive coating or layer, such as a titanium, platinum, stainless steel, or alloys thereof, may be applied to one or more discrete areas of the housing 30 to form, or define, the proximal housing-based electrode 24. In other examples, the proximal housing-based electrode 24 may be a component, such as a ring electrode, that is mounted or assembled onto the housing 30. The proximal housing-based electrode 24 may be electrically coupled to internal circuitry of the device 10, e.g., via the electrically-conductive housing 30 or an electrical conductor when the housing 30 is a non-conductive material.

In the example shown, the proximal housing-based electrode 24 is located nearer to the housing proximal end region 34 than the housing distal end region 32, and therefore, may be referred to as a proximal housing-based electrode 24. In other examples, however, the proximal housing-based electrode 24 may be located at other positions along the housing 30, e.g., more distal relative to the position shown.

At the distal end region 32, the device 10 may include a distal fixation and electrode assembly 36, which may include one or more fixation members 20 and one or more dart electrode assemblies 12 of equal or unequal length. In one such example as shown, a single dart electrode assembly 12 includes a shaft 40 extending distally away from the housing distal end region 32 and one or more electrode elements, such as a tip electrode 42 at or near the free, distal end region of the shaft 40. The tip electrode 42 may have a conical or hemi-spherical distal tip with a relatively narrow tip-diameter (e.g., less than about 1 millimeter (mm)) for penetrating into and through tissue layers without using a sharpened tip or needle-like tip having sharpened or beveled edges.

The dart electrode assembly 12 may be configured to pierce through one or more tissue layers to position the tip electrode 42 within a desired tissue layer such as, e.g., the ventricular myocardium. As such, the height 47, or length, of the shaft 40 may correspond to the expected pacing site depth, and the shaft 40 may have a relatively-high compressive strength along its longitudinal axis to resist bending in a lateral or radial direction when pressed against and into the implant region 4. If a second dart electrode assembly 12 is employed, its length may be unequal to the expected pacing site depth and may be configured to act as an indifferent electrode for delivering of pacing energy to and/or sensing signals from the tissue. In one embodiment, a longitudinal axial force may be applied against the tip electrode 42, e.g., by applying longitudinal pushing force to the proximal end 34 of the housing 30, to advance the dart electrode assembly 12 into the tissue within the target implant region.

The shaft 40 may be described as longitudinally non-compressive and/or elastically deformable in lateral or radial directions when subjected to lateral or radial forces to allow temporary flexing, e.g., with tissue motion, but may return to its normally straight position when lateral forces diminish. Thus, the dart electrode assembly 12 including the shaft 40 may be described as being resilient. When the shaft 40 is not exposed to any external force, or to only a force along its longitudinal central axis, the shaft 40 may retain a straight, linear position as shown.

In other words, the shaft 40 of the dart electrode assembly 12 may be a normally straight member and may be rigid. In other embodiments, the shaft 40 may be described as being relatively stiff but still possessing limited flexibility in lateral directions. Further, the shaft 40 may be non-rigid to allow some lateral flexing with heart motion. However, in a relaxed state, when not subjected to any external forces, the shaft 40 may maintain a straight position as shown to hold the tip electrode 42 spaced apart from the housing distal end region 32 at least by a height, or length, 47 of the shaft 40.

The one or more fixation members 20 may be described as one or more “tines” having a normally curved position. The tines may be held in a distally extended position within a delivery tool. The distal tips of tines may penetrate the heart tissue to a limited depth before elastically, or resiliently, curving back proximally into the normally curved position (shown) upon release from the delivery tool. Further, the fixation members 20 may include one or more aspects described in, for example, U.S. Pat. No. 9,675,579 (Grubac et al.), issued 13 Jun. 2017, and U.S. Pat. No. 9,119,959 (Rys et al.), issued 1 Sep. 2015, each of which is incorporated herein by reference in its entirety.

In some examples, the distal fixation and electrode assembly 36 includes a distal housing-based electrode 22. In the case of using the device 10 as a pacemaker for multiple chamber pacing (e.g., dual or triple chamber pacing) and sensing, the tip electrode 42 may be used as a cathode electrode paired with the proximal housing-based electrode 24 serving as a return anode electrode. Alternatively, the distal housing-based electrode 22 may serve as a return anode electrode paired with tip electrode 42 for sensing ventricular signals and delivering ventricular pacing pulses. In other examples, the distal housing-based electrode 22 may be a cathode electrode for sensing atrial signals and delivering pacing pulses to the atrial myocardium in the target implant region 4. When the distal housing-based electrode 22 serves as an atrial cathode electrode, the proximal housing-based electrode 24 may serve as the return anode paired with the tip electrode 42 for ventricular pacing and sensing and as the return anode paired with the distal housing-based electrode 22 for atrial pacing and sensing.

As shown in this illustration, the target implant region 4 in some pacing applications is along the atrial endocardium 18, generally inferior to the AV node 15 and the His bundle 5. The dart electrode assembly 12 may at least partially define the height 47, or length, of the shaft 40 for penetrating through the atrial endocardium 18 in the target implant region 4, through the central fibrous body 16, and into the ventricular myocardium 14 without perforating through the ventricular endocardial surface 17. When the height 47, or length, of the dart electrode assembly 12 is fully advanced into the target implant region 4, the tip electrode 42 may rest within the ventricular myocardium 14, and the distal housing-based electrode 22 may be positioned in intimate contact with or close proximity to the atrial endocardium 18. The dart electrode assembly 12 may have a total combined height 47, or length, of tip electrode 42 and shaft 40 from about 3 mm to about 8 mm in various examples. The diameter of the shaft 40 may be less than about 2 mm, and may be about 1 mm or less, or even about 0.6 mm or less.

The device 10 may include an acoustic and/or motion detector 11 within the housing 30. The acoustic or motion detector 11 may be operably coupled to one or more of a control circuit 80, a sensing circuit 86, or a therapy delivery circuit 84 as described with respect to FIG. 6. The acoustic and/or motion detector 11 may be used to monitor mechanical activity, such as atrial mechanical activity (e.g., an atrial contraction) and/or ventricular mechanical activity (e.g., a ventricular contraction). In some embodiments, the acoustic and/or motion detector 11 may be used to detect right atrial mechanical activity. A non-limiting example of an acoustic and/or motion detector 11 includes one or both of an accelerometer and a microphone. In some embodiments, the mechanical activity detected by the acoustic and/or motion detector 11 may be used to supplement or replace electrical activity detected by one or more of the electrodes of the device 10. For example, the acoustic and/or motion detector 11 may be used in addition to, or as an alternative to, the proximal housing-based electrode 24.

The acoustic and/or motion detector 11 may also be used for rate response detection or to provide a rate-responsive IMD. Various techniques related to rate response may be described in U.S. Pat. No. 5,154,170 (Bennett et al.), issued Oct. 13, 1992, entitled “Optimization for rate responsive cardiac pacemaker,” and U.S. Pat. No. 5,562,711 (Yerich et al.), issued Oct. 8, 1996, entitled “Method and apparatus for rate-responsive cardiac pacing,” each of which is incorporated herein by reference in its entirety.

In various embodiments, acoustic and/or motion sensor 11 may be used as a heart sound (HS) sensor and may be implemented as a microphone and/or a 1-, 2- or 3-axis accelerometer. In one embodiment, the acoustic and/or motion sensor 11 is implemented as a piezoelectric crystal mounted within the housing 30 that is responsive to the mechanical motion associated with heart sounds. Examples of other embodiments of acoustical sensors that may be adapted for implementation with the techniques of the present disclosure may be described generally in U.S. Pat. No. 4,546,777 (Groch, et al.), U.S. Pat. No. 6,869,404 (Schulhauser, et al.), U.S. Pat. No. 5,554,177 (Kieval, et al.), and U.S. Pat. No. 7,035,684 (Lee, et al.), each of which is incorporated herein by reference in its entirety.

In other words, various types of acoustic and/or motion sensors 11 may be used. For example, the acoustic and/or motion sensor 11 may be described as being any implantable or external sensor responsive to one or more of the heart sounds, and thereby, capable of producing, or generating, an electrical analog signal correlated in time and amplitude to the heart sounds. The analog signal may be then be processed, which may include digital conversion, by a HS sensing module to obtain HS parameters, such as amplitudes or relative time intervals, as derived by the HS sensing module or control circuit 80. The acoustic and/or motion sensor 11 and the HS sensing module may be incorporated in an IMD such as, e.g., device 10, capable of delivering CRT or another cardiac therapy being optimized or may be implemented in a separate device having wired or wireless communication with another IMD or an external programmer or computer used during a pace parameter optimization procedure as described herein.

FIG. 3 is a two-dimensional (2D) ventricular map 300 of a patient's heart (e.g., a top-down view) showing the left ventricle 320 in a standard 17 segment view and the right ventricle 322. The map 300 defines, or includes, a plurality of areas 326 corresponding to different regions of a human heart. As illustrated, the areas 326 are numerically labeled 1-17 (which, e.g., correspond to a standard 17 segment model of a human heart, correspond to 17 segments of the left ventricle of a human heart, etc.). Areas 326 of the map 300 may include basal anterior area 1, basal anteroseptal area 2, basal inferoseptal area 3, basal inferior area 4, basal inferolateral area 5, basal anterolateral area 6, mid-anterior area 7, mid-anteroseptal area 8, mid-inferoseptal area 9, mid-inferior area 10, mid-inferolateral area 11, mid-anterolateral area 12, apical anterior area 13, apical septal area 14, apical inferior area 15, apical lateral area 16, and apex area 17. The inferoseptal and anteroseptal areas of the right ventricle 322 are also illustrated, as well as the right bunch branch (RBB) 25 and left bundle branch (LBB) 27.

In some embodiments, any of the tissue-piercing electrodes of the present disclosure may be implanted in the basal and/or septal region of the left ventricular myocardium of the patient's heart. In particular, the tissue-piercing electrode may be implanted from the triangle of Koch region of the right atrium through the right atrial endocardium and central fibrous body. Once implanted, the tissue-piercing electrode may be positioned in the target implant region 4 (FIGS. 1-2), such as the basal and/or septal region of the left ventricular myocardium. With reference to map 300, the basal region includes one or more of the basal anterior area 1, basal anteroseptal area 2, basal inferoseptal area 3, basal inferior area 4, mid-anterior area 7, mid-anteroseptal area 8, mid-inferoseptal area 9, and mid-inferior area 10. With reference to map 300, the septal region includes one or more of the basal anteroseptal area 2, basal anteroseptal area 3, mid-anteroseptal area 8, mid-inferoseptal area 9, and apical septal area 14.

In some embodiments, the tissue-piercing electrode may be positioned in the basal septal region of the left ventricular myocardium when implanted. The basal septal region may include one or more of the basal anteroseptal area 2, basal inferoseptal area 3, mid-anteroseptal area 8, and mid-inferoseptal area 9.

In some embodiments, the tissue-piercing electrode may be positioned in the high inferior/posterior basal septal region of the left ventricular myocardium when implanted. The high inferior/posterior basal septal region of the left ventricular myocardium may include a portion of one or more of the basal inferoseptal area 3 and mid-inferoseptal area 9 (e.g., the basal inferoseptal area only, the mid-inferoseptal area only, or both the basal inferoseptal area and the mid-inferoseptal area). For example, the high inferior/posterior basal septal region may include region 324 illustrated generally as a dashed-line boundary. As shown, the dashed line boundary represents an approximation of where the high inferior/posterior basal septal region is located, which may take a somewhat different shape or size depending on the particular application.

FIG. 4 is a three-dimensional perspective view of the device 10 capable of delivering pacing therapy and sensing cardiac signals. As shown, the distal fixation and electrode assembly 36 includes the distal housing-based electrode 22 implemented as a ring electrode. The distal housing-based electrode 22 may be positioned in intimate contact with or operative proximity to atrial tissue when fixation member tines 20a, 20b and 20c of the fixation members 20, engage with the atrial tissue. The tines 20a, 20b and 20c, which may be elastically deformable, may be extended distally during delivery of device 10 to the implant site. For example, the tines 20a, 20b, and 20c may pierce the atrial endocardial surface as the device 10 is advanced out of the delivery tool and flex back into their normally curved position (as shown) when no longer constrained within the delivery tool. As the tines 20a, 20b and 20c curve back into their normal position, the fixation member 20 may “pull” the distal fixation member and electrode assembly 36 toward the atrial endocardial surface. As the distal fixation member and electrode assembly 36 is “pulled” toward the atrial endocardium, the tip electrode 42 may be advanced through the atrial myocardium and the central fibrous body and into the ventricular myocardium. The distal housing-based electrode 22 may then be positioned against, or adjacent, the atrial endocardial surface.

The distal housing-based electrode 22 may include (e.g., be formed of) an electrically conductive material, such as, e.g., titanium, platinum, iridium, or alloys thereof. In one embodiment, the distal housing-based electrode 22 may be a single, continuous ring electrode. In other examples, portions of the distal housing-based electrode 22 may be coated with an electrically insulating coating such as, e.g., parylene, polyurethane, silicone, epoxy, or other insulating coating, to reduce the electrically conductive surface area of the electrode. For instance, one or more sectors of the distal housing-based electrode 22 may be coated to separate two or more electrically conductive exposed surface areas of the distal housing-based electrode 22. Reducing the electrically conductive surface area of the distal housing-based electrode 22, e.g., by covering portions of the electrically conductive areas with an insulating coating, may increase the electrical impedance of the distal housing-based 22, and thereby, reduce the current delivered during a pacing pulse that captures the myocardium, e.g., the atrial myocardial tissue. A lower current drain may conserve the power source, e.g., one or more rechargeable or non-rechargeable batteries, of the device 10.

As described above, the distal housing-based electrode 22 may be configured as an atrial cathode electrode for delivering pacing pulses to the atrial tissue at the implant site 4 in combination with the proximal housing-based electrode 24 as the return anode. The electrodes 22 and 24 may be used to sense atrial P-waves for use in controlling atrial pacing pulses (delivered in the absence of a sensed P-wave) and for controlling atrial-synchronized ventricular pacing pulses delivered using the tip electrode 42 as a cathode and the proximal housing-based electrode 24 as the return anode. In other examples, the distal housing-based electrode 22 may be used as a return anode in conjunction with the cathode tip electrode 42 for ventricular pacing and sensing.

FIG. 5 is a three-dimensional perspective view of another leadless intracardiac medical device 310 that may be configured for determining cardiac conduction system capture, calibrating pacing therapy, and/or delivering pacing therapy for single or multiple chamber cardiac therapy (e.g., dual or triple chamber cardiac therapy) according to another example. The device 310 may include a housing 330 having an outer sidewall 335, shown as a cylindrical outer sidewall, extending from a housing distal end region 332 to a housing proximal end region 334. The housing 330 may enclose electronic circuitry configured to perform single or multiple chamber cardiac therapy, including atrial and ventricular cardiac electrical signal sensing and pacing the atrial and ventricular chambers. Delivery tool interface member 326 is shown on the housing proximal end region 334.

A distal fixation and electrode assembly 336 may be coupled to the housing distal end region 332. The distal fixation and electrode assembly 336 may include an electrically insulative distal member 372 coupled to the housing distal end region 332. The tissue-piercing electrode assembly 312 may extend away from the housing distal end region 332, and multiple non-tissue piercing electrodes 722 may be coupled directly to the insulative distal member 372. The tissue-piercing electrode assembly 312, as shown, extends in a longitudinal direction away from the housing distal end region 332 and may be coaxial with the longitudinal center axis 331 of the housing 330.

The distal tissue-piercing electrode assembly 312 may include an electrically insulated shaft 340 and a tip electrode 342 (e.g., tissue-piercing electrode). In some examples, the tissue-piercing electrode assembly 312 may be described as an active fixation member including a helical shaft 340 and a distal cathode tip electrode 342. The helical shaft 340 may extend from a shaft distal end region 343 to a shaft proximal end region 341, which may be directly coupled to the insulative distal member 372. The helical shaft 340 may be coated with an electrically insulating material, e.g., parylene or other examples listed herein, to avoid sensing or stimulation of cardiac tissue along the shaft length.

The tip electrode 342 is located, or positioned, at the shaft distal end region 343 and may serve as a cathode electrode for delivering ventricular pacing pulses and sensing ventricular electrical signals using the proximal housing-based electrode 324 as a return anode when the tip electrode 342 is advanced proximate or into ventricular tissue as described herein. The proximal housing-based electrode 324 may be a ring electrode circumscribing the housing 330 and may be defined by an uninsulated portion of the longitudinal sidewall 335. Other portions of the housing 330 not serving as an electrode may be coated with an electrically insulating material similar to as described above in conjunction with the device 10 of FIG. 4.

Using two or more tissue-piercing electrodes (e.g., of any type) penetrating into the LV myocardium may be used for more localized pacing capture and may mitigate ventricular pacing spikes affecting capturing atrial tissue. In some embodiments, multiple tissue-piercing electrodes may include two or more dart-type electrode assemblies (e.g., electrode assembly 12 of FIG. 4), a helical-type electrode. Non-limiting examples of multiple tissue-piercing electrodes include two dart electrode assemblies, a helix electrode with a dart electrode assembly extending therethrough (e.g., through the center), or dual intertwined helixes. Multiple tissue-piercing electrodes may also be used for bipolar or multi-polar pacing.

In some embodiments, one or more tissue-piercing electrodes (e.g., of any type) that penetrate into the LV myocardium may be a multi-polar tissue-piercing electrode. A multi-polar tissue-piercing electrode may include one or more electrically-active and electrically-separate elements, which may enable bipolar or multi-polar pacing from one or more tissue-piercing electrodes. In other words, each tissue piercing electrode may include one or more separate electrodes or electrically active segments, or areas, that are independent from one another.

Multiple non-tissue piercing electrodes 322 may be provided along a periphery of the insulative distal member 372, peripheral to the tissue-piercing electrode assembly 312. The insulative distal member 372 may define a distal-facing surface 338 of the device 310 and a circumferential surface 339 that circumscribes the device 310 adjacent to the housing longitudinal sidewall 335. Non-tissue piercing electrodes 322 may be formed of an electrically conductive material, such as titanium, platinum, iridium, or alloys thereof. In the illustrated embodiment, six non-tissue piercing electrodes 322 are spaced apart radially at equal distances along the outer periphery of insulative distal member 372, however, two or more non-tissue piercing electrodes 322 may be provided.

Non-tissue piercing electrodes 322 may be discrete components each retained within a respective recess 374 in the insulative member 372 sized and shaped to mate with the non-tissue piercing electrode 322. In other examples, the non-tissue piercing electrodes 322 may each be an uninsulated, exposed portion of a unitary member mounted within or on the insulative distal member 372. Intervening portions of the unitary member not functioning as an electrode may be insulated by the insulative distal member 372 or, if exposed to the surrounding environment, may be coated with an electrically insulating coating, e.g., parylene, polyurethane, silicone, epoxy, or other insulating coating.

When the tissue-piercing electrode assembly 312 is advanced into cardiac tissue, at least one non-tissue piercing electrode 322 may be positioned against, in intimate contact with, or in operative proximity to, a cardiac tissue surface for delivering pulses and/or sensing cardiac electrical signals produced by the patient's heart. For example, non-tissue piercing electrodes 322 may be positioned in contact with right atrial endocardial tissue for pacing and sensing in the atrium when the tissue-piercing electrode assembly 312 is advanced into the atrial tissue and through the central fibrous body until the distal tip electrode 342 is positioned in direct contact with ventricular tissue, e.g., ventricular myocardium and/or a portion of the ventricular conduction system.

Non-tissue piercing electrodes 322 may be coupled to therapy delivery circuit and sensing circuit as will be described herein with respect to FIG. 6 enclosed by the housing 330 to function collectively as a cathode electrode for delivering atrial pacing pulses and for sensing atrial electrical signals, e.g., P-waves, in combination with the proximal housing-based electrode 324 as a return anode. Switching circuitry included in a sensing circuit may be activated under the control of a control circuit to couple one or more of the non-tissue piercing electrodes to an atrial sensing channel. Distal, non-tissue piercing electrodes 322 may be electrically isolated from each other so that each individual one of the electrodes 322 may be individually selected by switching circuitry included in a therapy delivery circuit to serve alone or in a combination of two or more of the electrodes 322 as an atrial cathode electrode. Switching circuitry included in a therapy delivery circuit may be activated under the control of a control circuit to couple one or more of the non-tissue piercing electrodes 322 to an atrial pacing circuit. Two or more of the non-tissue piercing electrodes may be selected at a time to operate as a multi-point atrial cathode electrode.

Certain non-tissue piercing electrodes 322 selected for atrial pacing and/or atrial sensing may be selected based on atrial capture threshold tests, electrode impedance, P-wave signal strength in the cardiac electrical signal, or other factors. For example, a single one or any combination of two or more individual non-tissue piercing electrodes 322 functioning as a cathode electrode that provides an optimal combination of a low pacing capture threshold amplitude and relatively high electrode impedance may be selected to achieve reliable atrial pacing using minimal current drain from a power source.

In some instances, the distal-facing surface 338 may uniformly contact the atrial endocardial surface when the tissue-piercing electrode assembly 312 anchors the housing 330 at the implant site 4. In that case, all the electrodes 322 may be selected together to form the atrial cathode. Alternatively, every other one of the electrodes 322 may be selected together to form a multi-point atrial cathode having a higher electrical impedance that is still uniformly distributed along the distal-facing surface 338. Alternatively, a subset of one or more electrodes 322 along one side of the insulative distal member 372 may be selected to provide pacing at a desired site that achieves the lowest pacing capture threshold due to the relative location of the electrodes 322 to the atrial tissue being paced.

In other instances, the distal-facing surface 338 may be oriented at an angle relative to the adjacent endocardial surface depending on the positioning and orientation at which the tissue-piercing electrode assembly 312 enters the cardiac tissue. In this situation, one or more of the non-tissue piercing electrodes 322 may be positioned in closer contact with the adjacent endocardial tissue than other non-tissue piercing electrodes 322, which may be angled away from the endocardial surface. By providing multiple non-tissue piercing electrodes along the periphery of the insulative distal member 372, the angle of the tissue-piercing electrode assembly 312 and the housing distal end region 332 relative to the cardiac surface, e.g., the right atrial endocardial surface, may not be required to be substantially parallel. Anatomical and positional differences may cause the distal-facing surface 338 to be angled or oblique to the endocardial surface, however, multiple non-tissue piercing electrodes 322 distributed along the periphery of the insulative distal member 372 increase the likelihood of good contact between one or more electrodes 322 and the adjacent cardiac tissue to promote acceptable pacing thresholds and reliable cardiac event sensing using at least a subset of multiple electrodes 322. Contact or fixation circumferentially along the entire periphery of the insulative distal member 372 may not be required.

The non-tissue piercing electrodes 322 are shown to each include a first portion 322a extending along the distal-facing surface 338 and a second portion 322b extending along the circumferential surface 339. The first portion 322a and the second portion 722b may be continuous exposed surfaces such that the active electrode surface wraps around a peripheral edge 376 of the insulative distal member 372 that joins the distal facing surface 338 and the circumferential surface 339. The non-tissue piercing electrodes 322 may include one or more of the electrodes 322 along the distal-facing surface 338, one or more electrodes along the circumferential surface 339, one or more electrodes each extending along both of the distal-facing surface 338 and the circumferential surface 339, or any combination thereof. The exposed surface of each of the non-tissue piercing electrodes 322 may be flush with respective distal-facing surfaces 338 and/or circumferential surfaces. In other examples, each of the non-tissue piercing electrodes 322 may have a raised surface that protrudes from the insulative distal member 372. Any raised surface of the electrodes 322, however, may define a smooth or rounded, non-tissue piercing surface.

The distal fixation and electrode assembly 336 may seal the distal end region of the housing 330 and may provide a foundation on which the electrodes 322 are mounted. The electrodes 322 may be referred to as housing-based electrodes. The electrodes 322 may not be not carried by a shaft or other extension that extends the active electrode portion away from the housing 330, like the distal tip electrode 342 residing at the distal tip of the helical shaft 340 extending away from the housing 330. Other examples of non-tissue piercing electrodes presented herein that are coupled to a distal-facing surface and/or a circumferential surface of an insulative distal member include the distal housing-based electrode 22 as described herein with respect to device 10 of FIG. 4, the distal housing-based electrode extending circumferentially around the assembly 36 as described herein with respect to device 10 of FIG. 4, button electrodes, other housing-based electrodes, and other circumferential ring electrodes. Any non-tissue piercing electrodes directly coupled to a distal insulative member, peripherally to a central tissue-piercing electrode, may be provided to function individually, collectively, or in any combination as a cathode electrode for delivering pacing pulses to adjacent cardiac tissue. When a ring electrode, such as the distal housing-based electrode 22 and/or a circumferential ring electrode, is provided, portions of the ring electrode may be electrically insulated by a coating to provide multiple distributed non-tissue piercing electrodes along the distal-facing surface and/or the circumferential surface of the insulative distal member.

The non-tissue piercing electrodes 322 and other examples listed above are expected to provide more reliable and effective atrial pacing and sensing than a tissue-piercing electrode provided along the distal fixation and electrode assembly 336. The atrial chamber walls are relatively thin compared to ventricular chamber walls. A tissue-piercing atrial cathode electrode may extend too deep within the atrial tissue leading to inadvertent sustained or intermittent capture of ventricular tissue. A tissue-piercing atrial cathode electrode may lead to interference with sensing atrial signals due to ventricular signals having a larger signal strength in the cardiac electrical signal received via tissue-piercing atrial cathode electrodes that are in closer physical proximity to the ventricular tissue. The tissue-piercing electrode assembly 312 may be securely anchored into ventricular tissue for stabilizing the implant position of the device 310 and providing reasonable certainty that the tip electrode 342 is sensing and pacing in ventricular tissue while the non-tissue piercing electrodes 322 are reliably pacing and sensing in the atrium. When the device 310 is implanted in the target implant region 4, e.g., as shown in FIGS. 1-2 with respect to device 10, the tip electrode 342 may reach left ventricular tissue for pacing of the left ventricle while the non-tissue piercing electrodes 322 provide pacing and sensing in the right atrium. The tissue-piercing electrode assembly 312 may be in the range of about 4 to about 8 mm in length from the distal-facing surface 338 to reach left ventricular tissue. In some instances, the device 310 may achieve four-chamber pacing by delivering atrial pacing pulses from the atrial pacing circuit 83 via the non-tissue piercing electrodes 322 in the target implant region 4 to achieve bi-atrial (right and left atrial) capture and by delivering ventricular pacing pulses from a ventricular pacing circuit via the tip electrode 342 advanced into ventricular tissue from the target implant region 4 to achieve biventricular (right and left ventricular) capture.

FIG. 6 is a block diagram of circuitry that may be enclosed within the housings 30, 330 of the devices 10, 310 to provide the functions of sensing cardiac signals, determining capture, and/or delivering pacing therapy according to one example or within the housings of any other medical devices described herein. The separate medical device 50 as shown in FIG. 1 may include some or all the same components, which may be configured in a similar manner. The electronic circuitry enclosed within the housings 30, 330 may include software, firmware, and hardware that cooperatively monitor atrial and ventricular electrical cardiac signals, determine whether cardiac system capture has occurred, determine when a cardiac therapy is necessary, and/or deliver electrical pulses to the patient's heart according to programmed therapy mode and pulse control parameters. The electronic circuitry may include a control circuit 80 (e.g., including processing circuitry), a memory 82, a therapy delivery circuit 84, a sensing circuit 86, and/or a telemetry circuit 88. In some examples, the devices 10, 310 includes one or more sensors 90 for producing signals that are correlated to one or more physiological functions, states, or conditions of the patient. For example, the sensor(s) 90 may include a patient activity sensor, for use in determining a need for pacing therapy and/or controlling a pacing rate. Further, for example, the sensor(s) 90 may include an inertial measurement unit (e.g., accelerometer) to measure motion. Further, for example, the sensor(s) 90 may include an acoustic sensor to monitor cardiac sounds. Still further, for example, the sensor(s) 90 may include a patient activity sensor, which may include an accelerometer. An increase in the metabolic demand of the patient due to increased activity as indicated by the patient activity sensor may be determined using the patient activity sensor. In other words, the devices 10, 310 may include other sensors 90 for sensing signals from the patient for use in determining whether to deliver and/or controlling electrical stimulation therapies delivered by the therapy delivery circuit 84.

The power source 98 may provide power to the circuitry of the devices 10, 310 including each of the components 80, 82, 84, 86, 88, 90 as needed. The power source 98 may include one or more energy storage devices, such as one or more rechargeable or non-rechargeable batteries. The connections (not shown) between the power source 98 and each of the components 80, 82, 84, 86, 88, 90 may be understood from the general block diagram illustrated to one of ordinary skill in the art. For example, the power source 98 may be coupled to one or more charging circuits included in the therapy delivery circuit 84 for providing the power used to charge holding capacitors included in the therapy delivery circuit 84 that are discharged at appropriate times under the control of the control circuit 80 for delivering pacing pulses, e.g., according to a dual chamber pacing mode such as DDI(R). The power source 98 may also be coupled to components of the sensing circuit 86, such as sense amplifiers, analog-to-digital converters, switching circuitry, etc., sensors 90, the telemetry circuit 88, and the memory 82 to provide power to the various circuits.

The functional blocks shown represent functionality included in the devices 10, 310 and may include any discrete and/or integrated electronic circuit components that implement analog, and/or digital circuits capable of producing the functions attributed to the medical devices 10, 310 described herein. The various components may include processing circuitry, such as an application specific integrated circuit (ASIC), an electronic circuit, a processor (shared, dedicated, or group), and memory that execute one or more software or firmware programs, a combinational logic circuit, state machine, or other suitable components or combinations of components that provide the described functionality. The particular form of software, hardware, and/or firmware employed to implement the functionality disclosed herein will be determined primarily by the particular system architecture employed in the medical device and by the particular detection and therapy delivery methodologies employed by the medical device.

The memory 82 may include any volatile, non-volatile, magnetic, or electrical non-transitory computer readable storage media, such as random-access memory (RAM), read-only memory (ROM), non-volatile RAM (NVRAM), electrically-erasable programmable ROM (EEPROM), flash memory, or any other memory device. Furthermore, the memory 82 may include a non-transitory computer readable media storing instructions that, when executed by one or more processing circuits, cause the control circuit 80 and/or other processing circuitry to determine cardiac conduction system capture and/or perform a single, dual, or triple chamber calibrated pacing therapy (e.g., single or multiple chamber pacing), or other cardiac therapy functions (e.g., sensing or delivering therapy), attributed to the devices 10, 310. The non-transitory computer-readable media storing the instructions may include any of the media listed above.

The control circuit 80 may communicate, e.g., via a data bus, with the therapy delivery circuit 84 and the sensing circuit 86 for sensing cardiac electrical signals and controlling delivery of cardiac electrical stimulation therapies in response to sensed cardiac events, e.g., P-waves and R-waves, or the absence thereof. The tip electrodes 42, 342, the distal housing-based electrodes 22, 322, and the proximal housing-based electrodes 24, 324 may be electrically coupled to the therapy delivery circuit 84 for delivering electrical stimulation pulses to the patient's heart and to the sensing circuit 86 and for sensing cardiac electrical signals.

The sensing circuit 86 may include an atrial (A) sensing channel 87 and a ventricular (V) sensing channel 89. The distal housing-based electrodes 22, 322 and the proximal housing-based electrodes 24, 324 may be coupled to the atrial sensing channel 87 for sensing atrial signals, e.g., P-waves attendant to the depolarization of the atrial myocardium. In examples that include two or more selectable distal housing-based electrodes, the sensing circuit 86 may include switching circuitry for selectively coupling one or more of the available distal housing-based electrodes to cardiac event detection circuitry included in the atrial sensing channel 87. Switching circuitry may include a switch array, switch matrix, multiplexer, or any other type of switching device suitable to selectively couple components of the sensing circuit 86 to selected electrodes. The tip electrodes 42, 324 and the proximal housing-based electrodes 24, 324 may be coupled to the ventricular sensing channel 89 for sensing ventricular signals, e.g., R-waves attendant to the depolarization of the ventricular myocardium.

Each of the atrial sensing channel 87 and the ventricular sensing channel 89 may include cardiac event detection circuitry for detecting P-waves and R-waves, respectively, from the cardiac electrical signals received by the respective sensing channels. The cardiac event detection circuitry included in each of the channels 87 and 89 may be configured to amplify, filter, digitize, and rectify the cardiac electrical signal received from the selected electrodes to improve the signal quality for detecting cardiac electrical events. The cardiac event detection circuitry within each channel 87 and 89 may include one or more sense amplifiers, filters, rectifiers, threshold detectors, comparators, analog-to-digital converters (ADCs), timers, or other analog or digital components. A cardiac event sensing threshold, e.g., a P-wave sensing threshold and an R-wave sensing threshold, may be automatically adjusted by each respective sensing channel 87 and 89 under the control of the control circuit 80, e.g., based on timing intervals and sensing threshold values determined by the control circuit 80, stored in the memory 82, and/or controlled by hardware, firmware, and/or software of the control circuit 80 and/or the sensing circuit 86.

Upon detecting a cardiac electrical event based on a sensing threshold crossing, the sensing circuit 86 may produce a sensed event signal that is passed to the control circuit 80. For example, the atrial sensing channel 87 may produce a P-wave sensed event signal in response to a P-wave sensing threshold crossing. The ventricular sensing channel 89 may produce an R-wave sensed event signal in response to an R-wave sensing threshold crossing. The sensed event signals may be used by the control circuit 80 for setting pacing escape interval timers that control the basic time intervals used for scheduling cardiac pacing pulses. A sensed event signal may trigger or inhibit a pacing pulse depending on the particular programmed pacing mode. For example, a P-wave sensed event signal received from the atrial sensing channel 87 may cause the control circuit 80 to inhibit a scheduled atrial pacing pulse and schedule a ventricular pacing pulse at a programmed atrioventricular (A-V) pacing interval. If an R-wave is sensed before the A-V pacing interval expires, the ventricular pacing pulse may be inhibited. If the A-V pacing interval expires before the control circuit 80 receives an R-wave sensed event signal from the ventricular sensing channel 89, the control circuit 80 may use the therapy delivery circuit 84 to deliver the scheduled ventricular pacing pulse synchronized to the sensed P-wave.

In some examples, the devices 10, 310 may be configured to deliver a variety of pacing therapies including bradycardia pacing, cardiac resynchronization therapy, post-shock pacing, and/or tachycardia-related therapy, such as ATP, among others. For example, the devices 10, 310 may be configured to detect non-sinus tachycardia and deliver ATP. The control circuit 80 may determine cardiac event time intervals, e.g., P-P intervals between consecutive P-wave sensed event signals received from the atrial sensing channel 87, R-R intervals between consecutive R-wave sensed event signals received from the ventricular sensing channel 89, and P-R and/or R-P intervals received between P-wave sensed event signals and R-wave sensed event signals. These intervals may be compared to tachycardia detection intervals for detecting non-sinus tachycardia. Tachycardia may be detected in a given heart chamber based on a threshold number of tachycardia detection intervals being detected.

The therapy delivery circuit 84 may include atrial pacing circuit 83 and ventricular pacing circuit 85. Each pacing circuit 83, 85 may include charging circuitry, one or more charge storage devices such as one or more low voltage holding capacitors, an output capacitor, and/or switching circuitry that controls when the holding capacitor(s) are charged and discharged across the output capacitor to deliver a pacing pulse to the pacing electrode vector coupled to respective pacing circuits 83, 85. The tip electrodes 42, 342 and the proximal housing-based electrodes 24, 324 may be coupled to the ventricular pacing circuit 85 as a bipolar cathode and anode pair for delivering ventricular pacing pulses, e.g., upon expiration of an A-V or V-V pacing interval set by the control circuit 80 for providing atrial-synchronized ventricular pacing and a basic lower ventricular pacing rate.

The atrial pacing circuit 83 may be coupled to the distal housing-based electrodes 22, 322 and the proximal housing-based electrodes 24, 324 to deliver atrial pacing pulses. The control circuit 80 may set one or more atrial pacing intervals according to a programmed lower pacing rate or a temporary lower rate set according to a rate-responsive sensor indicated pacing rate. Atrial pacing circuit may be controlled to deliver an atrial pacing pulse if the atrial pacing interval expires before a P-wave sensed event signal is received from the atrial sensing channel 87. The control circuit 80 starts an A-V pacing interval in response to a delivered atrial pacing pulse to provide synchronized multiple chamber pacing (e.g., dual or triple chamber pacing).

Charging of a holding capacitor of the atrial or ventricular pacing circuit 83, 85 to a programmed pacing voltage amplitude and discharging of the capacitor for a programmed pacing pulse width may be performed by the therapy delivery circuit 84 according to control signals received from the control circuit 80. For example, a pace timing circuit included in the control circuit 80 may include programmable digital counters set by a microprocessor of the control circuit 80 for controlling the basic pacing time intervals associated with various single chamber or multiple chamber pacing (e.g., dual or triple chamber pacing) modes or anti-tachycardia pacing sequences. The microprocessor of the control circuit 80 may also set the amplitude, pulse width, polarity, or other characteristics of the cardiac pacing pulses, which may be based on programmed values stored in the memory 82.

Control parameters utilized by the control circuit 80 for sensing cardiac events and controlling pacing therapy delivery may be programmed into the memory 82 via the telemetry circuit 88, which may also be described as a communication interface. The telemetry circuit 88 includes a transceiver and antenna for communicating with an external device, such as a programmer or home monitor, using radio frequency communication or other communication protocols. The control circuit 80 may use the telemetry circuit 88 to receive downlink telemetry from and send uplink telemetry to the external device. In some cases, the telemetry circuit 88 may be used to transmit and receive communication signals to/from another medical device implanted in the patient.

The illustrative systems, methods, and devices described herein may be used, or configured, to determine whether the cardiac conduction system or other cardiac tissue such as, e.g., myocardial tissue, is captured by VfA cardiac pacing therapy. An illustrative method 200 of determining cardiac conduction system capture is depicted in FIG. 7. Generally, it may be described that the illustrative method 200 may be used to analyze electrical activity, either internally from cardiac tissue or externally (e.g., from the torso of the patient), adjust the VfA cardiac pacing therapy using a variety of diagnostic pacing settings, and then determine whether or not the VfA cardiac pacing therapy has captured (e.g., is pacing) the cardiac conduction system of the patient based on the monitored electrical activity. Additionally, the method 200 may be able to determine whether the patient has A-V block based on the monitored electrical activity.

As shown, the method 200 may include monitoring electrical activity 202. The electrical activity may be measured externally from the patient or internally form the patient. In other words, the electrical activity may be measured from tissue outside the patient's body (e.g., skin) or from tissue (e.g., heart tissue) inside the patient's body.

For example, the method 200 may include monitoring, or measuring, electrical activity using a plurality of external electrodes such as, e.g., shown and described with respect to FIGS. 9-11. More specifically, for instance, the plurality of external electrodes may be similar to the external electrodes provided by the electrode apparatus 110 as described herein with respect to FIGS. 9-11. In one embodiment, the plurality of external electrodes may be part, or incorporated into, a vest or band that is located about a patient's torso. More specifically, the plurality of electrodes may be described as being surface electrodes positioned in an array configured to be located proximate the skin of the torso of a patient. It may be described that when using a plurality of external electrodes, the monitoring process 202 may provide a plurality electrocardiograms (ECGs), signals representative of the depolarization and repolarization of the patient's heart, and/or a plurality of activation times.

Further, for example, the method 200 may include monitoring, or measuring, electrical activity using one or more implantable electrodes such as, e.g., shown and described with respect to FIGS. 1-6. In one or more embodiments, the implantable electrodes may be positioned inside of one or more chambers of the patient's heart such as one or more of the right atrium, left atrium, right ventricle, and left ventricle. In one or more embodiments, the implantable electrodes may be positioned proximate cardiac tissue such as one or more of the myocardium, endocardium, and the pericardial space. The electrical activity may be provided as one or more electrograms (EGMs) or electrical signals of the depolarization and repolarization of the patient's heart.

VfA cardiac therapy may be delivered to the left ventricle using an A-V delay or interval, which is the time period between an atrial event (e.g., paced depolarization or intrinsic depolarization) and the left ventricular pace. It is to be understood that the terms A-V delay and A-V interval are used interchangeably in the described provided herein. In other words, A-V interval is the same as A-V delay, and vice versa.

The method 200 may further include providing an initial diagnostic A-V interval 204. The diagnostic A-V interval may be described as being a selected, or determined, interval configured for use in the processes described herein with respect to illustrative method 200 in order to determine whether the VfA cardiac therapy has captured the cardiac conduction system and/or the patient has A-V block.

The initial diagnostic A-V interval may less than the patient's intrinsic A-V interval. The patient's intrinsic A-V interval is the time period between an atrial event (e.g., paced depolarization or intrinsic depolarization) and an intrinsic, or natural, left ventricular depolarization. The initial diagnostic A-V interval may be determined based on the patient's intrinsic A-V interval. For example, the patient's intrinsic A-V interval may be measured, or sensed, and then an initial diagnostic A-V interval may be generated, or calculated, based on the patient's intrinsic A-V interval.

In one embodiment, the initial diagnostic A-V interval may be a selected percentage of the patient's intrinsic A-V interval. The selected percentage may be between about 50% and about 90% of the patient's intrinsic A-V interval. In at least one embodiment, the selected percentage may be 70% of the patient's intrinsic A-V interval. For example, if patient's intrinsic A-V delay is 150 ms and the selected percentage is 70%, then the new, modified, diagnostic A-V interval may be set to 105 ms.

In another embodiment, the initial diagnostic A-V interval may be a selected time period less than the patient's intrinsic A-V interval. The selected time period may be between about 20 milliseconds (ms) and about 50 ms less than the patient's intrinsic A-V interval. For example, if patient's intrinsic A-V delay is 160 ms and the selected time period is 30 ms, then the new, modified diagnostic A-V interval intrinsic A-V interval may be set to 130 ms.

VfA pacing therapy may be delivered 206 using, or according to, the initial diagnostic A-V interval. It is to be understood that the during, or simultaneous with, delivery of VfA pacing therapy 206, the illustrative method 200 may continue monitoring, or collecting, electrical activity 202.

More specifically, the VfA cardiac therapy 206 using the initial diagnostic A-V interval or delay may be delivered by at least one electrode configured to electrically stimulate (e.g., depolarize, pace, etc.) the patient's left ventricle after either an atrial sense or atrial pace in left ventricular-only pacing or the patient's left ventricle and right ventricle after either an atrial sense or atrial pace in biventricular pacing. In some embodiments, the VfA pacing therapy using the initial diagnostic A-V interval may be delivered for a therapy period of time between about 5 seconds and about 30 seconds. In some embodiments, the VfA pacing therapy using the initial diagnostic A-V interval may be delivered for a therapy number of cardiac cycles between about 5 cardiac cycles and about 30 cardiac cycles.

In at least one embodiment, each of the electrodes may be coupled to one or more leads implanted in, or proximate to, the patient's heart. Further, in at least one embodiment, the cardiac therapy 206 may be delivered by a lead-less electrode such as shown and described with respect to FIGS. 1-6. Although such the systems and devices of FIGS. 1-6 are leadless, it is to be understood that the illustrative systems, devices, and methods described herein may be used with any type of cardiac pacing systems including a lead, two leads, three leads, and more than three leads. Further, in at least one embodiment, an illustrative device may be implanted in the patient's right atrium and one or more “leadlets,” or short leads, may extend from the device to another portion or region of cardiac tissue such as, e.g., another chamber (e.g., right ventricle), a different septal wall (e.g., atrial septum), etc. As described herein, although the cardiac therapy delivery may be described as being invasive, some of the illustrative systems, devices, and methods such as those described with respect to the FIGS. 9-11 may be described as being noninvasive.

Further, one or more illustrative cardiac therapies may utilize an leaded or leadless implantable cardiac device that includes a tissue-piercing electrode implantable from the triangle of Koch region of the right atrium through the right atrial endocardium and central fibrous body to deliver cardiac therapy to or sense electrical activity of the left ventricle in the basal and/or septal region of the left ventricular myocardium of a patient's heart as described in U.S. Provisional Patent Application Ser. No. 62/647,414 entitled “VfA CARDIAC THERAPY” and filed on Mar. 23, 2018, and U.S. Provisional Patent Application Ser. No. 62/725,763 entitled “ADAPTIVE VfA CARDIAC THERAPY” and filed on Aug. 31, 2018, each of which is incorporated by reference herein in their entireties.

The monitored electrical activity may be used to generate capture information 208 that may be further used to determine capture of the cardiac conduction system by the VfA cardiac therapy and, optionally, determine whether the patient has A-V block. It may be described that capture of the cardiac conduction system, as opposed to capture of other cardiac tissue, means that the pacing electrode of the VfA cardiac therapy that is intended to depolarize at least the left ventricle is delivering the electrical pace to the results in a fast propagation of electrical activation with a low degree of electrical heterogeneity of activation across the ventricles. The cardiac conduction system includes a specialized network of cells comprising the left and right bundle branches as well as a highly branched network of specialized Purkinje fibers that aids in rapid propagation of electrical activation across the ventricles and leads to a very synchronized action of the heart. The cardiac conduction system is part of the natural pathway of electrical conduction that comes down to the ventricles via the A-V node. However, during activation from conventional ventricular pacing, electrical activation propagates from one myocardial cell to another myocardial cell (also referred to as “cell-to-cell”) and is slower and asynchronous without any involvement of the specialized cardiac conduction system.

In one embodiment, the capture information 208 may include electrical heterogeneity information (EHI) generated from the monitored electrical activity during the VfA pacing therapy at the initial A-V diagnostic interval, as well as subsequent A-V diagnostic intervals as will be described further herein. The EHI may be described as information, or data, representative of at least one of mechanical cardiac functionality and electrical cardiac functionality. The EHI and other cardiac therapy information may be described in U.S. Provisional Patent Application No. 61/834,133 entitled “METRICS OF ELECTRICAL DYSSYNCHRONY AND ELECTRICAL ACTIVATION PATTERNS FROM SURFACE ECG ELECTRODES” and filed on Jun. 12, 2013, which is hereby incorporated by reference it its entirety.

Electrical heterogeneity information (e.g., data) may be defined as information indicative of at least one of mechanical synchrony or dyssynchrony of the heart and/or electrical synchrony or dyssynchrony of the heart. In other words, electrical heterogeneity information may represent a surrogate of actual mechanical and/or electrical functionality of a patient's heart. In at least one embodiment, relative changes in electrical heterogeneity information (e.g., from baseline heterogeneity information to therapy heterogeneity information, from a first set of heterogeneity information to a second set of therapy heterogeneity information, etc.) may be used to determine a surrogate value representative of the changes in hemodynamic response (e.g., acute changes in LV pressure gradients). The left ventricular pressure may be typically monitored invasively with a pressure sensor located in the left ventricular of a patient's heart. As such, the use of electrical heterogeneity information to determine a surrogate value representative of the left ventricular pressure may avoid invasive monitoring using a left ventricular pressure sensor.

In at least one embodiment, the electrical heterogeneity information may include a standard deviation of ventricular activation times measured using some or all of the external electrodes, e.g., of the electrode apparatus 110 described herein with respect FIGS. 9-11. Further, local, or regional, electrical heterogeneity information may include standard deviations and/or averages of activation times measured using electrodes located in certain anatomic areas of the torso. For example, external electrodes on the left side of the torso of a patient may be used to compute local, or regional, left electrical heterogeneity information.

The electrical heterogeneity information may be generated using one or more various systems and/or methods. For example, electrical heterogeneity information may be generated using an array, or a plurality, of surface electrodes and/or imaging systems as described in U.S. Pat. App. Pub. No. 2012/0283587 A1 published Nov. 8, 2012 and entitled “ASSESSING INRA-CARDIAC ACTIVATION PATTERNS AND ELECTRICAL DYSSYNCHRONY,” U.S. Pat. App. Pub. No. 2012/0284003 A1 published Nov. 8, 2012 and entitled “ASSESSING INTRA-CARDIAC ACTIVATION PATTERNS”, and U.S. Pat. No. 8,180,428 B2 issued May 15, 2012 and entitled “METHODS AND SYSTEMS FOR USE IN SELECTING CARDIAC PACING SITES,” each of which is incorporated herein by reference in its entirety.

Electrical heterogeneity information may include one or more metrics or indices. For example, one of the metrics, or indices, of electrical heterogeneity may be a standard deviation of activation times (SDAT) measured using some or all of the electrodes on the surface of the torso of a patient. In some examples, the SDAT may be calculated using the estimated cardiac activation times over the surface of a model heart.

Another metric, or index, of electrical heterogeneity may be a left standard deviation of surrogate electrical activation times (LVED) monitored by external electrodes located proximate the left side of a patient. Further, another metric, or index, of electrical heterogeneity may include an average of surrogate electrical activation times (LVAT) monitored by external electrodes located proximate the left side of a patient. The LVED and LVAT may be determined (e.g., calculated, computed, etc.) from electrical activity measured only by electrodes proximate the left side of the patient, which may be referred to as “left” electrodes. The left electrodes may be defined as any surface electrodes located proximate the left ventricle, which includes region to left of the patient's sternum and spine. In one embodiment, the left electrodes may include all anterior electrodes on the left of the sternum and all posterior electrodes to the left of the spine. In another embodiment, the left electrodes may include all anterior electrodes on the left of the sternum and all posterior electrodes. In yet another embodiment, the left electrodes may be designated based on the contour of the left and right sides of the heart as determined using imaging apparatus (e.g., x-ray, fluoroscopy, etc.).

Another illustrative metric, or index, of dyssynchrony may be a range of activation times (RAT) that may be computed as the difference between the maximum and the minimum torso-surface or cardiac activation times, e.g., overall, or for a region. The RAT reflects the span of activation times while the SDAT gives an estimate of the dispersion of the activation times from a mean. The SDAT also provides an estimate of the heterogeneity of the activation times, because if activation times are spatially heterogeneous, the individual activation times will be further away from the mean activation time, indicating that one or more regions of heart have been delayed in activation. In some examples, the RAT may be calculated using the estimated cardiac activation times over the surface of a model heart.

Another illustrative metric, or index, of electrical heterogeneity information may include estimates of a percentage of surface electrodes located within a particular region of interest for the torso or heart whose associated activation times are greater than a certain percentile, such as, for example the 70th percentile, of measured QRS complex duration or the determined activation times for surface electrodes. The region of interest may, e.g., be a posterior, left anterior, and/or left-ventricular region. The illustrative metric, or index, may be referred to as a percentage of late activation (PLAT). The PLAT may be described as providing an estimate of percentage of the region of interest, e.g., posterior and left-anterior area associated with the left ventricular area of heart, which activates late. A large value for PLAT may imply delayed activation of a substantial portion of the region, e.g., the left ventricle, and the potential benefit of electrical resynchronization through CRT by pre-exciting the late region, e.g., of left ventricle. In other examples, the PLAT may be determined for other subsets of electrodes in other regions, such as a right anterior region to evaluate delayed activation in the right ventricle. Furthermore, in some examples, the PLAT may be calculated using the estimated cardiac activation times over the surface of a model heart for either the whole heart or for a particular region, e.g., left or right ventricle, of the heart.

In one or more embodiments, the electrical heterogeneity information may include indicators of favorable changes in global cardiac electrical activation such as, e.g., described in Sweeney et al., “Analysis of Ventricular Activation Using Surface Electrocardiography to Predict Left Ventricular Reverse Volumetric Remodeling During Cardiac Resynchronization Therapy,” Circulation, 2010 Feb. 9, 121(5): 626-34 and/or Van Deursen, et al., “Vectorcardiography as a Tool for Easy Optimization of Cardiac Resynchronization Therapy in Canine LBBB Hearts,” Circulation Arrhythmia and Electrophysiology, 2012 Jun. 1, 5(3): 544-52, each of which is incorporated herein by reference in its entirety. Heterogeneity information may also include measurements of improved cardiac mechanical function measured by imaging or other systems to track motion of implanted leads within the heart as, e.g., described in Ryu et al., “Simultaneous Electrical and Mechanical Mapping Using 3D Cardiac Mapping System: Novel Approach for Optimal Cardiac Resynchronization Therapy,” Journal of Cardiovascular Electrophysiology, 2010 February, 21(2): 219-22, Sperzel et al., “Intraoperative Characterization of Interventricular Mechanical Dyssynchrony Using Electroanatomic Mapping System—A Feasibility Study,” Journal of Interventional Cardiac Electrophysiology, 2012 November, 35(2): 189-96, and/or U.S. Pat. App. Pub. No. 2009/0099619 A1 entitled “METHOD FOR OPTIMIZING CRT THERAPY” and published on Apr. 16, 2009, each of which is incorporated herein by reference in its entirety.

In one embodiment, the capture information 208 may include one or more metrics, or indices, of electrogram (EGM) signals data monitored, or measured, directly from cardiac tissue and/or include one or more metrics, or indices, of electrocardiogram (ECG) signals monitored, or measured, indirectly from a patient torso. For example, the QRS morphology, QRS, duration, timing intervals between fiducial points on a ventricular EGM during depolarization (for example difference between the timing of minimum amplitude and maximum amplitude), the peak-to-peak amplitude, amplitudes of slopes or derivatives, and a combination of two or more of these metrics or characteristics from one or both of the EGM and ECG signals may be generated and recorded.

The illustrative method 200 may further including modifying, or adjusting, the A-V diagnostic interval 210 after electrical activity has been monitored 202 during delivery of VfA pacing therapy 206 at the previous diagnostic A-V interval (which, in the first iteration, would be the initial diagnostic A-V interval provided by process 204).

In one embodiment, the A-V diagnostic interval 210 may be modified by decreasing the A-V diagnostic interval by a selected amount. For example, the selected amount may be between about 5 ms and about 25 ms. In one or more embodiments, the selected amount may be greater than or equal to about 5 ms, greater than or equal to about 7 ms, greater than or equal to about 10 ms, greater than or equal to about 12 ms, greater than or equal to about 15 ms, etc. and/or less than or equal to about 30 ms, less than or equal to about 25 ms, less than or equal to about 20 ms, less than or equal to about 17 ms, etc. Thus, if the previous diagnostic A-V interval is 140 ms, and the selected amount is 20 ms, then the modified, or adjusted, A-V diagnostic interval would be 120 ms.

In one embodiment, the A-V diagnostic interval 210 may be modified by decreasing the A-V diagnostic interval by a selected percentage. For example, the selected percentage may be between about 2% ms and about 20% ms. In one or more embodiments, the selected percentage may be greater than or equal to about 2%, greater than or equal to about 5%, greater than or equal to about 7%, etc. and/or less than or equal to about 15%, less than or equal to about 12%, less than or equal to about 10%, etc. Thus, if the previous diagnostic A-V interval is 150 ms, and the selected percentage is 10%, then the modified, or adjusted, A-V diagnostic interval would be 135 ms.

The method 200 may then check whether the modified diagnostic A-V interval is less than a minimum value 212. The minimum value 212 may be between about 40 ms and about 70 ms. In one embodiment, the minimum value 212 is 60 ms. If the modified diagnostic A-V interval is less than the minimum value 212, then the method 200 may proceed to determining whether the VfA pacing therapy has captured the cardiac conduction system 214 and/or determining whether the patient has A-V block 216 as will be described further herein.

If the modified diagnostic A-V interval is not less than a minimum value 212, then the method 200 may return to delivering VfA pacing therapy 206 according to the modified diagnostic A-V interval, generating capture information 208 using the monitored electrical activity 202 during such VfA pacing therapy 208, and then modifying the diagnostic A-V interval 210. The method 200 may continue in this loop until the modified diagnostic A-V interval is less than the minimum value 212.

Thus, the method 200 may be described as modifying the diagnostic A-V interval 210 to be a plurality of different diagnostic A-V intervals, each less than the patient's intrinsic A-V interval, and monitoring electrical activity 202 during each of the plurality of different diagnostic A-V intervals that, in turn, may be used to generate capture information 208. The method 200 may stop, or cease, delivery of the VfA pacing therapy using the diagnostic A-V interval when the diagnostic A-V interval is modified, or decreased, equal to or below the minimum value 212. In other words, it may be described that the diagnostic A-V interval may be “swept” from the initial diagnostic A-V interval to a minimum diagnostic A-V interval, and capture data may be collected during the “sweep.”

The method 200 may then utilize one or both of the monitored electrical activity 202 measured during the plurality of different diagnostic A-V intervals and the generated capture information 208 from such monitored electrical activity to determine whether the VfA pacing therapy has captured the cardiac conduction system 214 and/or determine whether the patient has A-V block 216 as will be described further herein.

Determining whether the VfA pacing therapy has captured the cardiac conduction system 214 may be performed using various processes and various capture information. For example, capture information including dyssynchrony information such as, e.g., EHI, may be utilized. Graphs of dyssynchrony over decreasing diagnostic A-V intervals depicting various scenarios of cardiac conduction system capture, no cardiac conduction system capture, and A-V block are depicted in FIGS. 8A-8C.

Two different sets of dyssynchrony information are depicted in FIG. 8A. The first set of dyssynchrony information 220 indicates successful capture of the cardiac conduction system while the second set of dyssynchrony information 222 indicates no, or unsuccessful, capture of the cardiac conduction system. As shown in FIG. 8A, as the diagnostic A-V interval decreases (i.e., moving rightward along the X-axis) the first set of dyssynchrony information 220 indicating successful cardiac conduction system capture does not increase or decrease—instead, the first set of dyssynchrony information 220 stays relatively constant such as, for example, within a certain predefined tolerance (e.g., +/−5%, +/−10%, +/−3 ms, +/−5 ms etc.). No change of dyssynchrony over a decreasing diagnostic A-V interval may indicate successful cardiac conduction system capture.

Conversely, as the diagnostic A-V interval decreases, the second set of dyssynchrony information 222 indicating no, or unsuccessful, capture of the cardiac conduction system decreases and then subsequently increases. In brief, the second set of dyssynchrony information 222 changes over time. Change of dyssynchrony over a decreasing diagnostic A-V interval may indicate unsuccessful, or no, cardiac conduction system capture.

Thus, change of dyssynchrony may be determined by increasing electrical heterogeneity or dyssynchrony during pacing at shorter A-V intervals without capturing conduction system, as the entire activation of the heart would take place by means of cell-to-cell propagation, which is much slower. In some cases, when there is considerable local tissue latency (e.g., measured by interval between delivery of pacing and onset of QRS), change of dyssynchrony may be determined by reduction of electrical dyssynchrony during pacing at shorter A-V intervals without capturing the conduction system.

Thus, the illustrative method 200 may determine that the VfA pacing therapy has not captured the cardiac conduction system 214 if the dyssynchrony information such as, e.g., EHI, changes as the diagnostic A-V interval decreases. Further, and likewise, the illustrative method 200 may determine that the VfA pacing therapy has captured the cardiac conduction system 214 if the dyssynchrony information such as, e.g., EHI, remains relatively constant as the diagnostic A-V interval decreases.

Two different sets of dyssynchrony information are depicted in FIG. 8B, and both the first set of dyssynchrony information 220 and the second set of dyssynchrony information 224 indicate successful capture of the cardiac conduction system because, e.g., they do not increase or decrease, both sets 220, 224 stay relatively constant, etc. However, the second set of dyssynchrony information 224 is above a threshold value 230, which may indicate A-V block. If the dyssynchrony metric being utilized is standard deviation of activation times (SDAT), the threshold value may be between about 20 ms and 25 ms.

Thus, the illustrative method 200 may determine that the patient has A-V block if the dyssynchrony information remains relatively constant and is above a selected threshold over a plurality of different diagnostic A-V intervals (e.g., as the diagnostic A-V interval decreases).

Two different sets of dyssynchrony information are depicted in FIG. 8C. The first set of dyssynchrony information 220 indicates successful capture of the cardiac conduction system while the second set of dyssynchrony information 226 indicates no, or unsuccessful, capture of the cardiac conduction system. As shown in FIG. 8C, as the diagnostic A-V interval decreases (i.e., moving rightward along the X-axis) the first set of dyssynchrony information 220 indicating successful cardiac conduction system capture does not increase or decrease—instead, the first set of dyssynchrony information 220 stays relatively constant. As before, no change of dyssynchrony over a decreasing diagnostic A-V interval may indicate successful cardiac conduction system capture.

Conversely, as the diagnostic A-V interval decreases, the second set of dyssynchrony information 226 indicating no, or unsuccessful, capture of the cardiac conduction system steadily increases. In brief, the second set of dyssynchrony information 226 changes over time. Change of dyssynchrony over a decreasing diagnostic A-V interval may indicate unsuccessful, or no, cardiac conduction system capture.

Determining whether the VfA pacing therapy has captured the cardiac conduction system 214 may be performed using various processes analyze and evaluate EGM, ECG signals, and/or portions thereof. For example, capture information may include a QRS segment in an EGM and/or ECG signal following a ventricular paced event. One or both of the morphology and duration may be compared over the plurality of different diagnostic A-V intervals to determine whether successful capture of the cardiac conduction system by the VfA pacing therapy has occurred.

In one embodiment, a morphology template of a QRS signal segment following a ventricular pacing event from the time of delivery of pacing to a certain predefined time interval (e.g., 250 ms after delivery of an atrial pace) may be stored during pacing at a certain diagnostic A-V interval (e.g., a short AV delay like 60 ms) and morphologic similarity of the QRS segment during pacing at other diagnostic A-V intervals (e.g., longer diagnostic A-V interval like 80 ms, 100 ms, 120 ms, etc.) may be determined based on simple correlation of the QRS signal segments in the same time-window following delivery of pacing. A similarity in morphology may be determined if the correlation coefficient exceeds a certain threshold (e.g., 90%). Other metrics like relative differences may be also used to determine similarity of electrogram morphology or other characteristics. If relative differences are less than a certain threshold (e.g., 5%, 10% etc.), then a match or similarity of characteristics is determined. If QRS signal segments at short A-V pacing intervals are similar (e.g., closely match, within a tolerance level, etc.) to the QRS signal segments at longer AV pacing intervals (e.g., in terms of one or both of QRS morphology and duration), then it may be determined that the VfA pacing therapy has successfully captured one or both of the left ventricle and right ventricle. Conversely, if QRS signal segments at short A-V pacing intervals are different than the QRS signal segments at longer AV pacing intervals (e.g., in terms of one or both of QRS morphology and duration), then it may be determined that the VfA pacing therapy has not successfully captured one or both of the left ventricle and right ventricle.

As described herein, one of the various ways, or processes, to monitor electrical activity during the plurality of different diagnostic A-V delays, and then generate capture information therefrom utilizes a plurality of electrocardiogram (ECG) signals (e.g., torso-surface potentials). The plurality of ECG signals may be measured, or monitored, using a plurality of external electrodes positioned about the surface, or skin, of a patient. The ECG signals may be used to determine cardiac conduction system capture of VfA therapy, e.g., provide by an implantable medical device performing VfA cardiac resynchronization therapy (CRT). As described herein, the ECG signals may be gathered or obtained noninvasively since, e.g., implantable electrodes may not be used to measure the ECG signals. Further, the ECG signals may be used to determine cardiac electrical activation times, which may be used to generate various metrics (e.g., electrical heterogeneity information) that may be used by to determine cardiac conduction system capture.

Various illustrative systems, methods, and graphical user interfaces may be configured to use electrode apparatus including external electrodes, display apparatus, and computing apparatus to noninvasively assist a user (e.g., a physician) in the evaluation of cardiac conduction system capture and/or the configuration (e.g., optimization) of cardiac therapy. An illustrative system 100 including electrode apparatus 110, computing apparatus 140, and a remote computing device 160 is depicted in FIG. 9.

The electrode apparatus 110 as shown includes a plurality of electrodes incorporated, or included, within a band wrapped around the chest, or torso, of a patient 114. The electrode apparatus 110 is operatively coupled to the computing apparatus 140 (e.g., through one or wired electrical connections, wirelessly, etc.) to provide electrical signals from each of the electrodes to the computing apparatus 140 for analysis, evaluation, etc. Illustrative electrode apparatus may be described in U.S. Pat. No. 9,320,446 entitled “Bioelectric Sensor Device and Methods” filed Mar. 27, 2014 and issued on Mar. 26, 2016, which is incorporated herein by reference in its entirety. Further, illustrative electrode apparatus 110 will be described in more detail in reference to FIGS. 2-3.

The computing apparatus 140 and the remote computing device 160 may each include display apparatus 130, 160, respectively, that may be configured to display and analyze data such as, e.g., electrical signals (e.g., electrocardiogram data), electrical activation times, electrical heterogeneity information, etc. For example, one cardiac cycle, or one heartbeat, of a plurality of cardiac cycles, or heartbeats, represented by the electrical signals collected or monitored by the electrode apparatus 110 may be analyzed and evaluated for one or more metrics including activation times and electrical heterogeneity information that may be pertinent to the determination of cardiac conduction system capture and detection of A-V block. More specifically, for example, the QRS complex of a single cardiac cycle may be evaluated for one or more metrics such as, e.g., QRS onset, QRS offset, QRS peak, electrical heterogeneity information (EHI), electrical activation times, left ventricular or thoracic standard deviation of electrical activation times (LVED), standard deviation of activation times (SDAT), average left ventricular or thoracic surrogate electrical activation times (LVAT), referenced to earliest activation time, QRS duration (e.g., interval between QRS onset to QRS offset), difference between average left surrogate and average right surrogate activation times, relative or absolute QRS morphology, difference between a higher percentile and a lower percentile of activation times (higher percentile may be 90%, 80%, 75%, 70%, etc. and lower percentile may be 10%, 15%, 20%, 25% and 30%, etc.), other statistical measures of central tendency (e.g., median or mode), dispersion (e.g., mean deviation, standard deviation, variance, interquartile deviations, range), etc. Further, each of the one or more metrics may be location specific. For example, some metrics may be computed from signals recorded, or monitored, from electrodes positioned about a selected area of the patient such as, e.g., the left side of the patient, the right side of the patient, etc.

In at least one embodiment, one or both of the computing apparatus 140 and the remote computing device 160 may be a server, a personal computer, or a tablet computer. The computing apparatus 140 may be configured to receive input from input apparatus 142 (e.g., a keyboard) and transmit output to the display apparatus 130, and the remote computing device 160 may be configured to receive input from input apparatus 162 (e.g., a touchscreen) and transmit output to the display apparatus 170. One or both of the computing apparatus 140 and the remote computing device 160 may include data storage that may allow for access to processing programs or routines and/or one or more other types of data, e.g., for analyzing a plurality of electrical signals captured by the electrode apparatus 110, for determining QRS onsets, QRS offsets, medians, modes, averages, peaks or maximum values, valleys or minimum values, for determining electrical activation times, for determining whether VfA pacing therapy has captured the cardiac conduction system, for determining whether the patient has A-V block, for driving a graphical user interface configured to noninvasively assist a user in configuring one or more pacing parameters, or settings, such as, e.g., pacing rate, ventricular pacing rate, A-V interval, V-V interval, pacing pulse width, pacing vector, multipoint pacing vector (e.g., left ventricular vector quad lead), pacing voltage, pacing configuration (e.g., biventricular pacing, right ventricle only pacing, left ventricle only pacing, etc.), and arrhythmia detection and treatment, rate adaptive settings and performance, etc.

The computing apparatus 140 may be operatively coupled to the input apparatus 142 and the display apparatus 130 to, e.g., transmit data to and from each of the input apparatus 142 and the display apparatus 130, and the remote computing device 160 may be operatively coupled to the input apparatus 162 and the display apparatus 170 to, e.g., transmit data to and from each of the input apparatus 162 and the display apparatus 170. For example, the computing apparatus 140 and the remote computing device 160 may be electrically coupled to the input apparatus 142, 162 and the display apparatus 130, 170 using, e.g., analog electrical connections, digital electrical connections, wireless connections, bus-based connections, network-based connections, internet-based connections, etc. As described further herein, a user may provide input to the input apparatus 142, 162 to view and/or select one or more pieces of cardiac conduction system capture information, A-V block information, and configuration information related to the cardiac therapy delivered by cardiac therapy apparatus such as, e.g., an implantable medical device.

Although as depicted the input apparatus 142 is a keyboard and the input apparatus 162 is a touchscreen, it is to be understood that the input apparatus 142, 162 may include any apparatus capable of providing input to the computing apparatus 140 and the computing device 160 to perform the functionality, methods, and/or logic described herein. For example, the input apparatus 142, 162 may include a keyboard, a mouse, a trackball, a touchscreen (e.g., capacitive touchscreen, a resistive touchscreen, a multi-touch touchscreen, etc.), etc. Likewise, the display apparatus 130, 170 may include any apparatus capable of displaying information to a user, such as a graphical user interface 132, 172 including electrode status information, graphical maps of electrical activation, a plurality of signals for the external electrodes over one or more heartbeats, QRS complexes, various cardiac therapy scenario selection regions, various rankings of cardiac therapy scenarios, various pacing parameters, electrical heterogeneity information (EHI), textual instructions, graphical depictions of anatomy of a human heart, images or graphical depictions of the patient's heart, graphical depictions of locations of one or more electrodes, graphical depictions of a human torso, images or graphical depictions of the patient's torso, graphical depictions or actual images of implanted electrodes and/or leads, etc. Further, the display apparatus 130, 170 may include a liquid crystal display, an organic light-emitting diode screen, a touchscreen, a cathode ray tube display, etc.

The processing programs or routines stored and/or executed by the computing apparatus 140 and the remote computing device 160 may include programs or routines for computational mathematics, matrix mathematics, decomposition algorithms, compression algorithms (e.g., data compression algorithms), calibration algorithms, image construction algorithms, signal processing algorithms (e.g., various filtering algorithms, Fourier transforms, fast Fourier transforms, etc.), standardization algorithms, comparison algorithms, vector mathematics, or any other processing used to implement one or more illustrative methods and/or processes described herein. Data stored and/or used by the computing apparatus 140 and the remote computing device 160 may include, for example, electrical signal/waveform data from the electrode apparatus 110 (e.g., a plurality of QRS complexes), electrical activation times from the electrode apparatus 110, cardiac sound/signal/waveform data from acoustic sensors, graphics (e.g., graphical elements, icons, buttons, windows, dialogs, pull-down menus, graphic areas, graphic regions, 3D graphics, etc.), graphical user interfaces, results from one or more processing programs or routines employed according to the disclosure herein (e.g., electrical signals, electrical heterogeneity information, etc.), or any other data that may be used for carrying out the one and/or more processes or methods described herein.

In one or more embodiments, the illustrative systems, methods, and interfaces may be implemented using one or more computer programs executed on programmable computers, such as computers that include, for example, processing capabilities, data storage (e.g., volatile or non-volatile memory and/or storage elements), input devices, and output devices. Program code and/or logic described herein may be applied to input data to perform functionality described herein and generate desired output information. The output information may be applied as input to one or more other devices and/or methods as described herein or as would be applied in a known fashion.

The one or more programs used to implement the systems, methods, and/or interfaces described herein may be provided using any programmable language, e.g., a high-level procedural and/or object orientated programming language that is suitable for communicating with a computer system. Any such programs may, for example, be stored on any suitable device, e.g., a storage media, that is readable by a general or special purpose program running on a computer system (e.g., including processing apparatus) for configuring and operating the computer system when the suitable device is read for performing the procedures described herein. In other words, at least in one embodiment, the illustrative systems, methods, and interfaces may be implemented using a computer readable storage medium, configured with a computer program, where the storage medium so configured causes the computer to operate in a specific and predefined manner to perform functions described herein. Further, in at least one embodiment, the illustrative systems, methods, and interfaces may be described as being implemented by logic (e.g., object code) encoded in one or more non-transitory media that includes code for execution and, when executed by a processor or processing circuitry, is operable to perform operations such as the methods, processes, and/or functionality described herein.

The computing apparatus 140 and the remote computing device 160 may be, for example, any fixed or mobile computer system (e.g., a controller, a microcontroller, a personal computer, minicomputer, tablet computer, etc.). The exact configurations of the computing apparatus 140 and the remote computing device 160 are not limiting, and essentially any device capable of providing suitable computing capabilities and control capabilities (e.g., signal analysis, mathematical functions such as medians, modes, averages, maximum value determination, minimum value determination, slope determination, minimum slope determination, maximum slope determination, graphics processing, etc.) may be used. As described herein, a digital file may be any medium (e.g., volatile or non-volatile memory, a CD-ROM, a punch card, magnetic recordable tape, etc.) containing digital bits (e.g., encoded in binary, trinary, etc.) that may be readable and/or writeable by the computing apparatus 140 and the remote computing device 160 described herein. Also, as described herein, a file in user-readable format may be any representation of data (e.g., ASCII text, binary numbers, hexadecimal numbers, decimal numbers, graphically, etc.) presentable on any medium (e.g., paper, a display, etc.) readable and/or understandable by a user.

In view of the above, it will be readily apparent that the functionality as described in one or more embodiments according to the present disclosure may be implemented in any manner as would be known to one skilled in the art. As such, the computer language, the computer system, or any other software/hardware which is to be used to implement the processes described herein shall not be limiting on the scope of the systems, processes, or programs (e.g., the functionality provided by such systems, processes, or programs) described herein.

The illustrative electrode apparatus 110 may be configured to measure body-surface potentials of a patient 114 and, more particularly, torso-surface potentials of a patient 114. As shown in FIG. 2, the illustrative electrode apparatus 110 may include a set, or array, of external electrodes 112, a strap 113, and interface/amplifier circuitry 116. The electrodes 112 may be attached, or coupled, to the strap 113 and the strap 113 may be configured to be wrapped around the torso of a patient 114 such that the electrodes 112 surround the patient's heart. As further illustrated, the electrodes 112 may be positioned around the circumference of a patient 114, including the posterior, lateral, posterolateral, anterolateral, and anterior locations of the torso of a patient 114.

The illustrative electrode apparatus 110 may be further configured to measure, or monitor, sounds from at least one or both the patient 114. As shown in FIG. 2, the illustrative electrode apparatus 110 may include a set, or array, of acoustic sensors 120 attached, or coupled, to the strap 113. The strap 113 may be configured to be wrapped around the torso of a patient 114 such that the acoustic sensors 120 surround the patient's heart. As further illustrated, the acoustic sensors 120 may be positioned around the circumference of a patient 114, including the posterior, lateral, posterolateral, anterolateral, and anterior locations of the torso of a patient 114.

Further, the electrodes 112 and the acoustic sensors 120 may be electrically connected to interface/amplifier circuitry 116 via wired connection 118. The interface/amplifier circuitry 116 may be configured to amplify the signals from the electrodes 112 and the acoustic sensors 120 and provide the signals to one or both of the computing apparatus 140 and the remote computing device 160. Other illustrative systems may use a wireless connection to transmit the signals sensed by electrodes 112 and the acoustic sensors 120 to the interface/amplifier circuitry 116 and, in turn, to one or both of the computing apparatus 140 and the remote computing device 160, e.g., as channels of data. In one or more embodiments, the interface/amplifier circuitry 116 may be electrically coupled to the computing apparatus 140 using, e.g., analog electrical connections, digital electrical connections, wireless connections, bus-based connections, network-based connections, internet-based connections, etc.

Although in the example of FIG. 2 the electrode apparatus 110 includes a strap 113, in other examples any of a variety of mechanisms, e.g., tape or adhesives, may be employed to aid in the spacing and placement of electrodes 112 and the acoustic sensors 120. In some examples, the strap 113 may include an elastic band, strip of tape, or cloth. Further, in some examples, the strap 113 may be part of, or integrated with, a piece of clothing such as, e.g., a t-shirt. In other examples, the electrodes 112 and the acoustic sensors 120 may be placed individually on the torso of a patient 114. Further, in other examples, one or both of the electrodes 112 (e.g., arranged in an array) and the acoustic sensors 120 (e.g., also arranged in an array) may be part of, or located within, patches, vests, and/or other manners of securing the electrodes 112 and the acoustic sensors 120 to the torso of the patient 114. Still further, in other examples, one or both of the electrodes 112 and the acoustic sensors 120 may be part of, or located within, two sections of material or two patches. One of the two patches may be located on the anterior side of the torso of the patient 114 (to, e.g., monitor electrical signals representative of the anterior side of the patient's heart, measure surrogate cardiac electrical activation times representative of the anterior side of the patient's heart, monitor or measure sounds of the anterior side of the patient, etc.) and the other patch may be located on the posterior side of the torso of the patient 114 (to, e.g., monitor electrical signals representative of the posterior side of the patient's heart, measure surrogate cardiac electrical activation times representative of the posterior side of the patient's heart, monitor or measure sounds of the posterior side of the patient, etc.). And still further, in other examples, one or both of the electrodes 112 and the acoustic sensors 120 may be arranged in a top row and bottom row that extend from the anterior side of the patient 114 across the left side of the patient 114 to the anterior side of the patient 114. Yet still further, in other examples, one or both of the electrodes 112 and the acoustic sensors 120 may be arranged in a curve around the armpit area and may have an electrode/sensor-density that less dense on the right thorax that the other remaining areas.

The electrodes 112 may be configured to surround the heart of the patient 114 and record, or monitor, the electrical signals associated with the depolarization and repolarization of the heart after the signals have propagated through the torso of a patient 114. Each of the electrodes 112 may be used in a unipolar configuration to sense the torso-surface potentials that reflect the cardiac signals. The interface/amplifier circuitry 116 may also be coupled to a return or indifferent electrode (not shown) that may be used in combination with each electrode 112 for unipolar sensing.

In some examples, there may be about 12 to about 50 electrodes 112 and about 12 to about 50 acoustic sensors 120 spatially distributed around the torso of a patient. Other configurations may have more or fewer electrodes 112 and more or fewer acoustic sensors 120. It is to be understood that the electrodes 112 and acoustic sensors 120 may not be arranged or distributed in an array extending all the way around or completely around the patient 114. Instead, the electrodes 112 and acoustic sensors 120 may be arranged in an array that extends only part of the way or partially around the patient 114. For example, the electrodes 112 and acoustic sensors 120 may be distributed on the anterior, posterior, and left sides of the patient with less or no electrodes and acoustic sensors proximate the right side (including posterior and anterior regions of the right side of the patient).

The computing apparatus 140 may record and analyze the torso-surface potential signals sensed by electrodes 112 and the sound signals sensed by the acoustic sensors 120, which are amplified/conditioned by the interface/amplifier circuitry 116. The computing apparatus 140 may be configured to analyze the electrical signals from the electrodes 112 to provide electrocardiogram (ECG) signals, information, or data from the patient's heart as will be further described herein. The computing apparatus 140 may be configured to analyze the electrical signals from the acoustic sensors 120 to provide sound signals, information, or data from the patient's body and/or devices implanted therein (such as a left ventricular assist device).

Additionally, the computing apparatus 140 and the remote computing device 160 may be configured to provide graphical user interfaces 132, 172 depicting various information related to the electrode apparatus 110 and the data gathered, or sensed, using the electrode apparatus 110. For example, the graphical user interfaces 132, 172 may depict ECGs including QRS complexes obtained using the electrode apparatus 110 and sound data including sound waves obtained using the acoustic sensors 120 as well as other information related thereto. Illustrative systems and methods may noninvasively use the electrical information collected using the electrode apparatus 110 and the sound information collected using the acoustic sensors 120 to evaluate a patient's cardiac health and to evaluate and configure cardiac therapy being delivered to the patient.

Further, the electrode apparatus 110 may further include reference electrodes and/or drive electrodes to be, e.g. positioned about the lower torso of the patient 114, that may be further used by the system 100. For example, the electrode apparatus 110 may include three reference electrodes, and the signals from the three reference electrodes may be combined to provide a reference signal. Further, the electrode apparatus 110 may use of three caudal reference electrodes (e.g., instead of standard references used in a Wilson Central Terminal) to get a “true” unipolar signal with less noise from averaging three caudally located reference signals.

FIG. 3 illustrates another illustrative electrode apparatus 110 that includes a plurality of electrodes 112 configured to surround the heart of the patient 114 and record, or monitor, the electrical signals associated with the depolarization and repolarization of the heart after the signals have propagated through the torso of the patient 114 and a plurality of acoustic sensors 120 configured to surround the heart of the patient 114 and record, or monitor, the sound signals associated with the heart after the signals have propagated through the torso of the patient 114. The electrode apparatus 110 may include a vest 114 upon which the plurality of electrodes 112 and the plurality of acoustic sensors 120 may be attached, or to which the electrodes 112 and the acoustic sensors 120 may be coupled. In at least one embodiment, the plurality, or array, of electrodes 112 may be used to collect electrical information such as, e.g., surrogate electrical activation times. Similar to the electrode apparatus 110 of FIG. 2, the electrode apparatus 110 of FIG. 3 may include interface/amplifier circuitry 116 electrically coupled to each of the electrodes 112 and the acoustic sensors 120 through a wired connection 118 and be configured to transmit signals from the electrodes 112 and the acoustic sensors 120 to computing apparatus 140. As illustrated, the electrodes 112 and the acoustic sensors 120 may be distributed over the torso of a patient 114, including, for example, the posterior, lateral, posterolateral, anterolateral, and anterior locations of the torso of a patient 114.

The vest 114 may be formed of fabric with the electrodes 112 and the acoustic sensors 120 attached to the fabric. The vest 114 may be configured to maintain the position and spacing of electrodes 112 and the acoustic sensors 120 on the torso of the patient 114. Further, the vest 114 may be marked to assist in determining the location of the electrodes 112 and the acoustic sensors 120 on the surface of the torso of the patient 114. In some examples, there may be about 25 to about 256 electrodes 112 and about 25 to about 256 acoustic sensors 120 distributed around the torso of the patient 114, though other configurations may have more or fewer electrodes 112 and more or fewer acoustic sensors 120.

The illustrative systems and methods may be used to provide noninvasive assistance to a user in the evaluation of a patient's cardiac health and/or evaluation and configuration of cardiac therapy being presently-delivered to the patient (e.g., by an implantable medical device such as a VfA pacing device, by a LVAD, etc.). For example, the illustrative systems and methods may be used to assist a user in determining whether one or more electrodes have successfully captured one or both ventricles for VfA pacing therapy and whether the patient is undergoing A-V block. Further, for example, the illustrative systems and methods may be used to assist a user in the configuration and/or adjustment of one or more cardiac therapy settings such as, e.g., optimization of the A-V interval, or delay, of pacing therapy (e.g., left ventricular-only, or left univentricular, pacing therapy) and the A-V interval, or delay, and the V-V interval, or delay, of pacing therapy (e.g., biventricular pacing therapy).

Further, it is to be understood that the computing apparatus 140 and the remote computing device 160 may be operatively coupled to each other in a plurality of different ways so as to perform, or execute, the functionality described herein. For example, in the embodiment depicted, the computing device 140 may be wireless operably coupled to the remote computing device 160 as depicted by the wireless signal lines emanating therebetween. Additionally, as opposed to wireless connections, one or more of the computing apparatus 140 and the remoting computing device 160 may be operably coupled through one or wired electrical connections.

The techniques described in this disclosure, including those attributed to the IMD 10, device 50, IMD 310, the computing apparatus 140, and the computing device 160 and/or various constituent components, may be implemented, at least in part, in hardware, software, firmware, or any combination thereof. For example, various aspects of the techniques may be implemented within one or more processors, including one or more microprocessors, DSPs, ASICs, FPGAs, or any other equivalent integrated or discrete logic circuitry, as well as any combinations of such components, embodied in programmers, such as physician or patient programmers, stimulators, image processing devices, or other devices. The term “module,” “processor,” or “processing circuitry” may generally refer to any of the foregoing logic circuitry, alone or in combination with other logic circuitry, or any other equivalent circuitry.

Such hardware, software, and/or firmware may be implemented within the same device or within separate devices to support the various operations and functions described in this disclosure. In addition, any of the described units, modules, or components may be implemented together or separately as discrete but interoperable logic devices. Depiction of different features as modules or units is intended to highlight different functional aspects and does not necessarily imply that such modules or units must be realized by separate hardware or software components. Rather, functionality associated with one or more modules or units may be performed by separate hardware or software components, or integrated within common or separate hardware or software components.

When implemented in software, the functionality ascribed to the systems, devices and techniques described in this disclosure may be embodied as instructions on a computer-readable medium such as RAM, ROM, NVRAM, EEPROM, FLASH memory, magnetic data storage media, optical data storage media, or the like. The instructions may be executed by processing circuitry and/or one or more processors to support one or more aspects of the functionality described in this disclosure.

All references and publications cited herein are expressly incorporated herein by reference in their entirety for all purposes, except to the extent any aspect incorporated directly contradicts this disclosure.

All scientific and technical terms used herein have meanings commonly used in the art unless otherwise specified. The definitions provided herein are to facilitate understanding of certain terms used frequently herein and are not meant to limit the scope of the present disclosure.

Unless otherwise indicated, all numbers expressing feature sizes, amounts, and physical properties used in the specification and claims may be understood as being modified either by the term “exactly” or “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the foregoing specification and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by those skilled in the art utilizing the teachings disclosed herein or, for example, within typical ranges of experimental error.

The recitation of numerical ranges by endpoints includes all numbers subsumed within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5) and any range within that range. Herein, the terms “up to” or “no greater than” a number (e.g., up to 50) includes the number (e.g., 50), and the term “no less than” a number (e.g., no less than 5) includes the number (e.g., 5).

The terms “coupled” or “connected” refer to elements being attached to each other either directly (in direct contact with each other) or indirectly (having one or more elements between and attaching the two elements). Either term may be modified by “operatively” and “operably,” which may be used interchangeably, to describe that the coupling or connection is configured to allow the components to interact to carry out at least some functionality (for example, a first medical device may be operatively coupled to another medical device to transmit information in the form of data or to receive data therefrom).

Terms related to orientation, such as “top,” “bottom,” “side,” and “end,” are used to describe relative positions of components and are not meant to limit the orientation of the embodiments contemplated. For example, an embodiment described as having a “top” and “bottom” also encompasses embodiments thereof rotated in various directions unless the content clearly dictates otherwise.

Reference to “one embodiment,” “an embodiment,” “certain embodiments,” or “some embodiments,” etc., means that a particular feature, configuration, composition, or characteristic described in connection with the embodiment is included in at least one embodiment of the disclosure. Thus, the appearances of such phrases in various places throughout are not necessarily referring to the same embodiment of the disclosure. Furthermore, the particular features, configurations, compositions, or characteristics may be combined in any suitable manner in one or more embodiments.

As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” encompass embodiments having plural referents, unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.

As used herein, “have,” “having,” “include,” “including,” “comprise,” “comprising” or the like are used in their open-ended sense, and generally mean “including, but not limited to.” It will be understood that “consisting essentially of,” “consisting of,” and the like are subsumed in “comprising,” and the like.

The term “and/or” means one or all the listed elements or a combination of at least two of the listed elements. The phrases “at least one of,” “comprises at least one of,” and “one or more of” followed by a list refers to any one of the items in the list and any combination of two or more items in the list.

ILLUSTRATIVE EMBODIMENTS
Embodiment 1

A system comprising:

electrode apparatus comprising a plurality of electrodes to monitor electrical activity from tissue of a patient; and

computing apparatus comprising processing circuitry and coupled to the electrode apparatus and configured to:

- monitor electrical activity of the patient's heart using one or more electrodes of the plurality of electrodes during delivery of ventricle from atrium (VfA) pacing therapy at a plurality of diagnostic A-V delays, wherein each of the plurality of diagnostic A-V delays are less than the patient's intrinsic A-V delay; and
- determine whether the VfA pacing therapy has captured the cardiac conduction system based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delays.

Embodiment 2

A method comprising:

monitoring electrical activity of the patient's heart using one or more electrodes of a plurality of electrodes during delivery of ventricle from atrium (VfA) pacing therapy at a plurality of diagnostic A-V delays, wherein each of the plurality of diagnostic A-V delays are less than the patient's intrinsic A-V delay; and

determining whether the VfA pacing therapy has captured the cardiac conduction system based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delays.

Embodiment 3

An implantable medical device comprising:

a plurality of electrodes comprising:

- a right atrial electrode positionable within the right atrium to deliver cardiac therapy to, or sense electrical activity of, the right atrium of a patient's heart, and
- a tissue-piercing electrode implantable through the right atrial endocardium and central fibrous body to deliver cardiac therapy to, or sense electrical activity of, the left ventricle of a patient's heart;

a therapy delivery circuit operably coupled to the plurality of electrodes to deliver cardiac therapy to the patient's heart;

a sensing circuit operably coupled to the plurality of electrodes to sense electrical activity of the patient's heart; and

a controller comprising processing circuitry operably coupled to the therapy delivery circuit and the sensing circuit, the controller configured to:

- deliver ventricle from atrium (VfA) pacing therapy using at least the tissue-piercing electrode at a plurality of diagnostic A-V delays, wherein each of the plurality of diagnostic A-V delays are less than the patient's intrinsic A-V delay;
- monitor electrical activity of the patient's heart using one or more electrodes of the plurality of electrodes during delivery of VfA pacing therapy at the plurality of diagnostic A-V delays; and
- determine whether the VfA pacing therapy has captured the cardiac conduction system based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delays.

Embodiment 4

The system, method, or device as set forth in any of embodiments 1-3, wherein the system further comprises a VfA pacing therapy apparatus, wherein the VfA pacing therapy apparatus comprises a tissue-piercing electrode implantable from the triangle of Koch region of the right atrium through the right atrial endocardium and central fibrous body to deliver the VfA pacing therapy to the left ventricle in the basal and/or septal region of the left ventricular myocardium of the patient's heart.

Embodiment 5

The system, method, or device as set forth in any of embodiments 1-4, wherein the longest diagnostic A-V delay of the plurality of diagnostic A-V delays is less than or equal to 70% of the patient's intrinsic A-V delay.

Embodiment 6

The system or method as set forth in any of embodiments 1-2 and 4-5, wherein the plurality of electrodes comprises a plurality of surface electrodes positioned in an array configured to be located proximate skin of a torso of the patient.

Embodiment 7

The system or method or device as set forth in any of embodiments 1-2 and 4-6, wherein the computing apparatus is further configured to execute or the method further comprises generating electrical heterogeneity information (EHI) based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delays, wherein determining whether the VfA pacing therapy has captured the cardiac conduction system based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delays comprises determining whether the VfA pacing therapy has captured the cardiac conduction system based on the EHI.

Embodiment 8

The system or method as set forth in any of embodiment 7, wherein delivery of VfA pacing therapy at a plurality of diagnostic A-V delays comprises decreasing the diagnostic A-V delay over time, and wherein determining whether the VfA pacing therapy has captured the cardiac conduction system based on the EHI comprises determining that the VfA pacing therapy has not captured the cardiac conduction system if the EHI changes as the A-V delay decreases.

Embodiment 9

The system or method as set forth in any of embodiments 1-2 and 4-8, wherein the plurality of electrodes comprises one or more implantable electrodes.

Embodiment 10

The system, method, or device as set forth in any of embodiments 1-9, wherein delivery of VfA pacing therapy at a plurality of diagnostic A-V delays comprises decreasing the diagnostic A-V delay over time, and

wherein determining whether the VfA pacing therapy has captured the cardiac conduction system based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delays comprises determining that the VfA pacing therapy has not captured the cardiac conduction system if one or both of cardiac signal morphology and duration of the monitored electrical activity changes as the present A-V delay decreases.

Embodiment 11

The system, method, or device as set forth in any of embodiments 1-10, wherein the computing apparatus is further configured to determine A-V block based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delays.

Embodiment 12

The system, method, or device as set forth in embodiment 11, wherein determining A-V block based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delays determining AV block if:

one or all of dyssynchrony, cardiac signal morphology, and cardiac signal duration of the monitored electrical activity remains consistent as the present A-V delay decreases; and one or all of dyssynchrony, cardiac signal morphology, and cardiac signal duration of the monitored electrical activity are above a selected A-V block threshold.

This disclosure has been provided with reference to illustrative embodiments and is not meant to be construed in a limiting sense. As described previously, one skilled in the art will recognize that other various illustrative applications may use the techniques as described herein to take advantage of the beneficial characteristics of the apparatus and methods described herein. Various modifications of the illustrative embodiments, as well as additional embodiments of the disclosure, will be apparent upon reference to this description.

Claims

1. A system comprising: electrode apparatus comprising a plurality of electrodes to monitor electrical activity from tissue of a patient; andcomputing apparatus comprising processing circuitry and coupled to the electrode apparatus and configured to: receive a patient's intrinsic A-V delay value;monitor electrical activity of the patient's heart using one or more electrodes of the plurality of electrodes during delivery of ventricle from atrium (VfA) pacing therapy at a plurality of diagnostic A-V delay values, wherein VfA pacing therapy comprises delivery of pacing therapy to at least the left ventricle of the patient's heart from one or more VfA electrodes implanted through the right atrial endocardium and central fibrous body of the patient's heart, and wherein each of the plurality of diagnostic A-V delay values are less than the patient's intrinsic A-V delay value; anddetermine whether the VfA pacing therapy has successfully captured the cardiac conduction system based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delay values.
2. The system of claim 1, wherein the system further comprises a VfA pacing therapy apparatus, wherein the VfA pacing therapy apparatus comprises a tissue-piercing electrode implantable from the triangle of Koch region of the right atrium through the right atrial endocardium and central fibrous body to deliver the VfA pacing therapy to the left ventricle in the basal and/or septal region of the left ventricular myocardium of the patient's heart.
3. The system of claim 1, wherein the longest diagnostic A-V delay value of the plurality of diagnostic A-V delay values is less than or equal to 70% of the patient's intrinsic A-V delay value.
4. The system of claim 1, wherein the plurality of electrodes comprises a plurality of surface electrodes positioned in an array configured to be located proximate skin of a torso of the patient.
5. The system of claim 1, wherein the computing apparatus is further configured to generate electrical heterogeneity information (EHI) based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delay values, wherein EHI is indicative of at least one of mechanical synchrony or dyssynchrony of the heart and/or electrical synchrony or dyssynchrony of the heart, wherein determining whether the VfA pacing therapy has successfully captured the cardiac conduction system based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delay values comprises determining whether the VfA pacing therapy has successfully captured the cardiac conduction system based on the EHI.
6. The system of claim 5, wherein delivery of VfA pacing therapy at a plurality of diagnostic A-V delay values comprises decreasing the diagnostic A-V delay value over time, and wherein determining whether the VfA pacing therapy has successfully captured the cardiac conduction system based on the EHI comprises determining that the VfA pacing therapy has not captured the cardiac conduction system if the EHI changes as the A-V delay value decreases.
7. The system of claim 1, wherein the plurality of electrodes comprises one or more implantable electrodes.
8. The system of claim 1, wherein delivery of VfA pacing therapy at a plurality of diagnostic A-V delay values comprises decreasing the diagnostic A-V delay value over time, and wherein determining whether the VfA pacing therapy has successfully captured the cardiac conduction system based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delay values comprises determining that the VfA pacing therapy has not captured the cardiac conduction system if one or both of cardiac signal morphology and duration of the monitored electrical activity changes as the presently applied diagnostic A-V delay value decreases.
9. The system of claim 1, wherein the computing apparatus is further configured to determine A-V block based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delay values.
10. The system of claim 9, wherein determining A-V block based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delay values determining AV block if: one or all of dyssynchrony, cardiac signal morphology, and cardiac signal duration of the monitored electrical activity remains consistent as the presently applied diagnostic A-V delay value decreases; andone or all of a dyssynchrony metric, a cardiac signal morphology metric, and cardiac signal duration of the monitored electrical activity are above a selected A-V block threshold.
11. A method comprising: receiving a patient's intrinsic A-V delay value;monitoring electrical activity of the patient's heart using one or more electrodes of a plurality of electrodes during delivery of ventricle from atrium (VfA) pacing therapy at a plurality of diagnostic A-V delay values, wherein VfA pacing therapy comprises delivery of pacing therapy to at least the left ventricle of the patient's heart from one or more VfA electrodes implanted through the right atrial endocardium and central fibrous body of the patient's heart, and wherein each of the plurality of diagnostic A-V delay values are less than the patient's intrinsic A-V delay value; anddetermining whether the VfA pacing therapy has successfully captured the cardiac conduction system based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delay values.
12. The method of claim 11, wherein the delivery of the VfA pacing therapy is performed by a VfA pacing therapy apparatus, wherein the VfA pacing therapy apparatus comprises a tissue-piercing electrode implantable from the triangle of Koch region of the right atrium through the right atrial endocardium and central fibrous body to deliver the VfA pacing therapy to the left ventricle in the basal and/or septal region of the left ventricular myocardium of the patient.
13. The method of claim 11, wherein the longest diagnostic A-V delay value of the plurality of diagnostic A-V delay values is less than or equal to 70% of the patient's intrinsic A-V delay value.
14. The method of claim 11, wherein the plurality of electrodes comprises a plurality of surface electrodes positioned in an array configured to be located proximate skin of a torso of the patient.
15. The method of claim 11, further comprising generating electrical heterogeneity information (EHI) based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delay values, wherein EHI is indicative of at least one of mechanical synchrony or dyssynchrony of the heart and/or electrical synchrony or dyssynchrony of the heart, wherein determining whether the VfA pacing therapy has successfully captured the cardiac conduction system based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delay values comprises determining whether the VfA pacing therapy has successfully captured the cardiac conduction system based on the EHI.
16. The method of claim 15, wherein delivery of VfA pacing therapy at a plurality of diagnostic A-V delay values comprises decreasing the diagnostic A-V delay value over time, and wherein determining whether the VfA pacing therapy has successfully captured the cardiac conduction system based on the EHI comprises determining that the VfA pacing therapy has not captured the cardiac conduction system if the EHI changes as the A-V delay value decreases.
17. The method of claim 11, wherein the plurality of electrodes comprises one or more implantable electrodes.
18. The method of claim 11, wherein delivery of VfA pacing therapy at a plurality of diagnostic A-V delay values comprises decreasing the diagnostic A-V delay value over time, and wherein determining whether the VfA pacing therapy has successfully captured the cardiac conduction system based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delay values comprises determining that the VfA pacing therapy has not captured the cardiac conduction system if one or both of cardiac signal morphology and duration of the monitored electrical activity changes as the presently applied diagnostic A-V delay value decreases.
19. The method of claim 11, further comprising determining A-V block based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delay values.
20. An implantable medical device comprising: a plurality of electrodes comprising: a right atrial electrode positionable within the right atrium of a patient's heart to deliver cardiac therapy to, or sense electrical activity of, the right atrium of the patient's heart, anda tissue-piercing electrode implantable through the right atrial endocardium and central fibrous body of the patient's heart to deliver cardiac therapy to, or sense electrical activity of, the left ventricle of the patient's heart;a therapy delivery circuit operably coupled to the plurality of electrodes to deliver cardiac therapy to the patient's heart;a sensing circuit operably coupled to the plurality of electrodes to sense electrical activity of the patient's heart; anda controller comprising processing circuitry operably coupled to the therapy delivery circuit and the sensing circuit, the controller configured to: monitor a patient's intrinsic A-V delay value using the plurality of electrodes;deliver ventricle from atrium (VfA) pacing therapy using at least the tissue-piercing electrode at a plurality of diagnostic A-V delay values, wherein each of the plurality of diagnostic A-V delay values are less than the patient's intrinsic A-V delay value;monitor electrical activity of the patient's heart using one or more electrodes of the plurality of electrodes during delivery of VfA pacing therapy at the plurality of diagnostic A-V delay values; anddetermine whether the VfA pacing therapy has successfully captured the cardiac conduction system based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delay values.
21. The device of claim 20, wherein the longest diagnostic A-V delay value of the plurality of diagnostic A-V delay values is less than or equal to 70% of the patient's intrinsic A-V delay value.
22. The device of claim 20, wherein delivering VfA pacing therapy at a plurality of diagnostic A-V delay values comprises decreasing the diagnostic A-V delay value over time, and wherein determining whether the VfA pacing therapy has successfully captured the cardiac conduction system based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delay values comprises determining that the VfA pacing therapy has not captured the cardiac conduction system if one or both of cardiac signal morphology and duration of the monitored electrical activity changes as the presently applied diagnostic A-V delay value decreases.
23. The device of claim 20, wherein the controller is further configured to determine A-V block based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delay values.
24. The device of claim 23, wherein determining A-V block based on the monitored electrical activity during delivery of VfA pacing therapy at the plurality of diagnostic A-V delay values determining AV block if: one or all of dyssynchrony, cardiac signal morphology, and cardiac signal duration of the monitored electrical activity remains consistent as the presently applied diagnostic A-V delay value decreases; andone or all of a dyssynchrony metric, a cardiac signal morphology metric, and cardiac signal duration of the monitored electrical activity are above a selected A-V block threshold.

US Referenced Citations (1677)

Number	Name	Date	Kind
3835864	Rasor et al.	Sep 1974	A
3865118	Bures	Feb 1975	A
3943936	Rasor et al.	Mar 1976	A
3949757	Sabel	Apr 1976	A
4142530	Wittkampf	Mar 1979	A
4151513	Menken et al.	Apr 1979	A
4157720	Greatbatch	Jun 1979	A
RE30366	Rasor et al.	Aug 1980	E
4233987	Feingold	Nov 1980	A
4243045	Mass	Jan 1981	A
4250884	Hartlaub et al.	Feb 1981	A
4256115	Bilitch	Mar 1981	A
4263919	Levin	Apr 1981	A
4280502	Baker, Jr. et al.	Jul 1981	A
4289144	Gilman	Sep 1981	A
4310000	Lindemans	Jan 1982	A
4312354	Walters	Jan 1982	A
4323081	Wiebusch	Apr 1982	A
4332259	McCorkle, Jr.	Jun 1982	A
4357946	Dutcher et al.	Nov 1982	A
4365639	Goldreyer	Dec 1982	A
4374382	Markowitz et al.	Feb 1983	A
4393883	Smyth et al.	Jul 1983	A
4402323	White	Sep 1983	A
4428378	Anderson et al.	Jan 1984	A
4440173	Hudziak et al.	Apr 1984	A
4476868	Thompson	Oct 1984	A
4479500	Smits	Oct 1984	A
4497326	Curry	Feb 1985	A
4522208	Buffet	Jun 1985	A
4537200	Widrow	Aug 1985	A
4546777	Groch et al.	Oct 1985	A
4556063	Thompson et al.	Dec 1985	A
4562841	Brockway et al.	Jan 1986	A
4566456	Koning et al.	Jan 1986	A
4574814	Buffet	Mar 1986	A
4593702	Kepski	Jun 1986	A
4593955	Leiber	Jun 1986	A
4630611	King	Dec 1986	A
4635639	Hakala et al.	Jan 1987	A
4674508	DeCote	Jun 1987	A
4674511	Cartmell	Jun 1987	A
4712554	Garson	Dec 1987	A
4729376	DeCote	Mar 1988	A
4754753	King	Jul 1988	A
4759366	Callaghan	Jul 1988	A
4763660	Kroll et al.	Aug 1988	A
4776338	Lekholm et al.	Oct 1988	A
4777955	Brayten et al.	Oct 1988	A
4787389	Tarjan	Nov 1988	A
4793353	Borkan	Dec 1988	A
4819662	Heil et al.	Apr 1989	A
4830006	Haluska et al.	May 1989	A
4858610	Callaghan et al.	Aug 1989	A
4865037	Chin et al.	Sep 1989	A
4886064	Strandberg	Dec 1989	A
4887609	Cole, Jr.	Dec 1989	A
4928688	Mower	May 1990	A
4953564	Berthelsen	Sep 1990	A
4967746	Vandegriff	Nov 1990	A
4979507	Heinz et al.	Dec 1990	A
4987897	Funke	Jan 1991	A
4989602	Sholder et al.	Feb 1991	A
5012806	De Bellis	May 1991	A
5036849	Hauck et al.	Aug 1991	A
5040534	Mann et al.	Aug 1991	A
5052388	Sivula et al.	Oct 1991	A
5054496	Wen et al.	Oct 1991	A
5058581	Silvian	Oct 1991	A
5078134	Heilman et al.	Jan 1992	A
5107850	Olive	Apr 1992	A
5109845	Yuuchi et al.	May 1992	A
5113859	Funke	May 1992	A
5113869	Nappholz et al.	May 1992	A
5117824	Keimel et al.	Jun 1992	A
5127401	Grievous et al.	Jul 1992	A
5133353	Hauser	Jul 1992	A
5144950	Stoop et al.	Sep 1992	A
5154170	Bennett et al.	Oct 1992	A
5170784	Ramon et al.	Dec 1992	A
5174289	Cohen	Dec 1992	A
5179945	Van Hofwegen et al.	Jan 1993	A
5193539	Schulman et al.	Mar 1993	A
5193540	Schulman et al.	Mar 1993	A
5241961	Henry	Sep 1993	A
5243977	Trabucco et al.	Sep 1993	A
5255692	Neubauer et al.	Oct 1993	A
5259387	dePinto	Nov 1993	A
5269326	Verrier	Dec 1993	A
5284136	Hauck et al.	Feb 1994	A
5300107	Stokes et al.	Apr 1994	A
5301677	Hsung	Apr 1994	A
5305760	McKown et al.	Apr 1994	A
5311873	Savard et al.	May 1994	A
5312439	Loeb	May 1994	A
5313953	Yomtov et al.	May 1994	A
5314459	Swanson et al.	May 1994	A
5318594	Limousin et al.	Jun 1994	A
5318597	Hauck et al.	Jun 1994	A
5324316	Schulman et al.	Jun 1994	A
5331960	Lavine	Jul 1994	A
5331966	Bennett et al.	Jul 1994	A
5334220	Sholder	Aug 1994	A
5334222	Salo et al.	Aug 1994	A
5342408	Decoriolis et al.	Aug 1994	A
5370667	Alt	Dec 1994	A
5372606	Lang et al.	Dec 1994	A
5376106	Stahmann et al.	Dec 1994	A
5383915	Adams	Jan 1995	A
5388578	Yomtov et al.	Feb 1995	A
5404877	Nolan et al.	Apr 1995	A
5405367	Schulman et al.	Apr 1995	A
5411031	Yomtov	May 1995	A
5411525	Swanson et al.	May 1995	A
5411535	Fujii et al.	May 1995	A
5443492	Stokes et al.	Aug 1995	A
5456691	Snell	Oct 1995	A
5458622	Alt	Oct 1995	A
5466246	Silvian	Nov 1995	A
5468254	Hahn et al.	Nov 1995	A
5472453	Alt	Dec 1995	A
5485849	Panescu et al.	Jan 1996	A
5514163	Markowitz et al.	May 1996	A
5522866	Fernald	Jun 1996	A
5540727	Tockman et al.	Jul 1996	A
5545186	Olson et al.	Aug 1996	A
5545202	Dahl et al.	Aug 1996	A
5552645	Weng	Sep 1996	A
5554177	Kieval et al.	Sep 1996	A
5562711	Yerich et al.	Oct 1996	A
5571146	Jones et al.	Nov 1996	A
5591214	Lu	Jan 1997	A
5601615	Markowitz	Feb 1997	A
5620466	Haefner et al.	Apr 1997	A
5628778	Kruse et al.	May 1997	A
5634938	Swanson et al.	Jun 1997	A
5649968	Alt et al.	Jul 1997	A
5662688	Haefner et al.	Sep 1997	A
5671752	Sinderby et al.	Sep 1997	A
5674259	Gray	Oct 1997	A
5683426	Greenhut et al.	Nov 1997	A
5683429	Mehra	Nov 1997	A
5683432	Goedeke et al.	Nov 1997	A
5687737	Branham et al.	Nov 1997	A
5706823	Wodlinger	Jan 1998	A
5709215	Perttu et al.	Jan 1998	A
5720770	Nappholz et al.	Feb 1998	A
5728140	Salo et al.	Mar 1998	A
5728154	Crossett et al.	Mar 1998	A
5741314	Daly et al.	Apr 1998	A
5741315	Lee et al.	Apr 1998	A
5749909	Schroeppel et al.	May 1998	A
5752976	Duffin et al.	May 1998	A
5752977	Grievous et al.	May 1998	A
5755736	Gillberg et al.	May 1998	A
5759199	Snell et al.	Jun 1998	A
5774501	Halpern et al.	Jun 1998	A
5792195	Carlson et al.	Aug 1998	A
5792202	Rueter	Aug 1998	A
5792203	Schroeppel	Aug 1998	A
5792205	Alt et al.	Aug 1998	A
5792208	Gray	Aug 1998	A
5810740	Paisner	Sep 1998	A
5814089	Stokes et al.	Sep 1998	A
5817130	Cox et al.	Oct 1998	A
5827216	Igo et al.	Oct 1998	A
5836985	Goyal et al.	Nov 1998	A
5836987	Baumann et al.	Nov 1998	A
5842977	Lesho et al.	Dec 1998	A
5855593	Olson et al.	Jan 1999	A
5873894	Vandegriff et al.	Feb 1999	A
5876336	Swanson et al.	Mar 1999	A
5891045	Albrecht et al.	Apr 1999	A
5891184	Lee et al.	Apr 1999	A
5897586	Molina	Apr 1999	A
5899876	Flower	May 1999	A
5899928	Sholder et al.	May 1999	A
5919214	Ciciarelli et al.	Jul 1999	A
5922014	Warman et al.	Jul 1999	A
5928271	Hess et al.	Jul 1999	A
5935078	Feierbach	Aug 1999	A
5941906	Barreras et al.	Aug 1999	A
5944744	Paul et al.	Aug 1999	A
5954757	Gray	Sep 1999	A
5978713	Prutchi et al.	Nov 1999	A
5991660	Goyal	Nov 1999	A
5991661	Park et al.	Nov 1999	A
5999848	Gord et al.	Dec 1999	A
5999857	Weijand et al.	Dec 1999	A
6016445	Baura	Jan 2000	A
6026320	Carlson et al.	Feb 2000	A
6029085	Olson et al.	Feb 2000	A
6041250	dePinto	Mar 2000	A
6044298	Salo et al.	Mar 2000	A
6044300	Gray	Mar 2000	A
6055448	Anderson et al.	Apr 2000	A
6055454	Heemels	Apr 2000	A
6073050	Griffith	Jun 2000	A
6076016	Feierbach	Jun 2000	A
6077236	Cunningham	Jun 2000	A
6080187	Alt et al.	Jun 2000	A
6083248	Thompson	Jul 2000	A
6106551	Crossett et al.	Aug 2000	A
6115636	Ryan	Sep 2000	A
6128526	Stadler et al.	Oct 2000	A
6128535	Maarse et al.	Oct 2000	A
6132456	Sommer et al.	Oct 2000	A
6141581	Olson et al.	Oct 2000	A
6141588	Cox et al.	Oct 2000	A
6141592	Pauly	Oct 2000	A
6144879	Gray	Nov 2000	A
6162195	Igo et al.	Dec 2000	A
6164284	Schulman et al.	Dec 2000	A
6167310	Grevious	Dec 2000	A
6187032	Ohyu et al.	Feb 2001	B1
6201993	Kruse et al.	Mar 2001	B1
6205357	Ideker et al.	Mar 2001	B1
6208894	Schulman et al.	Mar 2001	B1
6211799	Post et al.	Apr 2001	B1
6221011	Bardy	Apr 2001	B1
6226542	Reisfeld	May 2001	B1
6236883	Ciaccio et al.	May 2001	B1
6240316	Richmond et al.	May 2001	B1
6240317	Villaseca et al.	May 2001	B1
6243603	Ideker et al.	Jun 2001	B1
6246898	Vesely et al.	Jun 2001	B1
6256534	Dahl	Jul 2001	B1
6259947	Olson et al.	Jul 2001	B1
6266558	Gozani et al.	Jul 2001	B1
6266567	Ishikawa et al.	Jul 2001	B1
6270457	Bardy	Aug 2001	B1
6272377	Sweeney et al.	Aug 2001	B1
6273856	Sun et al.	Aug 2001	B1
6277072	Bardy	Aug 2001	B1
6280380	Bardy	Aug 2001	B1
6285903	Rosenthal et al.	Sep 2001	B1
6285907	Kramer et al.	Sep 2001	B1
6285908	Mann	Sep 2001	B1
6292698	Duffin et al.	Sep 2001	B1
6295473	Rosar	Sep 2001	B1
6297943	Carson	Oct 2001	B1
6298271	Weijand	Oct 2001	B1
6301496	Reisfeld	Oct 2001	B1
6307751	Bodony et al.	Oct 2001	B1
6311089	Mann et al.	Oct 2001	B1
6312378	Bardy	Nov 2001	B1
6315721	Schulman et al.	Nov 2001	B2
6330476	Ben-Haim et al.	Dec 2001	B1
6336903	Bardy	Jan 2002	B1
6345202	Richmond et al.	Feb 2002	B2
6351667	Godie	Feb 2002	B1
6351669	Hartley et al.	Feb 2002	B1
6353759	Hartley et al.	Mar 2002	B1
6358203	Bardy	Mar 2002	B2
6358214	Tereschouk	Mar 2002	B1
6361780	Ley et al.	Mar 2002	B1
6368284	Bardy	Apr 2002	B1
6371922	Baumann et al.	Apr 2002	B1
6377856	Carson	Apr 2002	B1
6381493	Stadler et al.	Apr 2002	B1
6393316	Gillberg et al.	May 2002	B1
6398728	Bardy	Jun 2002	B1
6400982	Sweeney et al.	Jun 2002	B2
6400990	Silvian	Jun 2002	B1
6408208	Sun	Jun 2002	B1
6409674	Brockway et al.	Jun 2002	B1
6411848	Kramer et al.	Jun 2002	B2
6418346	Nelson et al.	Jul 2002	B1
6424865	Ding	Jul 2002	B1
6434429	Kraus et al.	Aug 2002	B1
6438410	Hsu et al.	Aug 2002	B2
6438417	Rockwell et al.	Aug 2002	B1
6438421	Stahmann et al.	Aug 2002	B1
6440066	Bardy	Aug 2002	B1
6441747	Khair et al.	Aug 2002	B1
6442426	Kroll	Aug 2002	B1
6442432	Lee	Aug 2002	B2
6442433	Linberg	Aug 2002	B1
6443891	Grevious	Sep 2002	B1
6445953	Bulkes et al.	Sep 2002	B1
6453200	Koslar	Sep 2002	B1
6456867	Reisfeld	Sep 2002	B2
6459929	Hopper et al.	Oct 2002	B1
6470215	Kraus et al.	Oct 2002	B1
6471645	Warkentin et al.	Oct 2002	B1
6473638	Ferek-Petric	Oct 2002	B2
6480745	Nelson et al.	Nov 2002	B2
6484118	Govari	Nov 2002	B1
6487443	Olson et al.	Nov 2002	B2
6490487	Kraus et al.	Dec 2002	B1
6498951	Larson et al.	Dec 2002	B1
6507755	Gozani et al.	Jan 2003	B1
6507756	Heynen et al.	Jan 2003	B1
6507759	Prutchi et al.	Jan 2003	B1
6508771	Padmanabhan et al.	Jan 2003	B1
6512940	Brabec et al.	Jan 2003	B1
6522915	Ceballos et al.	Feb 2003	B1
6526311	Begemann	Feb 2003	B2
6532379	Stratbucker	Mar 2003	B2
6539253	Thompson et al.	Mar 2003	B2
6542775	Ding et al.	Apr 2003	B2
6544270	Zhang	Apr 2003	B1
6553258	Stahmann et al.	Apr 2003	B2
6561975	Pool et al.	May 2003	B1
6564807	Schulman et al.	May 2003	B1
6574506	Kramer et al.	Jun 2003	B2
6584343	Ransbury et al.	Jun 2003	B1
6584351	Ekwall	Jun 2003	B1
6584352	Combs et al.	Jun 2003	B2
6597948	Rockwell et al.	Jul 2003	B1
6597951	Kramer et al.	Jul 2003	B2
6599250	Webb et al.	Jul 2003	B2
6622046	Fraley et al.	Sep 2003	B2
6623518	Thompson et al.	Sep 2003	B2
6625482	Panescu et al.	Sep 2003	B1
6628985	Sweeney et al.	Sep 2003	B2
6640136	Helland et al.	Oct 2003	B1
6647292	Bardy et al.	Nov 2003	B1
6650927	Keidar	Nov 2003	B1
6666844	Igo et al.	Dec 2003	B1
6689117	Sweeney et al.	Feb 2004	B2
6690959	Thompson	Feb 2004	B2
6694189	Begemann	Feb 2004	B2
6704602	Berg et al.	Mar 2004	B2
6718212	Parry et al.	Apr 2004	B2
6721597	Bardy et al.	Apr 2004	B1
6738670	Almendinger et al.	May 2004	B1
6746797	Benson et al.	Jun 2004	B2
6749566	Russ	Jun 2004	B2
6754528	Bardy et al.	Jun 2004	B2
6758810	Lebel et al.	Jul 2004	B2
6763269	Cox	Jul 2004	B2
6766189	Yu et al.	Jul 2004	B2
6772004	Rudy	Aug 2004	B2
6778860	Ostroff et al.	Aug 2004	B2
6788971	Sloman et al.	Sep 2004	B1
6788974	Bardy et al.	Sep 2004	B2
6804555	Warkentin	Oct 2004	B2
6804558	Haller et al.	Oct 2004	B2
6807442	Myklebust et al.	Oct 2004	B1
6847836	Sujdak	Jan 2005	B1
6847844	Sun et al.	Jan 2005	B2
6856830	He	Feb 2005	B2
6869404	Schulhauser et al.	Mar 2005	B2
6871095	Stahmann et al.	Mar 2005	B2
6871096	Hill	Mar 2005	B2
6878112	Linberg et al.	Apr 2005	B2
6882882	Struble et al.	Apr 2005	B2
6885889	Chinchoy	Apr 2005	B2
6892094	Ousdigian et al.	May 2005	B2
6897788	Khair et al.	May 2005	B2
6904315	Panken et al.	Jun 2005	B2
6915149	Ben-Haim	Jul 2005	B2
6922592	Thompson et al.	Jul 2005	B2
6931282	Esler	Aug 2005	B2
6931286	Sigg et al.	Aug 2005	B2
6934585	Schloss et al.	Aug 2005	B1
6941169	Pappu	Sep 2005	B2
6957107	Rogers et al.	Oct 2005	B2
6968237	Doan et al.	Nov 2005	B2
6975900	Rudy et al.	Dec 2005	B2
6978176	Lattouf	Dec 2005	B2
6978184	Marcus et al.	Dec 2005	B1
6980675	Evron et al.	Dec 2005	B2
6985773	Von Arx et al.	Jan 2006	B2
6990375	Kloss et al.	Jan 2006	B2
6993389	Ding et al.	Jan 2006	B2
7001366	Ballard	Feb 2006	B2
7003350	Denker et al.	Feb 2006	B2
7006864	Echt et al.	Feb 2006	B2
7013176	Ding et al.	Mar 2006	B2
7013178	Reinke et al.	Mar 2006	B2
7016719	Rudy et al.	Mar 2006	B2
7027871	Burnes et al.	Apr 2006	B2
7031711	Brown et al.	Apr 2006	B2
7031771	Brown et al.	Apr 2006	B2
7031777	Hine et al.	Apr 2006	B2
7035684	Lee et al.	Apr 2006	B2
7050849	Echt et al.	May 2006	B2
7058443	Struble	Jun 2006	B2
7060031	Webb et al.	Jun 2006	B2
7062315	Koyrakh et al.	Jun 2006	B2
7063693	Guenst	Jun 2006	B2
7082336	Ransbury et al.	Jul 2006	B2
7085606	Flach et al.	Aug 2006	B2
7092758	Sun et al.	Aug 2006	B2
7092759	Nehls et al.	Aug 2006	B2
7110824	Amundson et al.	Sep 2006	B2
7120504	Osypka	Oct 2006	B2
7130681	Gebhardt et al.	Oct 2006	B2
7139613	Reinke et al.	Nov 2006	B2
7142912	Wagner et al.	Nov 2006	B2
7142922	Spinelli et al.	Nov 2006	B2
7146225	Guenst et al.	Dec 2006	B2
7146226	Lau et al.	Dec 2006	B2
7149581	Goedeke	Dec 2006	B2
7149588	Lau et al.	Dec 2006	B2
7158839	Lau	Jan 2007	B2
7162307	Patrias	Jan 2007	B2
7164952	Lau et al.	Jan 2007	B2
7177700	Cox	Feb 2007	B1
7181284	Burnes et al.	Feb 2007	B2
7181505	Haller et al.	Feb 2007	B2
7184830	Echt et al.	Feb 2007	B2
7184835	Kramer et al.	Feb 2007	B2
7186214	Ness	Mar 2007	B2
7191015	Lamson et al.	Mar 2007	B2
7200437	Nabutovsky et al.	Apr 2007	B1
7200439	Zdeblick et al.	Apr 2007	B2
7206423	Feng et al.	Apr 2007	B1
7209785	Kim et al.	Apr 2007	B2
7209790	Thompson et al.	Apr 2007	B2
7211884	Davis et al.	May 2007	B1
7212871	Morgan	May 2007	B1
7215998	Wesselink et al.	May 2007	B2
7226440	Gelfand et al.	Jun 2007	B2
7228183	Sun et al.	Jun 2007	B2
7231248	Kramer et al.	Jun 2007	B2
7231253	Tidemand et al.	Jun 2007	B2
7236821	Cates et al.	Jun 2007	B2
7236829	Farazi et al.	Jun 2007	B1
7238158	Abend	Jul 2007	B2
7254448	Almendinger et al.	Aug 2007	B2
7260436	Kilgore et al.	Aug 2007	B2
7270669	Sra	Sep 2007	B1
7272448	Morgan et al.	Sep 2007	B1
7277755	Falkenberg et al.	Oct 2007	B1
7280872	Mosesov et al.	Oct 2007	B1
7286866	Okerlund et al.	Oct 2007	B2
7288096	Chin	Oct 2007	B2
7289847	Gill et al.	Oct 2007	B1
7289852	Helfinstine et al.	Oct 2007	B2
7289853	Campbell et al.	Oct 2007	B1
7289855	Nghiem et al.	Oct 2007	B2
7302294	Kamath et al.	Nov 2007	B2
7305266	Kroll	Dec 2007	B1
7307321	Avanzino	Dec 2007	B1
7308297	Reddy et al.	Dec 2007	B2
7308299	Burrell et al.	Dec 2007	B2
7310556	Bulkes	Dec 2007	B2
7313444	Pianca et al.	Dec 2007	B2
7317950	Lee	Jan 2008	B2
7319905	Morgan et al.	Jan 2008	B1
7321677	Evron et al.	Jan 2008	B2
7321798	Muhlenberg et al.	Jan 2008	B2
7333853	Mazar et al.	Feb 2008	B2
7336994	Hettrick et al.	Feb 2008	B2
7346381	Okerlund et al.	Mar 2008	B2
7346393	Spinelli et al.	Mar 2008	B2
7347819	Lebel et al.	Mar 2008	B2
7366572	Heruth et al.	Apr 2008	B2
7373207	Lattouf	May 2008	B2
7384403	Sherman	Jun 2008	B2
7386342	Falkenberg et al.	Jun 2008	B1
7392090	Sweeney et al.	Jun 2008	B2
7398116	Edwards	Jul 2008	B2
7406105	DelMain et al.	Jul 2008	B2
7406349	Seeberger et al.	Jul 2008	B2
7410497	Hastings et al.	Aug 2008	B2
7425200	Brockway et al.	Sep 2008	B2
7426412	Schecter	Sep 2008	B1
7433739	Salys et al.	Oct 2008	B1
7454248	Burrell et al.	Nov 2008	B2
7496409	Greenhut et al.	Feb 2009	B2
7496410	Heil	Feb 2009	B2
7499743	Vass et al.	Mar 2009	B2
7502652	Gaunt et al.	Mar 2009	B2
7509170	Zhang et al.	Mar 2009	B2
7512448	Malick et al.	Mar 2009	B2
7515969	Tockman et al.	Apr 2009	B2
7526342	Chin et al.	Apr 2009	B2
7529589	Williams et al.	May 2009	B2
7532933	Hastings et al.	May 2009	B2
7536222	Bardy et al.	May 2009	B2
7536224	Ritscher et al.	May 2009	B2
7539541	Quiles et al.	May 2009	B2
7544197	Kelsch et al.	Jun 2009	B2
7546166	Michels et al.	Jun 2009	B2
7558626	Corbucci	Jul 2009	B2
7558631	Cowan et al.	Jul 2009	B2
7565190	Okerlund et al.	Jul 2009	B2
7565195	Kroll et al.	Jul 2009	B1
7584002	Burnes et al.	Sep 2009	B2
7587074	Zarkh et al.	Sep 2009	B2
7590455	Heruth et al.	Sep 2009	B2
7599730	Hunter et al.	Oct 2009	B2
7606621	Brisken et al.	Oct 2009	B2
7610088	Chinchoy	Oct 2009	B2
7610092	Cowan et al.	Oct 2009	B2
7610099	Almendinger et al.	Oct 2009	B2
7610104	Kaplan et al.	Oct 2009	B2
7613500	Vass et al.	Nov 2009	B2
7616991	Mann et al.	Nov 2009	B2
7616993	Müssig et al.	Nov 2009	B2
7617001	Penner et al.	Nov 2009	B2
7617007	Williams et al.	Nov 2009	B2
7630764	Ding et al.	Dec 2009	B2
7630767	Poore et al.	Dec 2009	B1
7634313	Kroll et al.	Dec 2009	B1
7635541	Scott et al.	Dec 2009	B2
7637867	Zdeblick	Dec 2009	B2
7640057	Libbus et al.	Dec 2009	B2
7640060	Zdeblick	Dec 2009	B2
7647109	Hastings et al.	Jan 2010	B2
7650186	Hastings et al.	Jan 2010	B2
7657311	Bardy et al.	Feb 2010	B2
7657313	Rom	Feb 2010	B2
7664550	Eick et al.	Feb 2010	B2
7668596	Von Arx et al.	Feb 2010	B2
7682316	Anderson et al.	Mar 2010	B2
7684863	Parikh et al.	Mar 2010	B2
7691047	Ferrari	Apr 2010	B2
7702392	Echt et al.	Apr 2010	B2
7706879	Burnes et al.	Apr 2010	B2
7713194	Zdeblick	May 2010	B2
7713195	Zdeblick	May 2010	B2
7729783	Michels et al.	Jun 2010	B2
7734333	Ghanem et al.	Jun 2010	B2
7734343	Ransbury et al.	Jun 2010	B2
7738958	Zdeblick et al.	Jun 2010	B2
7738964	Von Arx et al.	Jun 2010	B2
7742629	Zarkh et al.	Jun 2010	B2
7742812	Ghanem et al.	Jun 2010	B2
7742816	Masoud et al.	Jun 2010	B2
7742822	Masoud et al.	Jun 2010	B2
7743151	Vallapureddy et al.	Jun 2010	B2
7747047	Okerlund et al.	Jun 2010	B2
7747335	Williams	Jun 2010	B2
7751881	Cowan et al.	Jul 2010	B2
7751882	Helland et al.	Jul 2010	B1
7758521	Morris et al.	Jul 2010	B2
7761150	Ghanem et al.	Jul 2010	B2
7761164	Verhoef et al.	Jul 2010	B2
7765001	Echt et al.	Jul 2010	B2
7769451	Yang et al.	Aug 2010	B2
7769452	Ghanem et al.	Aug 2010	B2
7778685	Evron et al.	Aug 2010	B2
7778686	Vass et al.	Aug 2010	B2
7783362	Whitehurst et al.	Aug 2010	B2
7787951	Min	Aug 2010	B1
7792588	Harding	Sep 2010	B2
7797059	Bornzin et al.	Sep 2010	B1
7801596	Fischell et al.	Sep 2010	B2
7809438	Echt et al.	Oct 2010	B2
7813785	Okerlund et al.	Oct 2010	B2
7818040	Spear et al.	Oct 2010	B2
7840281	Kveen et al.	Nov 2010	B2
7844331	Li et al.	Nov 2010	B2
7844348	Swoyer et al.	Nov 2010	B2
7846088	Ness	Dec 2010	B2
7848807	Wang	Dec 2010	B2
7848815	Brisken et al.	Dec 2010	B2
7848823	Drasler et al.	Dec 2010	B2
7860455	Fukumoto et al.	Dec 2010	B2
7860580	Falk et al.	Dec 2010	B2
7871433	Lattouf	Jan 2011	B2
7877136	Moffitt et al.	Jan 2011	B1
7877142	Moaddeb et al.	Jan 2011	B2
7877144	Coles, Jr. et al.	Jan 2011	B2
7881786	Jackson	Feb 2011	B2
7881791	Sambelashvili et al.	Feb 2011	B2
7881798	Miesel et al.	Feb 2011	B2
7881810	Chitre et al.	Feb 2011	B1
7890173	Brisken et al.	Feb 2011	B2
7890181	Denzene et al.	Feb 2011	B2
7890192	Kelsch et al.	Feb 2011	B1
7894885	Bartal et al.	Feb 2011	B2
7894889	Zhang	Feb 2011	B2
7894894	Stadler et al.	Feb 2011	B2
7894902	Rom	Feb 2011	B2
7894907	Cowan et al.	Feb 2011	B2
7894910	Cowan et al.	Feb 2011	B2
7894915	Chitre et al.	Feb 2011	B1
7899537	Kroll et al.	Mar 2011	B1
7899541	Cowan et al.	Mar 2011	B2
7899542	Cowan et al.	Mar 2011	B2
7899554	Williams et al.	Mar 2011	B2
7901360	Yang et al.	Mar 2011	B1
7904170	Harding	Mar 2011	B2
7907993	Ghanem et al.	Mar 2011	B2
7912544	Min et al.	Mar 2011	B1
7917214	Gill et al.	Mar 2011	B1
7920928	Yang et al.	Apr 2011	B1
7925343	Min et al.	Apr 2011	B1
7930022	Zhang et al.	Apr 2011	B2
7930027	Prakash et al.	Apr 2011	B2
7930040	Kelsch et al.	Apr 2011	B1
7937135	Ghanem et al.	May 2011	B2
7937148	Jacobson	May 2011	B2
7937161	Hastings et al.	May 2011	B2
7941213	Markowitz et al.	May 2011	B2
7941214	Kleckner et al.	May 2011	B2
7941218	Sambelashvili et al.	May 2011	B2
7945333	Jacobson	May 2011	B2
7946997	Hubinette	May 2011	B2
7949404	Hill	May 2011	B2
7949405	Feher	May 2011	B2
7953475	Harlev et al.	May 2011	B2
7953482	Hess	May 2011	B2
7953486	Daum et al.	May 2011	B2
7953493	Fowler et al.	May 2011	B2
7962202	Bhunia	Jun 2011	B2
7974702	Fain et al.	Jul 2011	B1
7979136	Young et al.	Jul 2011	B2
7983743	Rudy et al.	Jul 2011	B2
7983753	Severin	Jul 2011	B2
7991467	Markowitz et al.	Aug 2011	B2
7991471	Ghanem et al.	Aug 2011	B2
7996063	Vass et al.	Aug 2011	B2
7996070	van Dam et al.	Aug 2011	B2
7996087	Cowan et al.	Aug 2011	B2
8000791	Sunagawa et al.	Aug 2011	B2
8000807	Morris et al.	Aug 2011	B2
8001975	DiSilvestro et al.	Aug 2011	B2
8002700	Ferek-Petric et al.	Aug 2011	B2
8002718	Buchholtz et al.	Aug 2011	B2
8010191	Zhu et al.	Aug 2011	B2
8010194	Muller	Aug 2011	B2
8010209	Jacobson	Aug 2011	B2
8014861	Zhu et al.	Sep 2011	B2
8019402	Kryzpow et al.	Sep 2011	B1
8019409	Rosenberg et al.	Sep 2011	B2
8019419	Panescu et al.	Sep 2011	B1
8019434	Quiles et al.	Sep 2011	B2
8027727	Freeberg	Sep 2011	B2
8027729	Sunagawa et al.	Sep 2011	B2
8032219	Neumann et al.	Oct 2011	B2
8032229	Gerber et al.	Oct 2011	B2
8036743	Savage et al.	Oct 2011	B2
8046065	Burnes et al.	Oct 2011	B2
8046079	Bange et al.	Oct 2011	B2
8046080	Von Arx et al.	Oct 2011	B2
8050297	Delmain et al.	Nov 2011	B2
8050759	Stegemann et al.	Nov 2011	B2
8050774	Kveen et al.	Nov 2011	B2
8055345	Li et al.	Nov 2011	B2
8055350	Roberts	Nov 2011	B2
8060185	Hunter et al.	Nov 2011	B2
8060212	Rios et al.	Nov 2011	B1
8065018	Haubrich et al.	Nov 2011	B2
8068920	Gaudiani	Nov 2011	B2
8073542	Doerr	Dec 2011	B2
8078278	Penner	Dec 2011	B2
8078283	Cowan et al.	Dec 2011	B2
8095123	Gray	Jan 2012	B2
8102789	Rosar et al.	Jan 2012	B2
8103359	Reddy	Jan 2012	B2
8103361	Moser	Jan 2012	B2
8105714	Schmidt et al.	Jan 2012	B2
8112148	Giftakis et al.	Feb 2012	B2
8114021	Robertson et al.	Feb 2012	B2
8121680	Falkenberg et al.	Feb 2012	B2
8123684	Zdeblick	Feb 2012	B2
8126545	Flach et al.	Feb 2012	B2
8131334	Lu et al.	Mar 2012	B2
8140161	Willerton et al.	Mar 2012	B2
8145308	Sambelashvili et al.	Mar 2012	B2
8150513	Chinchoy	Apr 2012	B2
8150521	Crowley et al.	Apr 2012	B2
8160672	Kim et al.	Apr 2012	B2
8160700	Ryu et al.	Apr 2012	B1
8160702	Mann et al.	Apr 2012	B2
8160704	Freeberg	Apr 2012	B2
8165694	Carbanaru et al.	Apr 2012	B2
8175703	Dong et al.	May 2012	B2
8175715	Cox	May 2012	B1
8180428	Kaiser et al.	May 2012	B2
8180451	Hickman et al.	May 2012	B2
8185213	Kveen et al.	May 2012	B2
8187161	Li et al.	May 2012	B2
8195292	Rosenberg et al.	Jun 2012	B2
8195293	Limousin et al.	Jun 2012	B2
8204590	Sambelashvili et al.	Jun 2012	B2
8204595	Pianca et al.	Jun 2012	B2
8204605	Hastings et al.	Jun 2012	B2
8209014	Doerr	Jun 2012	B2
8213693	Li	Jul 2012	B1
8214041	Van Gelder et al.	Jul 2012	B2
8214043	Matos	Jul 2012	B2
8224244	Kim et al.	Jul 2012	B2
8229556	Li	Jul 2012	B2
8233985	Bulkes et al.	Jul 2012	B2
8265738	Min et al.	Sep 2012	B1
8265748	Liu et al.	Sep 2012	B2
8265757	Mass et al.	Sep 2012	B2
8262578	Bharmi et al.	Oct 2012	B1
8280521	Haubrich et al.	Oct 2012	B2
8285377	Rosenberg et al.	Oct 2012	B2
8285387	Utsi et al.	Oct 2012	B2
8290598	Boon et al.	Oct 2012	B2
8290600	Hastings et al.	Oct 2012	B2
8295939	Jacobson	Oct 2012	B2
8295943	Eggen et al.	Oct 2012	B2
8301254	Mosesov et al.	Oct 2012	B2
8315701	Cowan et al.	Nov 2012	B2
8315708	Berthelsdorf et al.	Nov 2012	B2
8321014	Maskara et al.	Nov 2012	B2
8321021	Kisker et al.	Nov 2012	B2
8321036	Brockway et al.	Nov 2012	B2
8326419	Rosenberg et al.	Dec 2012	B2
8332030	Hess et al.	Dec 2012	B2
8332036	Hastings et al.	Dec 2012	B2
8335563	Stessman	Dec 2012	B2
8335568	Heruth et al.	Dec 2012	B2
8340750	Prakash et al.	Dec 2012	B2
8340780	Hastings et al.	Dec 2012	B2
8352025	Jacobson	Jan 2013	B2
8352027	Spinelli et al.	Jan 2013	B2
8352028	Wenger	Jan 2013	B2
8352038	Mao et al.	Jan 2013	B2
8359098	Lund et al.	Jan 2013	B2
8364261	Stubbs et al.	Jan 2013	B2
8364276	Willis	Jan 2013	B2
8369959	Meskens	Feb 2013	B2
8369962	Abrahamson	Feb 2013	B2
8380308	Rosenberg et al.	Feb 2013	B2
8380320	Spital	Feb 2013	B2
8383269	Scott et al.	Feb 2013	B2
8386051	Rys	Feb 2013	B2
8391964	Musley et al.	Mar 2013	B2
8391981	Mosesov	Mar 2013	B2
8391990	Smith et al.	Mar 2013	B2
8401616	Verard et al.	Mar 2013	B2
8406874	Liu et al.	Mar 2013	B2
8406879	Shuros et al.	Mar 2013	B2
8406886	Gaunt et al.	Mar 2013	B2
8406899	Reddy et al.	Mar 2013	B2
8412352	Griswold et al.	Apr 2013	B2
8417340	Goossen	Apr 2013	B2
8417341	Freeberg	Apr 2013	B2
8423149	Hennig	Apr 2013	B2
8428716	Mullen et al.	Apr 2013	B2
8428722	Verhoef et al.	Apr 2013	B2
8433402	Ruben et al.	Apr 2013	B2
8433409	Johnson et al.	Apr 2013	B2
8433420	Bange et al.	Apr 2013	B2
8447412	Dal Molin et al.	May 2013	B2
8452413	Young et al.	May 2013	B2
8457740	Osche	Jun 2013	B2
8457742	Jacobson	Jun 2013	B2
8457744	Janzig et al.	Jun 2013	B2
8457761	Wariar	Jun 2013	B2
8467871	Maskara	Jun 2013	B2
8478388	Nguyen et al.	Jul 2013	B2
8478407	Demmer et al.	Jul 2013	B2
8478408	Hastings et al.	Jul 2013	B2
8478431	Griswold et al.	Jul 2013	B2
8494632	Sun et al.	Jul 2013	B2
8504156	Bonner et al.	Aug 2013	B2
8509896	Doerr et al.	Aug 2013	B2
8509910	Sowder et al.	Aug 2013	B2
8509916	Byrd et al.	Aug 2013	B2
8515559	Roberts et al.	Aug 2013	B2
8521268	Zhang et al.	Aug 2013	B2
8525340	Eckhardt et al.	Sep 2013	B2
8527051	Hedberg et al.	Sep 2013	B1
8527068	Ostroff	Sep 2013	B2
8532790	Griswold	Sep 2013	B2
8538526	Stahmann et al.	Sep 2013	B2
8541131	Lund et al.	Sep 2013	B2
8543205	Ostroff	Sep 2013	B2
8547248	Zdeblick et al.	Oct 2013	B2
8548605	Ollivier	Oct 2013	B2
8554333	Wu et al.	Oct 2013	B2
8565882	Matoes	Oct 2013	B2
8565897	Regnier et al.	Oct 2013	B2
8571678	Wang	Oct 2013	B2
8577327	Makdissi et al.	Nov 2013	B2
8583230	Ryu et al.	Nov 2013	B2
8588926	Moore et al.	Nov 2013	B2
8594775	Ghosh et al.	Nov 2013	B2
8612002	Faltys et al.	Dec 2013	B2
8615298	Ghosh et al.	Dec 2013	B2
8615310	Khairkhahan et al.	Dec 2013	B2
8617082	Zhang et al.	Dec 2013	B2
8620433	Ghosh et al.	Dec 2013	B2
8626280	Allavatam et al.	Jan 2014	B2
8626294	Sheldon et al.	Jan 2014	B2
8634908	Cowan	Jan 2014	B2
8634912	Bornzin et al.	Jan 2014	B2
8634919	Hou et al.	Jan 2014	B1
8639333	Stadler et al.	Jan 2014	B2
8639335	Peichel et al.	Jan 2014	B2
8644934	Hastings et al.	Feb 2014	B2
8649859	Smith et al.	Feb 2014	B2
8670842	Bornzin et al.	Mar 2014	B1
8676314	Maskara et al.	Mar 2014	B2
8676319	Knoll	Mar 2014	B2
8676335	Katoozi et al.	Mar 2014	B2
8694099	Ghosh et al.	Apr 2014	B2
8700173	Edlund	Apr 2014	B2
8700181	Bornzin et al.	Apr 2014	B2
8705599	Dal Molin et al.	Apr 2014	B2
8718766	Wahlberg	May 2014	B2
8718773	Willis et al.	May 2014	B2
8725260	Shuros et al.	May 2014	B2
8731642	Zarkh et al.	May 2014	B2
8738132	Ghosh et al.	May 2014	B1
8738133	Shuros et al.	May 2014	B2
8738147	Hastings et al.	May 2014	B2
8744555	Allavatam et al.	Jun 2014	B2
8744572	Greenhut et al.	Jun 2014	B1
8744576	Munsterman et al.	Jun 2014	B2
8747314	Stahmann et al.	Jun 2014	B2
8750994	Ghosh et al.	Jun 2014	B2
8750998	Ghosh et al.	Jun 2014	B1
8755884	Demmer et al.	Jun 2014	B2
8758365	Bonner et al.	Jun 2014	B2
8768459	Ghosh et al.	Jul 2014	B2
8768465	Ghosh et al.	Jul 2014	B2
8768483	Schmitt et al.	Jul 2014	B2
8774572	Hamamoto	Jul 2014	B2
8781605	Bornzin et al.	Jul 2014	B2
8788035	Jacobson	Jul 2014	B2
8788053	Jacobson	Jul 2014	B2
8798740	Samade et al.	Aug 2014	B2
8798745	Jacobson	Aug 2014	B2
8798762	Fain et al.	Aug 2014	B2
8798770	Reddy	Aug 2014	B2
8805504	Sweeney	Aug 2014	B2
8805505	Roberts	Aug 2014	B1
8805528	Corndorf	Aug 2014	B2
8812109	Blomqvist et al.	Aug 2014	B2
8818504	Bodner et al.	Aug 2014	B2
8827913	Havel et al.	Sep 2014	B2
8831747	Min et al.	Sep 2014	B1
8855789	Jacobson	Oct 2014	B2
8861830	Brada et al.	Oct 2014	B2
8868186	Kroll	Oct 2014	B2
8886307	Sambelashvili et al.	Nov 2014	B2
8886311	Anderson et al.	Nov 2014	B2
8886339	Faltys et al.	Nov 2014	B2
8903473	Rogers et al.	Dec 2014	B2
8903513	Ollivier	Dec 2014	B2
8909336	Navarro-Paredes et al.	Dec 2014	B2
8914131	Bornzin et al.	Dec 2014	B2
8923795	Makdissi et al.	Dec 2014	B2
8923963	Bonner et al.	Dec 2014	B2
8938300	Rosero	Jan 2015	B2
8942806	Sheldon et al.	Jan 2015	B2
8948869	Ghosh et al.	Feb 2015	B2
8948883	Eggen et al.	Feb 2015	B2
8958892	Khairkhahan et al.	Feb 2015	B2
8965489	Ghosh	Feb 2015	B2
8972228	Ghosh et al.	Mar 2015	B2
8977358	Ewert et al.	Mar 2015	B2
8989873	Locsin	Mar 2015	B2
8996109	Karst et al.	Mar 2015	B2
9002467	Smith et al.	Apr 2015	B2
9008776	Cowan et al.	Apr 2015	B2
9008777	Dianaty et al.	Apr 2015	B2
9014818	Deterre et al.	Apr 2015	B2
9017341	Bornzin et al.	Apr 2015	B2
9020611	Khairkhahan et al.	Apr 2015	B2
9031642	Ghosh	May 2015	B2
9033996	West	May 2015	B1
9037238	Stadler et al.	May 2015	B2
9037262	Regnier et al.	May 2015	B2
9042984	Demmer et al.	May 2015	B2
9072872	Asleson et al.	Jul 2015	B2
9072911	Hastings et al.	Jul 2015	B2
9072913	Jacobson	Jul 2015	B2
9101281	Reinert et al.	Aug 2015	B2
9119959	Rys et al.	Sep 2015	B2
9155882	Grubac et al.	Oct 2015	B2
9155897	Ghosh et al.	Oct 2015	B2
9168372	Fain	Oct 2015	B2
9168380	Greenhut et al.	Oct 2015	B1
9168383	Jacobson et al.	Oct 2015	B2
9180285	Moore et al.	Nov 2015	B2
9192774	Jacobson	Nov 2015	B2
9199087	Stadler et al.	Dec 2015	B2
9205225	Khairkhahan et al.	Dec 2015	B2
9216285	Boling et al.	Dec 2015	B1
9216293	Berthiaume et al.	Dec 2015	B2
9216298	Jacobson	Dec 2015	B2
9227077	Jacobson	Jan 2016	B2
9238145	Wenzel et al.	Jan 2016	B2
9242102	Khairkhahan et al.	Jan 2016	B2
9242113	Smith et al.	Jan 2016	B2
9248300	Rys et al.	Feb 2016	B2
9265436	Min et al.	Feb 2016	B2
9265951	Sweeney	Feb 2016	B2
9265954	Ghosh	Feb 2016	B2
9265955	Ghosh	Feb 2016	B2
9265962	Dianaty et al.	Feb 2016	B2
9272155	Ostroff	Mar 2016	B2
9278218	Karst et al.	Mar 2016	B2
9278219	Ghosh	Mar 2016	B2
9278220	Ghosh	Mar 2016	B2
9278229	Reinke et al.	Mar 2016	B1
9282907	Ghosh	Mar 2016	B2
9283381	Grubac et al.	Mar 2016	B2
9283382	Berthiaume et al.	Mar 2016	B2
9289612	Sambelashbili et al.	Mar 2016	B1
9302115	Molin et al.	Apr 2016	B2
9320446	Gillberg et al.	Apr 2016	B2
9333364	Echt et al.	May 2016	B2
9358387	Suwito et al.	Jun 2016	B2
9358400	Jacobson	Jun 2016	B2
9364675	Deterre et al.	Jun 2016	B2
9370663	Moulder	Jun 2016	B2
9375580	Bonner et al.	Jun 2016	B2
9375581	Baru et al.	Jun 2016	B2
9381365	Kibler et al.	Jul 2016	B2
9393424	Demmer et al.	Jul 2016	B2
9393436	Doerr	Jul 2016	B2
9399139	Demmer et al.	Jul 2016	B2
9399140	Cho et al.	Jul 2016	B2
9409033	Jacobson	Aug 2016	B2
9427594	Bornzin et al.	Aug 2016	B1
9433368	Stahmann et al.	Sep 2016	B2
9433780	Regnier et al.	Sep 2016	B2
9457193	Klimovitch et al.	Oct 2016	B2
9474457	Ghosh et al.	Oct 2016	B2
9486151	Ghosh et al.	Nov 2016	B2
9492668	Sheldon et al.	Nov 2016	B2
9492669	Demmer et al.	Nov 2016	B2
9492674	Schmidt et al.	Nov 2016	B2
9492677	Greenhut et al.	Nov 2016	B2
9510763	Ghosh et al.	Dec 2016	B2
9511233	Sambelashvili	Dec 2016	B2
9511236	Varady et al.	Dec 2016	B2
9511237	Deterre et al.	Dec 2016	B2
9517336	Eggen et al.	Dec 2016	B2
9522276	Shen et al.	Dec 2016	B2
9522280	Fishler et al.	Dec 2016	B2
9526435	Ghosh	Dec 2016	B2
9526522	Wood et al.	Dec 2016	B2
9526891	Eggen et al.	Dec 2016	B2
9526909	Stahmann et al.	Dec 2016	B2
9533163	Klimovitch et al.	Jan 2017	B2
9561382	Persson et al.	Feb 2017	B2
9566012	Greenhut et al.	Feb 2017	B2
9579500	Rys et al.	Feb 2017	B2
9586050	Ghosh et al.	Mar 2017	B2
9586052	Gillberg et al.	Mar 2017	B2
9591982	Ghosh et al.	Mar 2017	B2
9603651	Ghosh	Mar 2017	B2
9610045	Du et al.	Apr 2017	B2
9623234	Anderson	Apr 2017	B2
9636511	Carney et al.	May 2017	B2
9643014	Zhang et al.	May 2017	B2
9675579	Rock et al.	Jun 2017	B2
9707399	Zielinski et al.	Jul 2017	B2
9724519	Demmer et al.	Aug 2017	B2
9737223	Du et al.	Aug 2017	B2
9750941	Ghosh	Sep 2017	B2
9764143	Ghosh et al.	Sep 2017	B2
9776009	Ghosh et al.	Oct 2017	B2
9782094	Du et al.	Oct 2017	B2
9789319	Sambelashvili	Oct 2017	B2
9808628	Sheldon et al.	Nov 2017	B2
9808633	Bonner et al.	Nov 2017	B2
9877789	Ghosh	Jan 2018	B2
9924884	Ghosh et al.	Mar 2018	B2
9974457	Ghosh et al.	May 2018	B2
10004467	Lahm et al.	Jun 2018	B2
10064567	Ghosh et al.	Sep 2018	B2
10099050	Chen et al.	Oct 2018	B2
10166396	Schrock et al.	Jan 2019	B2
10206601	Gillberg et al.	Feb 2019	B2
10251555	Ghosh et al.	Apr 2019	B2
20020026220	Groenewegen	Feb 2002	A1
20020032470	Linberg	Mar 2002	A1
20020035376	Bardy et al.	Mar 2002	A1
20020035377	Bardy et al.	Mar 2002	A1
20020035378	Bardy et al.	Mar 2002	A1
20020035380	Rissmann et al.	Mar 2002	A1
20020035381	Bardy et al.	Mar 2002	A1
20020042629	Bardy et al.	Apr 2002	A1
20020042630	Bardy et al.	Apr 2002	A1
20020042634	Bardy et al.	Apr 2002	A1
20020049475	Bardy et al.	Apr 2002	A1
20020049476	Bardy et al.	Apr 2002	A1
20020052636	Bardy et al.	May 2002	A1
20020068958	Bardy et al.	Jun 2002	A1
20020072682	Hopman et al.	Jun 2002	A1
20020072773	Bardy et al.	Jun 2002	A1
20020082665	Haller et al.	Jun 2002	A1
20020087089	Ben-Haim	Jul 2002	A1
20020091414	Bardy et al.	Jul 2002	A1
20020095196	Linberg	Jul 2002	A1
20020099423	Berg et al.	Jul 2002	A1
20020103510	Bardy et al.	Aug 2002	A1
20020107545	Rissmann et al.	Aug 2002	A1
20020107546	Ostroff et al.	Aug 2002	A1
20020107547	Erlinger et al.	Aug 2002	A1
20020107548	Bardy et al.	Aug 2002	A1
20020107549	Bardy et al.	Aug 2002	A1
20020107559	Sanders et al.	Aug 2002	A1
20020120299	Ostroff et al.	Aug 2002	A1
20020143264	Ding et al.	Oct 2002	A1
20020161307	Yu et al.	Oct 2002	A1
20020169484	Mathis et al.	Nov 2002	A1
20020173830	Starkweather et al.	Nov 2002	A1
20020193846	Pool et al.	Dec 2002	A1
20030004549	Hill et al.	Jan 2003	A1
20030009203	Lebel et al.	Jan 2003	A1
20030018277	He	Jan 2003	A1
20030028082	Thompson	Feb 2003	A1
20030040779	Engmark et al.	Feb 2003	A1
20030041866	Linberg et al.	Mar 2003	A1
20030045805	Sheldon et al.	Mar 2003	A1
20030050670	Spinelli et al.	Mar 2003	A1
20030088278	Bardy et al.	May 2003	A1
20030092995	Thompson	May 2003	A1
20030097153	Bardy et al.	May 2003	A1
20030105495	Yu et al.	Jun 2003	A1
20030105497	Zhu et al.	Jun 2003	A1
20030114908	Flach	Jun 2003	A1
20030144701	Mehra et al.	Jul 2003	A1
20030187460	Chin et al.	Oct 2003	A1
20030187461	Chin	Oct 2003	A1
20030236466	Tarjan et al.	Dec 2003	A1
20040015081	Kramer et al.	Jan 2004	A1
20040024435	Leckrone et al.	Feb 2004	A1
20040059237	Narayan et al.	Mar 2004	A1
20040064158	Klein et al.	Apr 2004	A1
20040068302	Rodgers et al.	Apr 2004	A1
20040087938	Leckrone et al.	May 2004	A1
20040088035	Guenst et al.	May 2004	A1
20040097806	Hunter et al.	May 2004	A1
20040102812	Yonce et al.	May 2004	A1
20040102830	Williams	May 2004	A1
20040122479	Spinelli et al.	Jun 2004	A1
20040127959	Amundson et al.	Jul 2004	A1
20040133242	Chapman et al.	Jul 2004	A1
20040147969	Mann et al.	Jul 2004	A1
20040147973	Hauser	Jul 2004	A1
20040162496	Yu et al.	Aug 2004	A1
20040167558	Igo et al.	Aug 2004	A1
20040167587	Thompson	Aug 2004	A1
20040172071	Bardy et al.	Sep 2004	A1
20040172077	Chinchoy	Sep 2004	A1
20040172078	Chinchoy	Sep 2004	A1
20040172079	Chinchoy	Sep 2004	A1
20040172104	Berg et al.	Sep 2004	A1
20040176817	Wahlstrand et al.	Sep 2004	A1
20040176818	Wahlstrand et al.	Sep 2004	A1
20040176830	Fang	Sep 2004	A1
20040186529	Bardy et al.	Sep 2004	A1
20040193223	Kramer et al.	Sep 2004	A1
20040204673	Flaherty	Oct 2004	A1
20040210292	Bardy et al.	Oct 2004	A1
20040210293	Bardy et al.	Oct 2004	A1
20040210294	Bardy et al.	Oct 2004	A1
20040215245	Stahmann et al.	Oct 2004	A1
20040215252	Verbeek et al.	Oct 2004	A1
20040215308	Bardy et al.	Oct 2004	A1
20040220624	Ritscher et al.	Nov 2004	A1
20040220626	Wagner	Nov 2004	A1
20040220635	Burnes	Nov 2004	A1
20040220639	Mulligan et al.	Nov 2004	A1
20040230283	Prinzen et al.	Dec 2004	A1
20040249431	Ransbury et al.	Dec 2004	A1
20040260348	Bakken et al.	Dec 2004	A1
20040267303	Guenst	Dec 2004	A1
20040267321	Boileau et al.	Dec 2004	A1
20050008210	Evron et al.	Jan 2005	A1
20050027320	Nehls et al.	Feb 2005	A1
20050038477	Kramer et al.	Feb 2005	A1
20050061320	Lee et al.	Mar 2005	A1
20050070962	Echt et al.	Mar 2005	A1
20050090870	Hine et al.	Apr 2005	A1
20050096522	Reddy et al.	May 2005	A1
20050102003	Grabek et al.	May 2005	A1
20050107839	Sanders	May 2005	A1
20050137629	Dyjach et al.	Jun 2005	A1
20050137671	Liu et al.	Jun 2005	A1
20050149138	Min et al.	Jul 2005	A1
20050165466	Morris et al.	Jul 2005	A1
20050182465	Ness	Aug 2005	A1
20050203410	Jenkins	Sep 2005	A1
20050277990	Ostroff et al.	Dec 2005	A1
20050283208	Von Arx et al.	Dec 2005	A1
20050288743	Ahn et al.	Dec 2005	A1
20060042830	Maghribi et al.	Mar 2006	A1
20060052829	Sun et al.	Mar 2006	A1
20060052830	Spinelli et al.	Mar 2006	A1
20060064135	Brockway	Mar 2006	A1
20060064149	Belacazar et al.	Mar 2006	A1
20060074285	Zarkh et al.	Apr 2006	A1
20060085039	Hastings et al.	Apr 2006	A1
20060085041	Hastings et al.	Apr 2006	A1
20060085042	Hastings et al.	Apr 2006	A1
20060095078	Tronnes	May 2006	A1
20060106442	Richardson et al.	May 2006	A1
20060116746	Chin	Jun 2006	A1
20060135999	Bodner et al.	Jun 2006	A1
20060136004	Cowan et al.	Jun 2006	A1
20060161061	Echt et al.	Jul 2006	A1
20060161205	Mitrani et al.	Jul 2006	A1
20060200002	Guenst	Sep 2006	A1
20060206151	Lu	Sep 2006	A1
20060212079	Routh et al.	Sep 2006	A1
20060224198	Dong et al.	Oct 2006	A1
20060235478	Van Gelder et al.	Oct 2006	A1
20060241701	Markowitz et al.	Oct 2006	A1
20060241705	Neumann et al.	Oct 2006	A1
20060247672	Vidlund et al.	Nov 2006	A1
20060253162	Zhang et al.	Nov 2006	A1
20060259088	Pastore et al.	Nov 2006	A1
20060265018	Smith et al.	Nov 2006	A1
20070004979	Wojciechowicz et al.	Jan 2007	A1
20070016098	Kim et al.	Jan 2007	A1
20070027508	Cowan	Feb 2007	A1
20070049975	Cates et al.	Mar 2007	A1
20070078490	Cowan et al.	Apr 2007	A1
20070088394	Jacobson	Apr 2007	A1
20070088396	Jacobson	Apr 2007	A1
20070088397	Jacobson	Apr 2007	A1
20070088398	Jacobson	Apr 2007	A1
20070088405	Jaconson	Apr 2007	A1
20070135882	Drasler et al.	Jun 2007	A1
20070135883	Drasler et al.	Jun 2007	A1
20070142871	Libbus et al.	Jun 2007	A1
20070150037	Hastings et al.	Jun 2007	A1
20070150038	Hastings et al.	Jun 2007	A1
20070156190	Cinbis	Jul 2007	A1
20070167809	Dala-Krishna	Jul 2007	A1
20070219525	Gelfand et al.	Sep 2007	A1
20070219590	Hastings et al.	Sep 2007	A1
20070225545	Ferrari	Sep 2007	A1
20070232943	Harel et al.	Oct 2007	A1
20070233206	Frikart et al.	Oct 2007	A1
20070233216	Liu et al.	Oct 2007	A1
20070239244	Morgan et al.	Oct 2007	A1
20070250129	Van Oort	Oct 2007	A1
20070255376	Michels et al.	Nov 2007	A1
20070265508	Sheikhzadeh-Nadjar et al.	Nov 2007	A1
20070276444	Gelbart et al.	Nov 2007	A1
20070293900	Sheldon et al.	Dec 2007	A1
20070293904	Gelbart et al.	Dec 2007	A1
20070299475	Levin et al.	Dec 2007	A1
20080004663	Jorgenson	Jan 2008	A1
20080021336	Dobak et al.	Jan 2008	A1
20080021505	Hastings et al.	Jan 2008	A1
20080021519	De Geest et al.	Jan 2008	A1
20080021532	Kveen et al.	Jan 2008	A1
20080027488	Coles	Jan 2008	A1
20080058656	Costello et al.	Mar 2008	A1
20080065183	Whitehurst et al.	Mar 2008	A1
20080065185	Worley	Mar 2008	A1
20080071318	Brooke et al.	Mar 2008	A1
20080109054	Hastings et al.	May 2008	A1
20080119903	Arcot-Krishnamurthy et al.	May 2008	A1
20080119911	Rosero	May 2008	A1
20080130670	Kim et al.	Jun 2008	A1
20080140143	Ettori et al.	Jun 2008	A1
20080146954	Bojovic et al.	Jun 2008	A1
20080154139	Shuros et al.	Jun 2008	A1
20080154322	Jackson et al.	Jun 2008	A1
20080228234	Stancer	Sep 2008	A1
20080234771	Chinchoy et al.	Sep 2008	A1
20080242976	Robertson et al.	Oct 2008	A1
20080243217	Wildon	Oct 2008	A1
20080269814	Rosero	Oct 2008	A1
20080269816	Prakash et al.	Oct 2008	A1
20080269818	Sullivan et al.	Oct 2008	A1
20080269823	Burnes et al.	Oct 2008	A1
20080269825	Chinchoy et al.	Oct 2008	A1
20080275518	Ghanem et al.	Nov 2008	A1
20080275519	Ghanem et al.	Nov 2008	A1
20080281195	Heimdal	Nov 2008	A1
20080288039	Reddy	Nov 2008	A1
20080294208	Willis et al.	Nov 2008	A1
20080294210	Rosero	Nov 2008	A1
20080294229	Friedman et al.	Nov 2008	A1
20080306359	Zdeblick et al.	Dec 2008	A1
20080306567	Park et al.	Dec 2008	A1
20080306568	Ding et al.	Dec 2008	A1
20090005832	Zhu et al.	Jan 2009	A1
20090018599	Hastings et al.	Jan 2009	A1
20090024180	Kisker et al.	Jan 2009	A1
20090036941	Corbucci	Feb 2009	A1
20090036947	Westlund et al.	Feb 2009	A1
20090043352	Brooke et al.	Feb 2009	A1
20090048528	Hopenfeld et al.	Feb 2009	A1
20090048646	Katoozi et al.	Feb 2009	A1
20090053102	Rudy et al.	Feb 2009	A2
20090054941	Eggen et al.	Feb 2009	A1
20090054946	Sommer et al.	Feb 2009	A1
20090062895	Stahmann et al.	Mar 2009	A1
20090082827	Kveen et al.	Mar 2009	A1
20090082828	Ostroff	Mar 2009	A1
20090084382	Jalde et al.	Apr 2009	A1
20090088813	Brockway et al.	Apr 2009	A1
20090093857	Markowitz et al.	Apr 2009	A1
20090099468	Thiagalingam et al.	Apr 2009	A1
20090099469	Flores	Apr 2009	A1
20090099619	Lessmeier et al.	Apr 2009	A1
20090112109	Kuklik et al.	Apr 2009	A1
20090131907	Chin et al.	May 2009	A1
20090135886	Robertson et al.	May 2009	A1
20090143835	Pastore et al.	Jun 2009	A1
20090143838	Libbus et al.	Jun 2009	A1
20090157134	Ziglio et al.	Jun 2009	A1
20090157136	Yang et al.	Jun 2009	A1
20090171408	Solem	Jul 2009	A1
20090171414	Kelly et al.	Jul 2009	A1
20090198298	Kaiser et al.	Aug 2009	A1
20090204163	Shuros et al.	Aug 2009	A1
20090204170	Hastings et al.	Aug 2009	A1
20090210024	Jason	Aug 2009	A1
20090216112	Assis et al.	Aug 2009	A1
20090216292	Pless et al.	Aug 2009	A1
20090232448	Barmash et al.	Sep 2009	A1
20090234407	Hastings et al.	Sep 2009	A1
20090234411	Sambelashvili et al.	Sep 2009	A1
20090234412	Sambelashvili	Sep 2009	A1
20090234413	Sambelashvili et al.	Sep 2009	A1
20090234414	Sambelashvili et al.	Sep 2009	A1
20090234415	Sambelashvili et al.	Sep 2009	A1
20090248103	Sambelashvili et al.	Oct 2009	A1
20090254140	Rosenberg et al.	Oct 2009	A1
20090266573	Engmark et al.	Oct 2009	A1
20090270729	Corbucci et al.	Oct 2009	A1
20090270937	Yonce et al.	Oct 2009	A1
20090275998	Burnes et al.	Nov 2009	A1
20090275999	Burnes et al.	Nov 2009	A1
20090299201	Gunderson	Dec 2009	A1
20090299423	Min	Dec 2009	A1
20090299447	Jensen et al.	Dec 2009	A1
20090306732	Rosenberg et al.	Dec 2009	A1
20090318995	Keel et al.	Dec 2009	A1
20100013668	Kantervik	Jan 2010	A1
20100016911	Willis et al.	Jan 2010	A1
20100016914	Mullen et al.	Jan 2010	A1
20100022873	Hunter et al.	Jan 2010	A1
20100023078	Dong et al.	Jan 2010	A1
20100023085	Wu et al.	Jan 2010	A1
20100030061	Canfield et al.	Feb 2010	A1
20100030327	Chatel	Feb 2010	A1
20100042108	Hibino	Feb 2010	A1
20100049063	Dobak, III	Feb 2010	A1
20100063375	Kassab et al.	Mar 2010	A1
20100063562	Cowan et al.	Mar 2010	A1
20100065871	Govari et al.	Mar 2010	A1
20100069987	Min et al.	Mar 2010	A1
20100087888	Maskara	Apr 2010	A1
20100094149	Kohut et al.	Apr 2010	A1
20100094367	Sen	Apr 2010	A1
20100113954	Zhou	May 2010	A1
20100114209	Krause et al.	May 2010	A1
20100114214	Morelli et al.	May 2010	A1
20100114229	Chinchoy	May 2010	A1
20100121403	Schecter et al.	May 2010	A1
20100125281	Jacobson et al.	May 2010	A1
20100145405	Min et al.	Jun 2010	A1
20100152798	Sanghera et al.	Jun 2010	A1
20100168761	Kassab et al.	Jul 2010	A1
20100168819	Freeberg	Jul 2010	A1
20100174137	Shim	Jul 2010	A1
20100185250	Rom	Jul 2010	A1
20100198288	Ostroff	Aug 2010	A1
20100198291	Sambelashvili et al.	Aug 2010	A1
20100198292	Honeck et al.	Aug 2010	A1
20100198304	Wang	Aug 2010	A1
20100217367	Belson	Aug 2010	A1
20100218147	Ishikawa	Aug 2010	A1
20100228138	Chen	Sep 2010	A1
20100228308	Cowan et al.	Sep 2010	A1
20100234906	Koh	Sep 2010	A1
20100234916	Turcott et al.	Sep 2010	A1
20100234924	Willis	Sep 2010	A1
20100241185	Mahapatra et al.	Sep 2010	A1
20100249622	Olson	Sep 2010	A1
20100249729	Morris et al.	Sep 2010	A1
20100254583	Chan et al.	Oct 2010	A1
20100268059	Ryu et al.	Oct 2010	A1
20100286541	Musley et al.	Nov 2010	A1
20100286626	Petersen	Nov 2010	A1
20100286744	Echt et al.	Nov 2010	A1
20100298841	Prinzen et al.	Nov 2010	A1
20100312309	Harding	Dec 2010	A1
20110004111	Gill et al.	Jan 2011	A1
20110004264	Siejko et al.	Jan 2011	A1
20110022112	Min	Jan 2011	A1
20110022113	Ideblick et al.	Jan 2011	A1
20110054286	Crosby	Mar 2011	A1
20110054559	Rosenberg et al.	Mar 2011	A1
20110054560	Rosenberg et al.	Mar 2011	A1
20110071586	Jacobson	Mar 2011	A1
20110075896	Matsumoto	Mar 2011	A1
20110077708	Ostroff	Mar 2011	A1
20110092809	Nguyen et al.	Apr 2011	A1
20110106202	Ding et al.	May 2011	A1
20110112398	Zarkh et al.	May 2011	A1
20110112600	Cowan et al.	May 2011	A1
20110118588	Komblau et al.	May 2011	A1
20110118803	Hou et al.	May 2011	A1
20110118810	Cowan et al.	May 2011	A1
20110137187	Yang et al.	Jun 2011	A1
20110137369	Ryu et al.	Jun 2011	A1
20110144510	Ryu et al.	Jun 2011	A1
20110144720	Cowan et al.	Jun 2011	A1
20110152970	Jollota et al.	Jun 2011	A1
20110160558	Rassatt et al.	Jun 2011	A1
20110160565	Stubbs	Jun 2011	A1
20110160801	Markowitz et al.	Jun 2011	A1
20110160806	Lyden et al.	Jun 2011	A1
20110166620	Cowan et al.	Jul 2011	A1
20110166621	Cowan et al.	Jul 2011	A1
20110172728	Wang	Jul 2011	A1
20110184297	Vitali et al.	Jul 2011	A1
20110184491	Kivi	Jul 2011	A1
20110190615	Phillips et al.	Aug 2011	A1
20110190835	Brockway et al.	Aug 2011	A1
20110190841	Sambelashvili et al.	Aug 2011	A1
20110196444	Prakash et al.	Aug 2011	A1
20110201915	Gogin et al.	Aug 2011	A1
20110208260	Jacobson	Aug 2011	A1
20110213260	Keel et al.	Sep 2011	A1
20110218587	Jacobson	Sep 2011	A1
20110230734	Fain et al.	Sep 2011	A1
20110237967	Moore et al.	Sep 2011	A1
20110245890	Brisben et al.	Oct 2011	A1
20110251660	Griswold	Oct 2011	A1
20110251662	Griswold et al.	Oct 2011	A1
20110270099	Ruben et al.	Nov 2011	A1
20110270339	Murray, III et al.	Nov 2011	A1
20110270340	Pellegrini et al.	Nov 2011	A1
20110276102	Cohen	Nov 2011	A1
20110282423	Jacobson	Nov 2011	A1
20110319954	Niazi et al.	Dec 2011	A1
20120004527	Thompson et al.	Jan 2012	A1
20120004567	Eberle et al.	Jan 2012	A1
20120029323	Zhao	Feb 2012	A1
20120035685	Saha et al.	Feb 2012	A1
20120041508	Rousso et al.	Feb 2012	A1
20120059433	Cowan et al.	Mar 2012	A1
20120059436	Fontaine et al.	Mar 2012	A1
20120065500	Rogers et al.	Mar 2012	A1
20120078322	Dal Molin et al.	Mar 2012	A1
20120089198	Ostroff	Apr 2012	A1
20120089214	Kroll et al.	Apr 2012	A1
20120093245	Makdissi et al.	Apr 2012	A1
20120095521	Hintz	Apr 2012	A1
20120095539	Khairkhahan et al.	Apr 2012	A1
20120101540	O'Brien et al.	Apr 2012	A1
20120101543	Demmer et al.	Apr 2012	A1
20120101546	Stadler et al.	Apr 2012	A1
20120101553	Reddy	Apr 2012	A1
20120109148	Bonner et al.	May 2012	A1
20120109149	Bonner et al.	May 2012	A1
20120109235	Sheldon et al.	May 2012	A1
20120109236	Jacobson et al.	May 2012	A1
20120109259	Bond et al.	May 2012	A1
20120116489	Khairkhahan et al.	May 2012	A1
20120150251	Giftakis et al.	Jun 2012	A1
20120158111	Khairkhahan et al.	Jun 2012	A1
20120165827	Khairkhahan et al.	Jun 2012	A1
20120172690	Anderson et al.	Jul 2012	A1
20120172891	Lee	Jul 2012	A1
20120172892	Grubac et al.	Jul 2012	A1
20120172942	Berg	Jul 2012	A1
20120197350	Roberts et al.	Aug 2012	A1
20120197373	Khairkhahan et al.	Aug 2012	A1
20120203090	Min	Aug 2012	A1
20120215285	Tahmasian et al.	Aug 2012	A1
20120232478	Haslinger	Sep 2012	A1
20120232563	Williams et al.	Sep 2012	A1
20120232565	Kveen et al.	Sep 2012	A1
20120245665	Friedman et al.	Sep 2012	A1
20120253419	Rosenberg et al.	Oct 2012	A1
20120263218	Dal Molin et al.	Oct 2012	A1
20120277600	Greenhut	Nov 2012	A1
20120277606	Ellingson et al.	Nov 2012	A1
20120277725	Kassab et al.	Nov 2012	A1
20120283587	Ghosh et al.	Nov 2012	A1
20120283795	Stancer et al.	Nov 2012	A1
20120283807	Deterre et al.	Nov 2012	A1
20120284003	Ghosh et al.	Nov 2012	A1
20120290025	Keimel	Nov 2012	A1
20120296228	Zhang et al.	Nov 2012	A1
20120296381	Matos	Nov 2012	A1
20120296387	Zhang et al.	Nov 2012	A1
20120296388	Zhang et al.	Nov 2012	A1
20120302904	Lian et al.	Nov 2012	A1
20120303082	Dong et al.	Nov 2012	A1
20120303084	Kleckner et al.	Nov 2012	A1
20120310297	Sweeney	Dec 2012	A1
20120316613	Keefe et al.	Dec 2012	A1
20120330179	Yuk et al.	Dec 2012	A1
20130006332	Sommer et al.	Jan 2013	A1
20130012151	Hankins	Jan 2013	A1
20130013017	Mullen et al.	Jan 2013	A1
20130018250	Caprio et al.	Jan 2013	A1
20130018251	Caprio et al.	Jan 2013	A1
20130023975	Locsin	Jan 2013	A1
20130030491	Stadler et al.	Jan 2013	A1
20130035748	Bonner et al.	Feb 2013	A1
20130041422	Jacobson	Feb 2013	A1
20130053906	Ghosh et al.	Feb 2013	A1
20130053908	Smith et al.	Feb 2013	A1
20130053915	Holmstrom et al.	Feb 2013	A1
20130053921	Bonner et al.	Feb 2013	A1
20130060298	Splett et al.	Mar 2013	A1
20130066169	Rys et al.	Mar 2013	A1
20130072770	Rao et al.	Mar 2013	A1
20130072790	Ludwig et al.	Mar 2013	A1
20130079798	Tran et al.	Mar 2013	A1
20130079861	Reinert et al.	Mar 2013	A1
20130085350	Schugt et al.	Apr 2013	A1
20130085403	Gunderson et al.	Apr 2013	A1
20130085550	Polefko et al.	Apr 2013	A1
20130096446	Michael et al.	Apr 2013	A1
20130096649	Martin et al.	Apr 2013	A1
20130103047	Steingisser et al.	Apr 2013	A1
20130103109	Jacobson	Apr 2013	A1
20130110008	Bourget et al.	May 2013	A1
20130110127	Bornzin et al.	May 2013	A1
20130110192	Tran et al.	May 2013	A1
20130110219	Bornzin et al.	May 2013	A1
20130116529	Min et al.	May 2013	A1
20130116738	Samade et al.	May 2013	A1
20130116739	Brada et al.	May 2013	A1
20130116740	Bornzin et al.	May 2013	A1
20130116741	Bornzin et al.	May 2013	A1
20130123872	Bornzin et al.	May 2013	A1
20130123875	Varady et al.	May 2013	A1
20130131529	Jia et al.	May 2013	A1
20130131591	Berthiaume et al.	May 2013	A1
20130131693	Berthiaume et al.	May 2013	A1
20130131749	Sheldon et al.	May 2013	A1
20130131750	Stadler et al.	May 2013	A1
20130131751	Stadler et al.	May 2013	A1
20130136035	Bange et al.	May 2013	A1
20130150695	Biela et al.	Jun 2013	A1
20130150911	Perschbacher et al.	Jun 2013	A1
20130150912	Perschbacher et al.	Jun 2013	A1
20130150913	Bornzin et al.	Jun 2013	A1
20130165983	Ghosh et al.	Jun 2013	A1
20130165988	Ghosh	Jun 2013	A1
20130184776	Shuros et al.	Jul 2013	A1
20130196703	Masoud et al.	Aug 2013	A1
20130197599	Sambelashvili et al.	Aug 2013	A1
20130197609	Moore et al.	Aug 2013	A1
20130231710	Jacobson	Sep 2013	A1
20130238072	Deterre et al.	Sep 2013	A1
20130238073	Makdissi et al.	Sep 2013	A1
20130253342	Griswold et al.	Sep 2013	A1
20130253343	Walfhauser et al.	Sep 2013	A1
20130253344	Griswold et al.	Sep 2013	A1
20130253345	Griswold et al.	Sep 2013	A1
20130253346	Griswold et al.	Sep 2013	A1
20130253347	Griswold et al.	Sep 2013	A1
20130261471	Saha et al.	Oct 2013	A1
20130261497	Pertijs et al.	Oct 2013	A1
20130261688	Dong et al.	Oct 2013	A1
20130265144	Banna et al.	Oct 2013	A1
20130268017	Zhang et al.	Oct 2013	A1
20130268042	Hastings et al.	Oct 2013	A1
20130274828	Willis	Oct 2013	A1
20130274847	Ostroff	Oct 2013	A1
20130282070	Cowan et al.	Oct 2013	A1
20130282073	Cowan et al.	Oct 2013	A1
20130289640	Zhang et al.	Oct 2013	A1
20130138006	Bornzin et al.	Nov 2013	A1
20130296726	Niebauer et al.	Nov 2013	A1
20130296727	Sullivan et al.	Nov 2013	A1
20130303872	Taff et al.	Nov 2013	A1
20130304407	George et al.	Nov 2013	A1
20130324825	Ostroff et al.	Dec 2013	A1
20130324828	Nishiwaki et al.	Dec 2013	A1
20130325081	Karst et al.	Dec 2013	A1
20130345770	Dianaty et al.	Dec 2013	A1
20140005563	Ramanathan et al.	Jan 2014	A1
20140012344	Hastings et al.	Jan 2014	A1
20140018872	Siejko et al.	Jan 2014	A1
20140018876	Ostroff	Jan 2014	A1
20140018877	Demmer et al.	Jan 2014	A1
20140031836	Ollivier	Jan 2014	A1
20140039591	Drasler et al.	Feb 2014	A1
20140043146	Makdissi et al.	Feb 2014	A1
20140046395	Regnier et al.	Feb 2014	A1
20140046420	Moore et al.	Feb 2014	A1
20140058240	Mothilal et al.	Feb 2014	A1
20140058494	Ostroff et al.	Feb 2014	A1
20140339570	Carroll et al.	Feb 2014	A1
20140074114	Khairkhahan et al.	Mar 2014	A1
20140074186	Faltys et al.	Mar 2014	A1
20140094891	Pare et al.	Apr 2014	A1
20140100627	Min	Apr 2014	A1
20140107507	Ghosh et al.	Apr 2014	A1
20140107723	Hou	Apr 2014	A1
20140114173	Bar-Tal et al.	Apr 2014	A1
20140114372	Ghosh et al.	Apr 2014	A1
20140121719	Bonner et al.	May 2014	A1
20140121720	Bonner et al.	May 2014	A1
20140121722	Sheldon et al.	May 2014	A1
20140128935	Kumar et al.	May 2014	A1
20140135865	Hastings et al.	May 2014	A1
20140135866	Ramanathan et al.	May 2014	A1
20140135867	Demmer et al.	May 2014	A1
20140142648	Smith et al.	May 2014	A1
20140148675	Nordstrom et al.	May 2014	A1
20140148815	Wenzel et al.	May 2014	A1
20140155950	Hastings et al.	Jun 2014	A1
20140163633	Ghosh et al.	Jun 2014	A1
20140169162	Romano et al.	Jun 2014	A1
20140172060	Bornzin et al.	Jun 2014	A1
20140180306	Grubac et al.	Jun 2014	A1
20140180366	Edlund	Jun 2014	A1
20140207149	Hastings et al.	Jul 2014	A1
20140207210	Willis et al.	Jul 2014	A1
20140214104	Greenhut et al.	Jul 2014	A1
20140222098	Baru et al.	Aug 2014	A1
20140222099	Sweeney	Aug 2014	A1
20140222109	Moulder	Aug 2014	A1
20140228913	Molin et al.	Aug 2014	A1
20140236172	Hastings et al.	Aug 2014	A1
20140236252	Ghosh et al.	Aug 2014	A1
20140243848	Auricchio et al.	Aug 2014	A1
20140255298	Cole et al.	Sep 2014	A1
20140257324	Fain	Sep 2014	A1
20140257422	Herken	Sep 2014	A1
20140257444	Cole et al.	Sep 2014	A1
20140276125	Hou et al.	Sep 2014	A1
20140276929	Foster et al.	Sep 2014	A1
20140277233	Ghosh	Sep 2014	A1
20140303704	Suwito et al.	Oct 2014	A1
20140309706	Jacobson	Oct 2014	A1
20140323882	Ghosh et al.	Oct 2014	A1
20140323892	Ghosh et al.	Oct 2014	A1
20140323893	Ghosh et al.	Oct 2014	A1
20140330208	Christie et al.	Nov 2014	A1
20140330287	Thompson-Nauman et al.	Nov 2014	A1
20140330326	Thompson-Nauman et al.	Nov 2014	A1
20140358135	Sambelashvili et al.	Dec 2014	A1
20140371807	Ghosh et al.	Dec 2014	A1
20140371808	Ghosh et al.	Dec 2014	A1
20140371832	Ghosh et al.	Dec 2014	A1
20140371833	Ghosh et al.	Dec 2014	A1
20140379041	Foster	Dec 2014	A1
20150025612	Haasl et al.	Jan 2015	A1
20150032016	Ghosh	Jan 2015	A1
20150032171	Ghosh	Jan 2015	A1
20150032172	Ghosh	Jan 2015	A1
20150032173	Ghosh	Jan 2015	A1
20150039041	Smith et al.	Feb 2015	A1
20150045849	Ghosh et al.	Feb 2015	A1
20150051609	Schmidt et al.	Feb 2015	A1
20150051610	Schmidt et al.	Feb 2015	A1
20150051611	Schmidt et al.	Feb 2015	A1
20150051612	Schmidt et al.	Feb 2015	A1
20150051613	Schmidt et al.	Feb 2015	A1
20150051614	Schmidt et al.	Feb 2015	A1
20150051615	Schmidt et al.	Feb 2015	A1
20150051616	Haasl et al.	Feb 2015	A1
20150051682	Schmidt et al.	Feb 2015	A1
20150057520	Foster et al.	Feb 2015	A1
20150057558	Stahmann et al.	Feb 2015	A1
20150057721	Stahmann et al.	Feb 2015	A1
20150088155	Foster et al.	Mar 2015	A1
20150105836	Bonner et al.	Apr 2015	A1
20150142069	Sambelashvili	May 2015	A1
20150142070	Sambelashvili	May 2015	A1
20150148697	Burnes et al.	May 2015	A1
20150149096	Soykan	May 2015	A1
20150157225	Gillberg et al.	Jun 2015	A1
20150157231	Gillberg et al.	Jun 2015	A1
20150157232	Gillberg et al.	Jun 2015	A1
20150157861	Aghassian	Jun 2015	A1
20150157865	Gillberg et al.	Jun 2015	A1
20150173655	Demmer et al.	Jun 2015	A1
20150190638	Smith et al.	Jul 2015	A1
20150196756	Stahmann et al.	Jul 2015	A1
20150196757	Stahmann et al.	Jul 2015	A1
20150196758	Stahmann et al.	Jul 2015	A1
20150196769	Stahmann et al.	Jul 2015	A1
20150216434	Ghosh et al.	Aug 2015	A1
20150217119	Nikolski et al.	Aug 2015	A1
20150221898	Chi et al.	Aug 2015	A1
20150224315	Stahmann	Aug 2015	A1
20150224320	Stahmann	Aug 2015	A1
20150258345	Smith et al.	Sep 2015	A1
20150265840	Ghosh et al.	Sep 2015	A1
20150290468	Zhang	Oct 2015	A1
20150297905	Greenhut et al.	Oct 2015	A1
20150297907	Zhang	Oct 2015	A1
20150305637	Greenhut et al.	Oct 2015	A1
20150305638	Zhang	Oct 2015	A1
20150305639	Greenhut et al.	Oct 2015	A1
20150305640	Reinke et al.	Oct 2015	A1
20150305641	Stadler et al.	Oct 2015	A1
20150305642	Reinke et al.	Oct 2015	A1
20150305695	Lahm et al.	Oct 2015	A1
20150306374	Seifert et al.	Oct 2015	A1
20150306375	Marshall et al.	Oct 2015	A1
20150306406	Crutchfield et al.	Oct 2015	A1
20150306407	Crutchfield et al.	Oct 2015	A1
20150306408	Greenhut et al.	Oct 2015	A1
20150321016	O'Brien et al.	Nov 2015	A1
20150328459	Chin et al.	Nov 2015	A1
20150335894	Bornzin et al.	Nov 2015	A1
20160015287	Anderson et al.	Jan 2016	A1
20160015322	Anderson et al.	Jan 2016	A1
20160022164	Brockway et al.	Jan 2016	A1
20160023000	Cho et al.	Jan 2016	A1
20160030747	Thakur et al.	Feb 2016	A1
20160030751	Ghosh et al.	Feb 2016	A1
20160030757	Jacobson	Feb 2016	A1
20160033177	Barot et al.	Feb 2016	A1
20160045737	Ghosh et al.	Feb 2016	A1
20160045738	Ghosh et al.	Feb 2016	A1
20160045744	Gillberg et al.	Feb 2016	A1
20160051821	Sambelashvili et al.	Feb 2016	A1
20160059002	Grubac et al.	Mar 2016	A1
20160067486	Brown et al.	Mar 2016	A1
20160067487	Demmer et al.	Mar 2016	A1
20160067490	Carney et al.	Mar 2016	A1
20160114161	Amblard et al.	Apr 2016	A1
20160121127	Klimovitch et al.	May 2016	A1
20160121128	Fishler et al.	May 2016	A1
20160121129	Persson et al.	May 2016	A1
20160129239	Anderson	May 2016	A1
20160184590	Ghosh	Jun 2016	A1
20160213919	Suwito et al.	Jul 2016	A1
20160213937	Reinke et al.	Jul 2016	A1
20160213939	Carney et al.	Jul 2016	A1
20160228026	Jackson	Aug 2016	A1
20160310733	Sheldon et al.	Oct 2016	A1
20160317825	Jacobson	Nov 2016	A1
20160339248	Schrock et al.	Nov 2016	A1
20160367823	Cowan et al.	Dec 2016	A1
20170014629	Ghosh et al.	Jan 2017	A1
20170035315	Jackson	Feb 2017	A1
20170043173	Sharma et al.	Feb 2017	A1
20170043174	Greenhut et al.	Feb 2017	A1
20170056670	Sheldon et al.	Mar 2017	A1
20170182327	Liu	Jun 2017	A1
20170189681	Anderson	Jul 2017	A1
20170209689	Chen	Jul 2017	A1
20170216575	Asleson et al.	Aug 2017	A1
20170246460	Ghosh	Aug 2017	A1
20170246461	Ghosh	Aug 2017	A1
20170304624	Friedman et al.	Oct 2017	A1
20170326369	Koop et al.	Nov 2017	A1
20170340885	Sambelashvili	Nov 2017	A1
20180008829	An et al.	Jan 2018	A1
20180020938	Du et al.	Jan 2018	A1
20180021567	An et al.	Jan 2018	A1
20180021581	An et al.	Jan 2018	A1
20180021582	An et al.	Jan 2018	A1
20180050208	Shuros et al.	Feb 2018	A1
20180078773	Thakur et al.	Mar 2018	A1
20180078779	An et al.	Mar 2018	A1
20180117324	Schilling et al.	May 2018	A1
20180140847	Taff et al.	May 2018	A1
20180140848	Stahmann	May 2018	A1
20180178007	Shuros et al.	Jun 2018	A1
20180199843	Ghosh et al.	Jul 2018	A1
20180212451	Schmidt et al.	Jul 2018	A1
20180250514	Ghosh	Sep 2018	A1
20180263522	Ghosh et al.	Sep 2018	A1
20180264262	Haasl et al.	Sep 2018	A1
20180264272	Haasl et al.	Sep 2018	A1
20180264273	Haasl et al.	Sep 2018	A1
20180264274	Haasl et al.	Sep 2018	A1
20180280686	Shuros et al.	Oct 2018	A1
20180303840	Chopra et al.	Oct 2018	A1
20180326215	Ghosh	Nov 2018	A1
20190030331	Ghosh et al.	Jan 2019	A1
20190030346	Li	Jan 2019	A1
20190038906	Koop et al.	Feb 2019	A1
20190083779	Yang et al.	Mar 2019	A1
20190083800	Yang et al.	Mar 2019	A1
20190083801	Yang et al.	Mar 2019	A1
20190143117	Ghosh	May 2019	A1
20190160288	Stegemann et al.	May 2019	A1
20190183370	Gillberg et al.	Jun 2019	A1
20190192023	Ghosh	Jun 2019	A1
20190192860	Ghosh et al.	Jun 2019	A1
20190269926	Ghosh	Sep 2019	A1
20190290909	Ghosh	Sep 2019	A1

Foreign Referenced Citations (96)

Number	Date	Country
2008279789	Oct 2011	AU
2008329620	May 2014	AU
2014203793	Jul 2014	AU
1043621	Jul 1990	CN
1253761	May 2000	CN
1878595	Dec 2006	CN
101073502	Nov 2007	CN
202933393	May 2013	CN
0362611	Apr 1990	EP
0459 239	Dec 1991	EP
0 728 497	Aug 1996	EP
1 072 284	Jan 2001	EP
1 504 713	Feb 2005	EP
1 541 191	Jun 2005	EP
1 702 648	Sep 2006	EP
2 016 976	Jan 2009	EP
1 904 166	Jun 2011	EP
2 391 270	Jul 2011	EP
1 925 337	Mar 2012	EP
2 436 309	Apr 2012	EP
2 452 721	May 2012	EP
2 471 452	Jul 2012	EP
2 435 132	Aug 2013	EP
2 662 113	Nov 2013	EP
1 703 944	Jul 2015	EP
2005245215	Sep 2005	JP
WO 9500202	Jan 1995	WO
WO 9636134	Nov 1996	WO
WO 9724981	Jul 1997	WO
WO 1998026712	Jun 1998	WO
WO 1999006112	Feb 1999	WO
WO 2000045700	Aug 2000	WO
WO 2001067950	Sep 2001	WO
WO 0222206	Mar 2002	WO
WO 2003070323	Aug 2003	WO
WO 03092800	Nov 2003	WO
WO 2005000206	Jan 2005	WO
WO 2005042089	May 2005	WO
WO 2005056108	Jun 2005	WO
WO 2006069215	Jun 2006	WO
WO 2006086435	Aug 2006	WO
WO 2006105474	Oct 2006	WO
WO 2006113659	Oct 2006	WO
WO 2006115777	Nov 2006	WO
WO 2006117773	Nov 2006	WO
WO 2007013994	Feb 2007	WO
WO 2007027940	Mar 2007	WO
WO 2007013994	Apr 2007	WO
WO 2007027940	Jun 2007	WO
WO 2007073435	Jun 2007	WO
WO 2007075974	Jul 2007	WO
WO 2007139456	Dec 2007	WO
WO 2008151077	Dec 2008	WO
WO 2009006531	Jan 2009	WO
WO 2006069215	Jun 2009	WO
WO 2009079344	Jun 2009	WO
WO 2009139911	Nov 2009	WO
WO 2009148429	Dec 2009	WO
WO 2010019494	Feb 2010	WO
WO 2010071520	Jun 2010	WO
WO 2010088040	Aug 2010	WO
WO 2010088485	Aug 2010	WO
WO 2011070166	Jun 2011	WO
WO 2011090622	Jul 2011	WO
WO 2011099992	Aug 2011	WO
WO 2012037471	Mar 2012	WO
WO 2012037471	Jun 2012	WO
WO 2012106297	Aug 2012	WO
WO 2012109618	Aug 2012	WO
WO 2012110940	Aug 2012	WO
WO 2012109618	Nov 2012	WO
WO 2012151364	Nov 2012	WO
WO 2012151389	Nov 2012	WO
WO 2013006724	Jan 2013	WO
WO 2013010165	Jan 2013	WO
WO 2013010184	Jan 2013	WO
WO 2013006724	Apr 2013	WO
WO 2013080038	Jun 2013	WO
WO 2013098644	Jul 2013	WO
WO 2014179454	Nov 2014	WO
WO 2014179459	Nov 2014	WO
WO 2014179459	Jan 2015	WO
WO 2015013271	Jan 2015	WO
WO 2015013493	Jan 2015	WO
WO 2015013574	Jan 2015	WO
WO 2015081221	Jun 2015	WO
WO 2016011042	Jan 2016	WO
WO 2016077099	May 2016	WO
WO 2016110856	Jul 2016	WO
WO 2016171891	Oct 2016	WO
WO 2017075193	May 2017	WO
WO 2018009569	Jan 2018	WO
WO 2018017226	Jan 2018	WO
WO 2018017361	Jan 2018	WO
WO 2018035343	Feb 2018	WO
WO 2018081519	May 2018	WO

Non-Patent Literature Citations (293)

Entry
US 8,886,318 B2, 11/2014, Jacobson et al. (withdrawn)
International Search Report and Written Opinion from PCT Application No. PCT/US2020/019589 dated Jun. 4, 2020, 11 pages.
International Search Report and Written Opinion dated May 3, 2012 for International Application No. PCT/US2012/036262; 9 pages.
International Search Report and Written Opinion dated May 3, 2012 for International Application No. PCT/US2012/036302; 9 pages.
International Search Report and Written Opinion dated Aug. 6, 2014 for International Application No. PCT/US2014/036153; 14 pages.
International Search Report and Written Opinion dated Nov. 7, 2014 for International Application No. PCT/US2014/036163; 12 pages.
International Search Report and Written Opinion dated Oct. 28, 2014 for International Application No. PCT/US2014/041928; 15 pages.
International Search Report and Written Opinion dated Oct. 24, 2014 for International Application No. PCT/US2014/041929; 14 pages.
International Search Report and Written Opinion dated Nov. 4, 2014 for International Application No. PCT/US2014/0247583; 7 pages.
International Search Report and Written Opinion dated Nov. 12, 2014 for International Application No. PCT/US2014/047971; 7 pages.
International Search Report and Written Opinion dated Nov. 12, 2014 for International Application No. PCT/US2014/048120; 7 pages.
International Search Report and Written Opinion dated Mar. 9, 2015 for International Application No. PCT/US2014/069214; 11 pages.
International Search Report and Written Opinion dated Mar. 17, 2015, for International Application No. PCT/US2014/069192; 11 pages.
International Search Report and Written Opinion dated Mar. 16, 2015 for International Application No. PCT/US2014/069182; 11 pages.
International Search Report and Written Opinion dated Apr. 8, 2015 for International Application No. PCT/US2014/069070; 11 pages.
International Search Report and Written Opinion dated Jun. 11, 2015 for International Application No. PCT/US2015/021442; 13 pages.
Biffi et al., “Occurrence of Phrenic Nerve Stimulation in Cardiac Resynchronization Therapy Patients: the Role of Left Ventricular Lead Type and Placement Site,” Europace, 2013; 15:77-82.
Botker MD, PhD., et al., “Electromechanical Mapping for Detection of Myocardial Viability in Patients with ischemia Cardiomyopathy,” Circulation, Mar. 2001; vol. 103, No. 12, pp.
“CardioGuide System Enables Real-Time Navigation of Left Ventricular Leads During Medtronic CRT Implants,” Press Release, Apr. 9, 2013, Medtronic, Inc., 2 pgs.
Cuculich, P.S., et al., “The Electrophysiological Cardiac Ventricular Substrate in Patients After Myocardial Infection” J. Am. Coll. Cardiol. 2011; 58:1893-1902.
Czerwinska et al., “Method of Segmentation of Thorax Organs Images Applied to Modeling the Cardiac Electrical Field,” Engineering in Medicine and Biology Society, Proceedings of the 22nd Annual International Conference of the IEEE, vol. 1, 23, Jul. 23, 2000.; pp. 402-405.
Dawoud, F. et al., “Inverse Electrocardiographic Imaging to Assess Electrical Dyssynchrony in Cardiac Resynchronization Therapy Patients,” Computing in Cardiology, 2012; 39:993-996.
Freund et al., “A Decision-Theoretic Generalization of Online Learning and an Application to Boosting,” Journal of Computer and System Sciences, 1997; 55(1):119-139.
Friedman, “Greedy Function Approximation: A Gradient Boosting Machine,” Annals of Statistics, 2001; 29(5):1189-1232.
Friedman, “Stochastic Gradient Boosting,” Computational Statistics and Data Analysis, 2002; 38(4):367-378.
Friedman et al., “Additive Logistic Regression: a Statistical View of Boosting,” Annals of Statistics, 2000; 28(2):337-374.
Fung et al., Chapter 20, Optimization of Cardiac Resynchronization Therapy, Cardiac Resynchronization Therapy, Second Edition, Copyright 2008, Blackwell Publishing Ltd., pp. 356-373.
Ghosh et al. “Accuracy of Quadratic Versus Linear Interpolation in Noninvasive Electrocardiographic Imaging (ECGI),” Annuals of Biomedical Engineering, vol. 33, No. 9. Sep. 2005; pp. 1187-1201.
Ghosh et al., “Cardiac Memory in Patents with Wolff-Parkinson-White Syndrome: Noninvasive Imaging of Activation and Repolarization Before and After Catheter Ablation” Circulation, 2008; 118:907-915. Published online Aug. 12, 2008.
Ghosh et al. “Application of L1-Norm Regularization to Epicardial Potential Solution of the Inverse Electrocardiography Problem,” Annuals of Biomedical Engineering, vol. 37, No. 5, May 2009; pp. 902-912.
Ghosh et al., “Electrophysiological Substrate and Intraventricular LV Dyssynchrony in Non-ischemic Heart Failure Patients Undergoing Cardiac Resynchronization Therapy,” Heart rhythm : the official journal of the Heart Rhythm Society, 2011; 8(5):692-699.
Gold et al., “Comparison of Stimulation Sites within Left Ventricular Veins on the Acute Hemodynamic Effects of Cardiac Resynchronization Therapy” Heart Rhythm, Apr. 2005; 2(4):376-381.
Gulrajani, “The Forward and Inverse Problems of Electrocardiography,” IEEE Engineering in Medicine and Biology, IEEE Service Center, vol. 17, No. 5, Sep. 1, 1988; pp. 84-101, 122.
Hansen, “Regularization Tools: A Matlab Package for Analysis and Solution of Discrete Ill-Posed Problems,” Version 4.1 for Matlab 7.3; Mar. 2008; 128 pages. Retrieved from the Internet: Jun. 19, 2014 http://www.mathworks.com/matlabcentral/fileexchange/52-regtools.
Hayes et al., “Cardiac Resynchronization Therapy and the Relationship of Percent Biventricular Pacing to Symptoms and Survival,” Heart Rhythm, Sep. 2011; 8(9):1469-1475.
“Heart Failure Management” datasheet [online]. Medtronic, Minneapolis, Minnesota, [Last updated on Jun. 3, 2013].Retrieved from the Internet: www.medtronic.com; 9 pages.
Hopenfeld et al., “The Effect of Conductivity on ST-Segment Epicardial Potentials Arising from Subendocardial Ischemia,” Annals of Biomedical Eng., Jun. 2005; vol. 33, No. 6, pp. 751-763.
Jia et al., “Electrocardiographic Imaging of Cardiac Resynchronization Therapy in Heart Failure: Observation of Variable Electrophysiologic Responses,” Heart Rhythm, vol. 3, No. 3; Mar. 1, 2006, pp. 296-310.
Kornreich, “Body Surface Potential Mapping of ST Segment Changes in Acute Myocardial Infarction,” Circulation, 1993; 87: 773-782.
Lumason™, Brochure, Bracco Diagnostocs. Oct. 2014.
Medtronic Vitatron Carelink Encore® Programmer Model 29901 Reference Manual, 2013, Medtronic, Inc., Minneapolis, MN.
Miri et al., “Applicability of body surface potential map in computerized optimization of biventricular pacing,” Annals of Biomedical Engineering, vol. 38, No. 3, Mar. 2010, pp. 865-875.
Miri et al., “Comparison of the electrophysiologically based optimization methods with different pacing parameters in patient undergoing resynchronization treatment,” 30th Annual International IEEE EMBS Conference, Aug. 2008, pp. 1741-1744.
Miri et al., “Computerized Optimization of Biventricular Pacing Using Body Surface Potential Map,” 31st Annual International Conference of the IEEE EMBS, Sep. 2009, pp. 2815-2818.
Miri et al., “Efficiency of Timing Delays and Electrode Positions in Optimization of Biventricular Pacing: A Simulation Study,” IEEE Transactions on Biomedical Engineering, Nov. 2009, pp. 2573-2582.
Modre et al., “Noninvasive Myocardial Activation Time Imaging: A Novel Inverse Algorithm Applied to Clinical ECG Mapping Data” IEEE Transactions on Biomedical Engineering, vol. 49; No. 10, Oct. 2002; pp. 1153-1161.
Nash et al., “An Experimental-Computational Framework for Validating in-vivo ECG Inverse Algorithms,” International Journal of Bioelectromagnetism, vol. 2, No. 2, Dec. 31, 2000, 9 pp.
Potse et al., “Mathematical Modeling and Simulation of Ventricular Activation Sequences: Implications for Cardiac Resynchronization Therapy,” J. of Cardiovasc. Trans. Res., 2012; 5:146-158.
Prinzen et al., “Cardiac Resynchronization Therapy State-of-the-Art of Current Applications, Guidelines, Ongoing Trials, and Areas of Controversy” Circulation, 2013; 128: 2407-2418.
Ridgeway, “The State of Boosting,” Computing Science and Statistics, 1999; 31:172-181.
Ryu et al., “Simultaneous Electrical and Mechanical Mapping Using 3D Cardiac Mapping System: Novel Approach for Optimal Cardiac Resynchronization Therapy,” Journal of Cardiovascular Electrophysiology, Feb. 2010; 21(2):219-22.
Silva et al., “Cardiac Resynchronization Therapy in Pediatric Congenital Heart Disease: Insights from Noninvasive Electrocardiographic Imaging” Heart Rhythm, vol. 6, No. 8. Aug. 1, 2009; pp. 1178-1185.
Singh et al., “Left Ventricular Lead Position and Clinical Outcome in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) Trial,” Circulation, 2011; 123:1159-1166.
Sperzel et al., “Intraoperative Characterization of Interventricular Mechanical Dyssynchrony Using Electroanatomic Mapping System—A Feasibility Study,” Journal of Interventional Cardiac Electrophysiology, Nov. 2012; 35(2):189-96.
Steinhaus BM., “Estimating cardiac transmembrane activation and recovery times from unipolar and bipolar extracellular electrograms: a simulation study,” Circulation Research, 1989, 64:449-462.
Strik et al., “Electrical and Mechanical Ventricular Activation During Left Bundle Branch Block and Resynchronization,” J. of Cardiovasc. Trans. Res., 2012; 5:117-126.
Svendsen et al., “Computational Models of Cardiac Electrical Activation,” Chapter 5, Computational Nov. 2010, pp. 73-88.
Sweeney et al., “Analysis of Ventricular Activation Using Surface Electrocardiography to Predict Left Ventricular Reverse Volumetric Remodeling During Cardiac Resynchronization Therapy,” Circulation, Feb. 9, 2010; 121(5):626-34. Available online Jan. 25, 2010.
Sweeney et al., QRS Fusion Complex Analysis Using Wave Interference to Predict Reverse Remodeling During Cardiac Resynchronization Therapy, heart Rhythm, 2014, 11:806-813.
Turner et al, “Electrical and Mechanical Components of Dyssynchrony in Heart Failure Patients with Normal QRS Duration and Left Bundle-Branch Block,” Circulation 2004; 109:2544-2549.
Van Deursen et al., “Vectorcardiography as a Tool for Easy Optimization of Cardiac Resynchronization Therapy in Canine LBBB Hearts,” Circulation Arrhythmia and Electrophysiology, Jun. 1, 2012; 5(3):544-52. Available online Apr. 24, 2012.
Vardas et al., The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association, European Heart Journal, 2007; 28:2256-2295.
Varma et al., “Placebo CRT,” Journal of Cardiovascular Electrophysiology, vol. 19, Aug. 2008; p. 878.
Wang et al., “Application of the Method of Fundamental Solutions to Potential-based Inverse Electrocardiography,” Annals of Biomedical Engineering, Aug. 2006, pp. 1272-1288.
Wellens, MD et al., “The Electrocardiogram 102 Years After Einthoven,” Circulation, Feb. 2004; vol. 109, No. 5, pp. 562-564.
Williams et al., “Short-Term Hemodynamic Effects of Cardiac Resynchronization Therapy in Patients With Heart Failure, a Narrow QRS Duration, and No Dyssynchrony,” Circulation, Oct. 27, 2009; 120: 1687-1694.
http://www.isrctn.com/ISRCTN47824547, public posting published Aug. 2019.
Abed et al., “Obesity results in progressive atrial structural and electrical remodeling: Implications for atrial fibrillation,” Heart Rhythm Society, Jan. 2013; 10(1):90-100.
Adragão et al., “Ablation of pulmonary vein foci for the treatment of atrial fibrillation; percutaneous electroanatomical guided approach,” Europace, Oct. 2002; 4(4):391-9.
Aliot et al., “Arrhythmia detection by dual-chamber implantable cardioverter defibrillators: A review of current algorithms,” Europace, Jul. 2004; 6(4):273-86.
Amirahmadi et al., “Ventricular Tachycardia Caused by Mesothelial Cyst,” Indian Pacing and Electrophysiology Journal, 2013; 13(1):43-44.
Ammirabile et al., “Pitx2 confers left morphological, molecular, and functional identity to the sinus venosus myocardium,” Cardiovasc Res., Feb. 2012; 93(2):291-301.
Anfinsen, “Non-pharmacological Treatment of Atrial Fibrillation,” Indian Pacing and Electrophysiology Journal, Jan. 2002; 2(1):4-14.
Anné et al., “Ablation of post-surgical intra-atrial reentrant Tachycardia,” European Heart Journal, 2002; 23:169-1616.
Arenal et al., “Dominant frequency differences in atrial fibrillation patients with and without left ventricular systolic dysfunction,” Europace, Apr. 2009; 11(4):450-457.
Arriagada et al., “Predictors of arrhythmia recurrence in patients with lone atrial fibrillation,” Europace, Jan. 2008; 10(1):9-14.
Asirvatham et al., “Cardiac Anatomic Considerations in Pediatric Electrophysiology,” Indian Pacing and Electrophysiology Journal, Apr. 2008; 8(Suppl 1):S75-S91.
Asirvatham et al., “Intramyocardial Pacing and Sensing for the Enhancement of Cardiac Stimulation and Sensing Specificity,” Pacing Clin. Electrophysiol., Jun. 2007; 30(6):748-754.
Asirvatham et al., “Letter to the Editor,” J Cardiovasc Electrophysiol., Mar. 2010; 21(3): E77.
Balmer et al., “Long-term follow up of children with congenital complete atrioventricular block and the impact of pacemaker therapy,” Europace, Oct. 2002; 4(4):345-349.
Barold et al., “Conventional and biventricular pacing in patients with first-degree atrioventricular block,” Europace, Oct. 2012; 14(10):1414-9.
Barold et al., “The effect of hyperkalaemia on cardiac rhythm devices,” Europace, Apr. 2014; 16(4):467-76.
Bayrak et al., “Added value of transoesophageal echocardiography during transseptal puncture performed by inexperienced operators,” Europace, May 2012; 14(5):661-5.
Bergau et al., “Measurement of Left Atrial Pressure is a Good Predictor of Freedom From Atrial Fibrillation,” Indian Pacing and Electrophysiology Journal, Jul. 2014; 14(4):181-93.
Bernstein et al., “The revised NASPE/BPEG generic code for antibradycardia, adaptive-rate, and multisite pacing. North American Society of Pacing and Electrophysiology/British Pacing and Electrophysiology Group,” Pacing Clin Electrophysiol., Feb. 2002; 25(2):260-4.
Bito et al., “Early exercise training after myocardial infarction prevents contractile but not electrical remodeling or hypertrophy,” Cardiovascular Research, Apr. 2010; 86(1):72-81.
Bollmann et al., “Analysis of surface electrocardiograms in atrial fibrillation: techniques, research, and clinical applications,” Europace, Nov. 2006; 8(11):911-926.
Bortone et al., “Evidence for an incomplete mitral isthmus block after failed ablation of a left postero-inferior concealed accessory pathway,” Europace, Jun. 2006; 8(6):434-7.
Boulos et al., “Electroanatomical mapping and radiofrequency ablation of an accessory pathway associated with a large aneurysm of the coronary sinus,” Europace, Nov. 2004; 6(6):608-12.
Brembilla-Perrot et al., “Incidence and prognostic significance of spontaneous and inducible antidromic tachycardia,” Europace, Jun. 2013; 15(6):871-876.
Buber et al., “Morphological features of the P-waves at surface electrocardiogram as surrogate to mechanical function of the left atrium following a successful modified maze procedure,” Europace, Apr. 2014; 16(4):578-86.
Burashnikov et al., “Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation,” Pacing Clin Electrophysiol., Mar. 2006; 29(3):290-5.
Burashnikov et al., “Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation,” Heart Rhythm, Jan. 2012; 9(1):125-31.
Calvo et al., “Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes,” Europace, Jan. 2010; 12(1):30-6.
Can et al., ““Atrial torsades de pointes” Induced by Low-Energy Shock From Implantable-Cardioverter Defibrillator,” Indian Pacing and Electrophysiology Journal, Sep. 2013; 13(5):194-199.
Carroz et al., “Pseudo-pacemaker syndrome in a young woman with first-degree atrio-ventricular block,” Europace, Apr. 2010; 12(4):594-596.
Catanchin et al., “Wolff-Parkinson-White syndrome with an unroofed coronary sinus without persistent left superior vena cava treated with catheter cryoablation,” Indian Pacing and Electrophysiology Journal, Aug. 2008; 8(3):227-233.
Cazeau et al., “Cardiac resynchronization therapy,” Europace, Sep. 2004; 5 Suppl 1:S42-8.
Chandra et al., “Evaluation of KCB-328, a new IKr blocking antiarrhythmic agent in pacing induced canine atrial fibrillation,” Europace, Sep. 2004; 6(5):384-91.
Chang et al., “Electrophysiological characteristics and catheter ablation in patients with paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation,” J Cardiovasc Electrophysiol., Apr. 2008; 19(4):367-73.
Charron et al., “A familial form of conduction defect related to a mutation in the PRKAG2 gene,” Europace, Aug. 2007; 9(8):597-600.
Chou et al., “Effects of SEA0400 on Arrhythmogenicity in a Langendorff-Perfused 1-Month Myocardial Infarction Rabbit Model,” Pacing Clin Electrophysiol., May 2013; 36(5):596-606.
Ciploetta et al., “Posterior Coronary Vein as the Substrate for an Epicardial Accessory Pathway,” Indian Pacing and Electrophysiology Journal, Aug. 2013; 13(4):142-7.
Climent et al., “Effects of endocardial microwave energy ablation,” Indian Pacing and Electrophysiology Journal, Jul. 2005; 5(3):233-43.
Comtois et al., “Of circles and spirals: bridging the gap between the leading circle and spiral wave concepts of cardiac reentry,” Europace, Sep. 2005; 7 Suppl 2:10-20.
Crick et al., “Anatomy of the pig heart: comparisons with normal human cardiac structure,” J. Anat.,1998, 193:105-119.
Daoulah et al., “Unintended Harm and Benefit of the Implantable Defibrillator in an Unfortunate 19-Year-Old Male: Featuring a Sequence of Rare Life-threatening Complications of Cardiac Procedures,” Indian Pacing and Electrophysiology Journal, Aug. 2013; 13(4):151-6.
De Mattia et al., “Paroxysmal atrial fibrillation triggered by a monomorphic ventricular couplet in a patient with acute coronary syndrome,” Indian Pacing and Electrophysiology Journal, Jan. 2012; 12(1):19-23.
DeSimone et al., “New approach to cardiac resynchronization therapy: CRT without left ventricular lead,” Apr. 25, 2014, 2 pages.
De Sisti et al., “Electrophysiological determinants of atrial fibrillation in sinus node dysfunction despite atrial pacing,” Europace, Oct. 2000; 2(4):304-11.
De Voogt et al., “Electrical characteristics of low atrial septum pacing compared with right atrial appendage pacing,” Europace, Jan. 2005; 7(1):60-6.
De Voogt et al., “A technique of lead insertion for low atrial septal pacing,” Pacing Clin Electrophysiol., Jul. 2005; 28(7):639-46.
Dizon et al. “Real-time stroke vol. measurements for the optimization of cardiac resynchronization therapy parameters,” Europace, Sep. 2010; 12(9):1270-1274.
Duckett et al., “Relationship between endocardial activation sequences defined by high-density mapping to early septal contraction (septal flash) in patients with left bundle branch block undergoing cardiac resynchronization therapy,” Europace, Jan. 2012; 14(1):99-106.
Eksik et al., “Influence of atrioventricular nodal reentrant tachycardia ablation on right to left inter-atrial conduction,” Indian Pacing and Electrophysiology Journal, Oct. 2005; 5(4):279-88.
Fiala et al., “Left Atrial Voltage during Atrial Fibrillation in Paroxysmal and Persistent Atrial Fibrillation Patients,” Pace, May 2010; 33(5):541-548.
Fragakis et al., “Acute beta-adrenoceptor blockade improves efficacy of ibutilide in conversion of atrial fibrillation with a rapid ventricular rate,” Europace, Jan. 2009; 11(1):70-4.
Frogoudaki et al., “Pacing for adult patients with left atrial isomerism: efficacy and technical considerations,” Europace, Apr. 2003; 5(2):189-193.
Ganapathy et al., “Implantable Device to Monitor Cardiac Activity with Sternal Wires,” Pacing Clin. Electrophysiol., Dec. 2014; Epub Aug. 24, 2014; 37(12):1630-40.
Geddes, “Accuracy limitations of chronaxie values,” IEEE Trans Biomed Eng., Jan. 2004; 51(1):176-81.
Gertz et al., “The impact of mitral regurgitation on patients undergoing catheter ablation of atrial fibrillation,” Europace, Aug. 2011; 13(8):1127-32.
Girmatsion et al., “Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation,” Heart Rhythm, Dec. 2009; 6(12):1802-9.
Goette et al., “Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles,” European Heart Journal, Jun. 2009; 30(11):1411-20.
Goette et al., “Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms,” Europace, Feb. 2008; 10(2):238-41.
Gómez et al., “Nitric oxide inhibits Kv4.3 and human cardiac transient outward potassium current (Ito1),” Cardiovasc Res., Dec. 2008; 80(3):375-84.
Gros et al., “Connexin 30 is expressed in the mouse sino-atrial node and modulates heart rate,” Cardiovascular Research, Jan. 2010; 85(1):45-55.
Guenther et al., “Substernal Lead Implantation: A Novel Option to Manage OFT Failure in S-ICD patients,” Clinical Research Cardiology, Feb. 2015; Epub Oct. 2, 2014; 104(2):189-91.
Guillem et al., “Noninvasive mapping of human atrial fibrillation,” J Cardiovasc Electrophysiol., May 2009; 20(5):507-513.
Hachisuka et al., “Development and Performance Analysis of an Intra-Body Communication Device,” The 12th International Conference on Solid State Sensors, Actuators and Microsystems, vol. 4A1.3, pp. 1722-1725, 2003.
Hakacova et al., “Septal atrial pacing for the prevention of atrial fibrillation,” Europace, 2007; 9:1124-1128.
Hasan et al., “Safety, efficacy, and performance of implanted recycled cardiac rhythm management (CRM) devices in underprivileged patients,” Pacing Clin Electrophysiol., Jun. 2011; 34(6):653-8.
Hawkins, “Epicardial Wireless Pacemaker for Improved Left Ventricular Reynchronization (Conceptual Design)”, Dec. 2010, A Thesis presented to the Faculty of California Polytechnic State University, San Luis Obispo, 57 pp.
He et al., “Three-dimensional cardiac electrical imaging from intracavity recordings,” IEEE Trans Biomed Eng., Aug. 2007; 54(8):1454-60.
Heist et al., “Direct visualization of epicardial structures and ablation utilizing a visually guided laser balloon catheter: preliminary findings,” J Cardiovasc Electrophysiol., Jul. 2011; 22(7):808-12.
Henz et al., “Synchronous Ventricular Pacing without Crossing the Tricuspid Valve or Entering the Coronary Sinus—Preliminary Results,” J Cardiovasc Electrophysiol., Dec. 2009; 20(12):1391-1397.
Hiippala et al., “Automatic Atrial Threshold Measurement and Adjustment in Pediatric Patients,” Pacing Clin Electrophysiol., Mar. 2010; 33(3):309-13.
Ho, “Letter to the Editor” J Cardiovasc Electrophysiol., Mar. 2010; 21(3): E76.
Höijer et al., “Improved cardiac function and quality of life following upgrade to dual chamber pacing after long-term ventricular stimulation,” European Heart Journal, Mar. 2002; 23(6):490-497.
Huang et al., “A Novel Pacing Strategy With Low and Stable Output: Pacing the Left Bundle Branch Immediately Beyond the Conduction Block,” Can J Cardiol., Dec. 2007; Epub Sep. 22, 2017; 33(12):1736.e1-1736.e.
Inter-Office Memo, Model 6426-85 Canine Feasibility AV Septal 8 mm Screw-In Right Single Pass DDD Lead Final Report (AR # 0120A0207).
Ishigaki et al., “Prevention of immediate recurrence of atrial fibrillation with low-dose landiolol after radiofrequency catheter ablation,” Journal of Arrhythmia, Oct. 2015; 31(5):279-285.
Israel, “The role of pacing mode in the development of atrial fibrillation,” Europace, Feb. 2006; 8(2):89-95.
Janion et al., “Dispersion of P wave duration and P wave vector in patients with atrial septal aneurysm,” Europace, Jul. 2007; 9(7):471-4.
Kabra et al., “Recent Trends in Imaging for Atrial Fibrillation Ablation,” Indian Pacing and Electrophysiology Journal, 2010; 10(5):215-227.
Kalbfleisch et al., “Catheter Ablation with Radiofrequency Energy: Biophysical Aspects and Clinical Applications,” Journal of Cardiovascular Electrophysiology, Oct. 2008; 3(2):173-186.
Katritsis et al., “Classification and differential diagnosis of atrioventricular nodal re-entrant tachycardia,” Europace, Jan. 2006; 8(1):29-36.
Katritsis et al., “Anatomically left-sided septal slow pathway ablation in dextrocardia and situs inversus totalis,” Europace, Aug. 2008; 10(8):1004-5.
Khairy et al., “Cardiac Arrhythmias in Congenital Heart Diseases,” Indian Pacing and Electrophysiology Journal, Nov.-Dec. 2009; 9(6):299-317.
Kimmel et al., “Single-site ventricular and biventricular pacing: investigation of latest depolarization strategy,” Europace, Dec. 2007; 9(12):1163-1170.
Knackstedt et al., “Electro-anatomic mapping systems in arrhythmias,” Europace, Nov. 2008; 10 Suppl 3:iii28-iii34.
Kobayashi et al., “Successful Ablation of Antero-septal Accessory Pathway in the Non-Coronary Cusp in a Child,” Indian Pacing and Electrophysiology Journal, 2012; 12(3):124-130.
Kojodjojo et al., “4:2:1 conduction of an AF initiating trigger,” Indian Pacing and Electrophysiology Journal, Nov. 2015; 15(5):255-8.
Kołodzińska et al., “Differences in encapsulating lead tissue in patients who underwent transvenous lead removal,” Europace, Jul. 2012; 14(7):994-1001.
Konecny et al., “Synchronous intra-myocardial ventricular pacing without crossing the tricuspid valve or entering the coronary sinus,” Cardiovascular Revascularization Medicine, 2013; 14:137-138.
Kriatselis et al., “Ectopic atrial tachycardias with early activation at His site: radiofrequency ablation through a retrograde approach,” Europace, Jun. 2008; 10(6):698-704.
Lalu et al., “Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart,” Eur Heart J., Jan. 2005; 26(1):27-35.
Laske et al., “Excitation of the Intrinsic Conduction System Through His and Interventricular Septal Pacing,” Pacing Clin. Electrophysiol., Apr. 2006; 29(4):397-405.
Leclercq, “Problems and troubleshooting in regular follow-up of patients with cardiac resynchronization therapy,” Europace, Nov. 2009; 11 Suppl 5:v66-71.
Lee et al., “An unusual atrial tachycardia in a patient with Friedreich ataxia,” Europace, Nov. 2011; 13(11):1660-1.
Lee et al., “Blunted Proarrhythmic Effect of Nicorandil in a Langendorff-Perfused Phase-2 Myocardial Infarction Rabbit Model,” Pacing Clin Electrophysiol., Feb. 2013; 36(2):142-51.
Lemay et al., “Spatial dynamics of atrial activity assessed by the vectorcardiogram: from sinus rhythm to atrial fibrillation,” Europace, Nov. 2007; 9 Suppl 6:vi109-18.
Levy et al., “Does the mechanism of action of biatrial pacing for atrial fibrillation involve changes in cardiac haemodynamics? Assessment by Doppler echocardiography and natriuretic peptide measurements,” Europace, Apr. 2000; 2(2):127-35.
Lewalter et al., “Comparison of spontaneous atrial fibrillation electrogram potentials to the P wave electrogram amplitude in dual chamber pacing with unipolar atrial sensing,” Europace, Apr. 2000; 2(2):136-40.
Liakopoulos et al., “Sequential deformation and physiological considerations in unipolar right and left ventricular pacing,” European Journal of Cardio-thoracic Surgery, Apr. 1, 2006; 29S1:S188-197.
Lian et al., “Computer modeling of ventricular rhythm during atrial fibrillation and ventricular pacing,” IEEE Transactions on Biomedical Engineering, Aug. 2006; 53(8):1512-1520.
Lim et al., “Right ventricular lead implantation facilitated by a guiding sheath in a patient with severe chamber dilatation with tricuspid regurgitation,” Indian Pacing and Electrophysiology Journal, Sep. 2011; 11(5):156-8.
Lim et al., “Coupled pacing improves left ventricular function during simulated atrial fibrillation without mechanical dyssynchrony,” Europace, Mar. 2010; 12(3):430-6.
Lou et al., “Tachy-brady arrhythmias: The critical role of adenosine-induced sinoatrial conduction block in post-tachycardia pauses,” Heart Rhythm., Jan. 2013; 10(1):110-8.
Lutomsky et al., “Catheter ablation of paroxysmal atrial fibrillation improves cardiac function: a prospective study on the impact of atrial fibrillation ablation on left ventricular function assessed by magnetic resonance imaging,” Europace, May 2008; 10(5):593-9.
Macedo et al, “Septal accessory pathway: anatomy, causes for difficulty, and an approach to ablation,” Indian Pacing and Electrophysiology Journal, Jul. 2010; 10(7):292-309.
Mafi-Rad et al., “Feasibility and Acute Hemodynamic Effect of Left Ventricular Septal Pacing by Transvenous Approach Through the Interventricular Septum,” Circ Arrhythm Electrophysoil., Mar. 2016; 9(3):e003344.
Mani et al., “Dual Atrioventricular Nodal Pathways Physiology: A Review of Relevant Anatomy, Electrophysiology, and Electrocardiographic Manifestations,” Indian Pacing and Electrophysiology Journal, Jan. 2014; 14(1):12-25.
Manios et al., “Effects of successful cardioversion of persistent atrial fibrillation on right ventricular refractoriness and repolarization,” Europace, Jan. 2005; 7(1):34-9.
Manolis et al., “Prevention of atrial fibrillation by inter-atrial septum pacing guided by electrophysiological testing, in patients with delayed interatrial conduction,” Europace, Apr. 2002; 4(2):165-174.
Marino et al., “Inappropriate mode switching clarified by using a chest radiograph,” Journal of Arrhythmia, Aug. 2015; 31(4):246-248.
Markowitz et al., “Time course and predictors of autonomic dysfunction after ablation of the slow atrioventricular nodal pathway,” Pacing Clin Electrophysiol., Dec. 2004; 27(12):1638-43.
Marshall et al., “The effects of temperature on cardiac pacing thresholds,” Pacing Clin Electrophysiol., Jul. 2010; 33(7):826-833.
McSharry et al., “A Dynamical Model for Generating Synthetic Electrocardiogram Signals,” IEEE Transactions on Biomedical Engineering, Mar. 2003; 50(3):289-294.
Meijler et al., “Scaling of Atrioventricular Transmission in Mammalian Species: An Evolutionary Riddle!,” Journal of Cfardiovascular Electrophysiology, Aug. 2002; 13(8):826-830.
Meiltz et al., “Permanent form of junctional reciprocating tachycardia in adults: peculiar features and results of radiofrequency catheter ablation,” Europace, Jan. 2006; 8(1):21-8.
Mellin et al., “Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure,” Eur Heart J., Aug. 2005; 26(15):1544-50.
Mestan et al., “The influence of fluid and diuretic administration on the index of atrial contribution in sequentially paced patients,” Europace, Apr. 2006; 8(4):273-8.
Metin et al., “Assessment of the P Wave Dispersion and Duration in Elite Women Basketball Players,” Indian Pacing and Electrophysiology Journal, 2010; 10(1):11-20.
Mills et al., “Left Ventricular Septal and Left Ventricular Apical Pacing Chronically Maintain Cardiac Contractile Coordination, Pump Function and Efficiency,” Circ Arrhythm Electrophysoil., Oct. 2009; 2(5):571-579.
Mitchell et al., “How do atrial pacing algorithms prevent atrial arrhythmias?” Europace, Jul. 2004; 6(4):351-62.
Mirzoyev et al., “Embryology of the Conduction System for the Electrophysiologist,” Indian Pacing and Electrophysiology Journal, 2010; 10(8):329-338.
Modre et al., “Noninvasive Myocardial Activation Time Imaging: A Novel Inverse Algorithm Applied to Clinical ECG Mapping Data,” IEE Transactions on Biomedical Engineering, Oct. 2002; 49(10):1153-1161.
Montgomery et al., “Measurement of diffuse ventricular fibrosis with myocardial T1 in patients with atrial fibrillation,” J Arrhythm., Feb. 2016; 32(1):51-6.
Mulpuru et al., “Synchronous ventricular pacing with direct capture of the atrioventricular conduction system: Functional anatomy, terminology, and challenges,” Heart Rhythm, Nov. 2016; Epub Aug. 3, 2016; 13(11):2237-2246.
Musa et al, “Inhibition of Platelet-Derived Growth Factor-AB Signaling Prevents Electromechanical Remodeling of Adult Atrial Myocytes that Contact Myofibroblasts,” Heart Rhythm, Jul. 2013; 10(7):1044-1051.
Nagy et al., “Wnt-11 signalling controls ventricular myocardium development by patterning N-cadherin and β-catenin expression,” Cardiovascular Research, Jan. 2010; 85(1):100-9.
Namboodiri et al., “Electrophysiological features of atrial flutter in cardiac sarcoidosis: a report of two cases,” Indian Pacing and Electrophysiology Journal, Nov. 2012; 12(6):284-9.
Nanthakumar et al., “Assessment of accessory pathway and atrial refractoriness by transesophageal and intracardiac atrial stimulation: An analysis of methodological agreement,” Europace, Jan. 1999; 1(1):55-62.
Neto et al., “Temporary atrial pacing in the prevention of postoperative atrial fibrillation,” Pacing Clin Electrophysiol., Jan. 2007; 30(Suppl 1):S79-83.
Nishijima et al., “Tetrahydrobiopterin depletion and NOS2 uncoupling contribute to heart failure-induced alterations in atrial electrophysiology,” Cardiovasc Res., Jul. 2011; 91(1):71-9.
Niwano et al., “Effect of oral L-type calcium channel blocker on repetitive paroxysmal atrial fibrillation: spectral analysis of fibrillation waves in the Holter monitoring,” Europace, Dec. 2007; 9(12):1209-1215.
Okumura et al., “Effects of a high-fat diet on the electrical properties of porcine atria,” Journal of Arrhythmia, Dec. 2015; 31(6):352-358.
Olesen et al., “Mutations in sodium channel β-subunit SCN3B are associated with early-onset lone atrial fibrillation,” Cardiovascular Research, Mar. 2011; 89(4):786-93.
Ozmen et al., “P wave dispersion is increased in pulmonary stenosis,” Indian Pacing and Electrophysiology Journal, Jan. 2006; 6(1):25-30.
Packer et al., “New generation of electro-anatomic mapping: Full intracardiac image integration,” Europace, Nov. 2008; 10 Suppl 3:iii35-41.
Page et al., “Ischemic ventricular tachycardia presenting as a narrow complex tachycardia,” Indian Pacing and Electrophysiology Journal, Jul. 2014; 14(4):203-210.
Pakarinen et al., “Pre-implant determinants of adequate long-term function of single lead VDD pacemakers,” Europace, Apr. 2002; 4:137-141.
Patel et al., “Atrial Fibrillation after Cardiac Surgery: Where are we now?” Indian Pacing and Electrophysiology Journal, Oct.-Dec. 2008; 8(4):281-291.
Patel et al., “Successful ablation of a left-sided accessory pathway in a patient with coronary sinus atresia and arteriovenous fistula: clinical and developmental insights,” Indian Pacing and Electrophysiology Journal, Mar. 2011; 11(2):43-49.
Peschar et al., “Left Ventricular Septal and Apex Pacing for Optimal Pump Function in Canine Hearts,” J Am Coll Cardiol., Apr. 2, 2003; 41(7):1218-1226.
Physiological Research Laboratories, Final Report for an Acute Study for Model 6426-85 AV Septal Leads, Feb. 1996.
Porciani et al., “Interatrial septum pacing avoids the adverse effect of interatrial delay in biventricular pacing: an echo-Doppler evaluation,” Europace, Jul. 2002; 4(3):317-324.
Potse et al., “A Comparison of Monodomain and Bidomain Reaction-Diffusion Models for Action Potential Propagation in the Human Heart,” IEEE Transactions on Biomedical Engineering, Dec. 2006; 53(12 Pt 1):2425-35.
Prystowsky et al., “Case studies with the experts: management decisions in atrial fibrillation,” J Cardiovasc Electrophysiol., Feb. 2008; 19(Suppl. 1):S1-12.
Prystowsky, “The history of atrial fibrillation: the last 100 years,” J Cardiovasc Electrophysiol, Jun. 2008; 19(6):575-582.
Pytkowski et al., “Paroxysmal atrial fibrillation is associated with increased intra-atrial conduction delay,” Europace, Dec. 2008; 10(12):1415-20.
Qu et al., “Dynamics and cardiac arrhythmias,” J Cardiovasc Electrophysiol., Sep. 2006; 17(9):1042-9.
Ravens et al., “Role of potassium currents in cardiac arrhythmias,” Europace, Oct. 2008; 10(10):1133-7.
Ricci et al., Efficacy of a dual chamber defibrillator with atrial antitachycardia functions in treating spontaneous atrial tachyarrhythmias in patients with life-threatening ventricular tachyarrhythmias, European Heart Journal, Sep. 2002; 23(18):1471-9.
Roberts-Thomson et al., “Focal atrial tachycardia II: management,” Pacing Clin Electrophysiol., Jul. 2006; 29(7):769-78.
Rossi et al., “Endocardial vagal atrioventricular node stimulation in humans: reproducibility on 18-month follow-up,” Europace, Dec. 2010; 12(12):1719-24.
Rouzet et al., “Contraction delay of the RV outflow tract in patients with Brugada syndrome is dependent on the spontaneous ST-segment elevation pattern,” Heart Rhythm, Dec. 2011; 8(12):1905-12.
Russo et al., “Atrial Fibrillation and Beta Thalassemia Major: The Predictive Role of the 12-lead Electrocardiogram Analysis,” Indian Pacing and Electrophysiology Journal, May 2014; 14(3):121-32.
Sairaku et al., “Prediction of sinus node dysfunction in patients with persistent atrial flutter using the flutter cycle length,” Europace, Mar. 2012; 14(3):380-7.
Santini et al., “Immediate and long-term atrial sensing stability in single-lead VDD pacing depends on right atrial dimensions,” Europace, Oct. 2001; 3(4):324-31.
Saremi et al., “Cardiac Conduction System: Delineation of Anatomic Landmarks With Multidetector CT,” Indian Pacing and Electrophysiology Journal, Nov. 2009; 9(6):318-33.
Savelieva et al., “Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches,” Europace, Jun. 2008; 10(6):647-665.
Schmidt et al., “Navigated Dense strain imaging for post-radiofrequency ablation lesion assessment in the swine left atria,” Europace, Jan. 2014; 16(1):133-41.
Schoonderwoerd et al., “Rapid Pacing Results in Changes in Atrial but not in Ventricular Refractoriness,” Pacing Clin Electrophysiol., Mar. 2002; 25(3):287-90.
Schoonderwoerd et al., “Atrial natriuretic peptides during experimental atrial tachycardia: role of developing tachycardiomyopathy,” J Cardiovasc Electrophysiol., Aug. 2004; 15(8):927-32.
Schoonderwoerd et al., “Atrial ultrastructural changes during experimental atrial tachycardia depend on high ventricular rate,” J Cardiovasc Electrophysiol., Oct. 2004; 15(10):1167-74.
Sedmera, “Function and form in the developing cardiovascular system,” Cardiovasc Res., Jul. 2011; 91(2):252-9.
Severi et al., “Alterations of atrial electrophysiology induced by electrolyte variations: combined computational and P-wave analysis,” Europace, Jun. 2010; 12(6):842-9.
Seyedi et al., “A Survey on Intrabody Communications for Body Area Network Application,” IEEE Transactions on Biomedical Engineering, vol. 60(8): 2067-2079, 2013.
Shah et al., “Stable atrial sensing on long-term follow up of VDD pacemakers,” Indian Pacing and Electrophysiology Journal, Oct. 2006; 6(4):189-93.
Shenthar et al., “Permanent pacemaker implantation in a patient with situs solitus, dextrocardia, and corrected transposition of the great arteries using a novel angiographic technique,” Journal of Arrhythmia, Apr. 2014; 30(2):134-138.
Shenthar et al., “Transvenous permanent pacemaker implantation in dextrocardia: technique, challenges, outcome, and a brief review of literature,” Europace, Sep. 2014; 16(9):1327-33.
Shirayama, “Role of atrial fibrillation threshold evaluation on guiding treatment,” Indian Pacing and Electrophysiology Journal, Oct. 2003; 3(4):224-230.
Spickler et al., “Totally Self-Contained Intracardiac Pacemaker,” Journal of Electrocardiology, vol. 3(3&4): 324-331, 1970.
Sreeram et al., “Indications for Electrophysiology Study in children,” Indian Pacing and Electrophysiology Journal, Apr.-Jun. 2008; 8(Suppl. 1):S36-S54.
Stockburger et al., “Optimization of cardiac resynchronization guided by Doppler echocardiography: haemodynamic improvement and intraindividual variability with different pacing configurations and atrioventricular delays,” Europace, Oct. 2006; 8(10):881-6.
Stroobandt et al., “Prediction of Wenckebach Behavior and Block Response in DDD Pacemakers,” Pacing Clin Electrophysiol., Jun. 2006; 9(6):1040-6.
Suenari et al., “Idiopathic left ventricular tachycardia with dual electrocardiogram morphologies in a single patient,” Europace, Apr. 2010; 12(4):592-4.
Sweeney et al., “Analysis of Ventricular Activation Using Surface Electrocardiography to Predict Left Ventricular Reverse Volumetric Remodeling During Cardiac Resynchronization Therapy,” Circulation, Feb. 9, 2010, 121(5): 626-34.
Tan et al., “Electrocardiographic evidence of ventricular repolarization remodelling during atrial fibrillation,” Europace, Jan. 2008; 10(1):99-104.
Taramasco et al., “Internal low-energy cardioversion: a therapeutic option for restoring sinus rhythm in chronic atrial fibrillation after failure of external cardioversion,” Europace, Jul. 1999; 1(3):179-82.
Testa et al., “Rate-control or rhythm-control: where do we stand?” Indian Pacing and Electrophysiology Journal, Oct. 2005; 5(4):296-304.
Thejus et al., “N-terminal Pro-Brain Natriuretic Peptide and Atrial Fibrillation,” Indian Pacing and Electrophysiology Journal, Jan. 2009; 9(1):1-4.
Thornton et al., “Magnetic Assisted Navigation in Electrophysiology and Cardiac Resynchronisation: A Review,” Indian Pacing and Electrophysiology Journal, Oct. 2006; 6(4):202-13.
Tilz et al., “In vivo left-ventricular contact force analysis: comparison of antegrade transseptal with retrograde transaortic mapping strategies and correlation of impedance and electrical amplitude with contact force,” Europace, Sep. 2014; 16(9):1387-95.
Tomaske et al., “Do daily threshold trend fluctuations of epicardial leads correlate with pacing and sensing characteristics in paediatric patients?” Europace, Aug. 2007, 9(8):662-668.
Tomioka et al., “The effect of ventricular sequential contraction on helical heart during pacing: high septal pacing versus biventricular pacing,” European Journal of Cardio-thoracic Surgery, Apr. 1, 2006; 29S1:S198-206.
Tournoux et al., “A ‘Regularly Irregular’ tachycardia: What is the diagnosis?” Europace, Dec. 2008; 10(12):1445-6.
Traykov et al., “Electrogram analysis at the His bundle region and the proximal coronary sinus as a tool to predict left atrial origin of focal atrial tachycardias,” Europace, Jul. 2011; 13(7):1022-7.
Trudel et al., “Simulation of QRST integral maps with a membrane-based computer heart model employing parallel processing,” IEEE Trans Biomed Eng., Aug. 2004; 51(8):1319-29.
Tse et al., “Cardiac dynamics: Alternans and arrhythmogenesis,” Journal of Arrhythmia, Oct. 2016; 32(5):411-417.
Tse, “Mechanisms of cardiac arrhythmias,” Journal of Arrhythmia, Apr. 2016; 32(2):75-81.
Ueda et al., “Outcomes of single- or dual-chamber implantable cardioverter defibrillator systems in Japanese patients,” Journal of Arrhythmia, Apr. 2016; 32(2):89-94.
Van Dam et al., “Volume conductor effects involved in the genesis of the P wave,” Europace, Sep. 2005; 7 Suppl 2:30-8.
Van den Berg et al., “Depletion of atrial natriuretic peptide during longstanding atrial fibrillation,” Europace, Sep. 2004; 6(5):433-7.
Van Deursen, et al., “Vectorcardiography as a Tool for Easy Optimization of Cardiac Resynchronization Therapy in Canine LBBB Hearts,” Circulation Arrhythmia and Electrophysiology, Jun. 1, 2012, 5(3): 544-52.
Van Opstal et al., “Paradoxical increase of stimulus to atrium interval despite His-bundle capture during para-Hisian pacing,” Europace, Dec. 2009; 11(12):1702-4.
Veenhuyzen et al., “Diagnostic pacing maneuvers for supraventricular tachycardia: part 1,” Pacing Clin Electrophysiol., Jun. 2011; 34(6):767-82.
Veenhuyzen et al., “Diagnostic pacing maneuvers for supraventricular tachycardias: part 2,” Pacing Clin Electrophysiol., Jun. 2012; 35(6):757-69.
Veenhuyzen et al., “Principles of Entrainment: Diagnostic Utility for Supraventricular Tachycardia,” Indian Pacing and Electrophysiology Journal, 2008; 8(1):51-65.
Verbrugge et al., “Revisiting diastolic filling time as mechanistic insight for response to cardiac resynchronization therapy,” Europace, Dec. 2013; 15(12):1747-56.
Verrier et al., “Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation,” Europace, Mar. 2013; 15(3):317-324.
Verrijcken et al., “Pacemaker-mediated tachycardia with varying cycle length: what is the mechanism?” Europace, Oct. 2009; 11(10):1400-2.
Villani et al., “Reproducibility of internal atrial defibrillation threshold in paroxysmal and persistent atrial fibrillation,” Europace, Jul. 2004; 6(4):267-72.
Violi et al., “Antioxidants for prevention of atrial fibrillation: a potentially useful future therapeutic approach? A review of the literature and meta-analysis,” Europace, Aug. 2014; 16(8):1107-1116.
Weber et al., “Adenosine sensitive focal atrial tachycardia originating from the non-coronary aortic cusp,” Europace, Jun. 2009; 11(6):823-6.
Weber et al., “Open-irrigated laser catheter ablation: relationship between the level of energy, myocardial thickness, and collateral damages in a dog model,” Europace, Jan. 2014; 16(1):142-8.
Wegmoller, “Intra-Body Communication for Biomedical Sensor Networks,” Diss. ETH, No. 17323, 1-173, 2007.
Wei et al., “Comparative simulation of excitation and body surface electrocardiogram with isotropic and anisotropic computer heart models,” IEEE Trans Biomed Eng., Apr. 1995; 42(4):343-57.
Weijs et al., “Clinical and echocardiographic correlates of intra-atrial conduction delay,” Europace, Dec. 2011; 13(12):1681-7.
Weiss et al., “The influence of fibre orientation, extracted from different segments of the human left ventricle, on the activation and repolarization sequence: a simulation study,” Europace, Nov. 2007; 9(Suppl. 6):vi96-vi104.
Wetzel et al., “A stepwise mapping approach for localization and ablation of ectopic right, left, and septal atrial foci using electroanatomic mapping,” European Heart Journal, Sep. 2002; 23(17):1387-1393.
Wlodarska et al., “Thromboembolic complications in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy,” Europace, Aug. 2006; 8(8):596-600.
Wong et al., “A review of mitral isthmus ablation,” Indian Pacing and Electrophysiology Journal, 2012; 12(4):152-170.
Wu et al., “Acute and long-term outcome after catheter ablation of supraventricular tachycardia in patients after the Mustard or Senning operation for D-transposition of the great arteries,” Europace, Jun. 2013; 15(6):886-91.
Xia et al., “Asymmetric dimethylarginine concentration and early recurrence of atrial fibrillation after electrical cardioversion,” Pacing Clin Electrophysiol., Aug. 2008; 31(8):1036-40.
Yamazaki et al., “Acute Regional Left Atrial Ischemia Causes Acceleration of Atrial Drivers during Atrial Fibrillation,” Heart Rhythm, Jun. 2013; 10(6):901-9.
Yang et al., “Focal atrial tachycardia originating from the distal portion of the left atrial appendage: Characteristics and long-term outcomes of radiofrequency ablation,” Europace, Feb. 2012; 14(2):254-60.
Yiginer et al., “Advanced Age, Female Gender and Delay in Pacemaker Implantation May Cause TdP in Patients With Complete Atrioventricular Block,” Indian Pacing and Electrophysiology Journal, Oct. 2010; 10(10):454-63.
Yoon et al., “Measurement of thoracic current flow in pigs for the study of defibrillation and cardioversion,” IEEE Transactions on Biomedical Engineering, Oct. 2003; 50(10):1167-1773.
Yuan et al., “Recording monophasic action potentials using a platinum-electrode ablation catheter,” Europace, Oct. 2000; 2(4):312-9.
Yusuf et al., “5-Hydroxytryptamine and Atrial Fibrillation: How Significant is This Piece in the Puzzle?” J Cardiovasc Electrophysiol., Feb. 2003; 14(2):209-14.
Zaugg et al., “Current concepts on ventricular fibrillation: a vicious circle of cardiomyocyte calcium overload in the initiation, maintenance, and termination of ventricular fibrillation,” Indian Pacing and Electrophysiology Journal, Apr. 2004; 4(2):85-92.
Zhang et al., “Acute atrial arrhythmogenicity and altered Ca(2+) homeostasis in murine RyR2-P2328S hearts,” Cardiovascular Research, Mar. 2011; 89(4):794-804.
Zoghi et al., “Electrical stunning and hibernation: suggestion of new terms for short- and long-term cardiac memory,” Europace, Sep. 2004; 6(5):418-24.
Zografos et al., “Inhibition of the renin-angiotensin system for prevention of atrial fibrillation,” Pacing Clin Electrophysiol., Oct. 2010; 33(10):1270-85.
(PCT/US2014/066792) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority.
(PCT/US2014/013601) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority.
(PCT/US2014/036782) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, dated Aug. 22, 2014, 11 pages.
International Search Report and Written Opinion for Application No. PCT/US2017/047378, 8 pages, dated Dec. 6, 2017.
(PCT/US2018/050988) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, dated Nov. 14, 2018, 11 pages.
(PCT/US2018/050993) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, dated Nov. 16, 2018, 7 pages.
(PCT/US2019/023642) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, dated Jun. 28, 2019, 14 pages.

Related Publications (1)

	Number	Date	Country
	20200306546 A1	Oct 2020	US

Cardiac conduction system capture

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications